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Abstract 
Cancer drug resistance is almost inevitable in the majority of patients with 
advanced metastatic tumours. Intra-tumour heterogeneity, facilitating rapid tumour 
evolution, is a main cause of resistance to cancer therapies.  
In this thesis, I explore how cancer genome sequencing data can shed light intra-
tumour heterogeneity and the processes shaping cancer genome evolution over 
space and time. Multi-region and single-sample sequencing data was harnessed to 
temporally and clonally dissect mutations across 10 major cancer-types. The 
existence of branched tumour evolution and widespread heterogeneity was 
demonstrated. Although mutations in known cancer genes typically occurred early 
in cancer evolution, subclonal ‘actionable’ mutations, including BRAF (V600E), 
IDH1 (R132H), PIK3CA (E545K), and EGFR (L858R), were also identified.  
Temporal dissection of mutational signatures revealed that APOBEC-mediated-
mutagenesis is frequently a late event in cancer evolution and plays a key role in 
the acquisition of subclonal driver mutations.  
Copy number analysis suggested that genome doubling is prevalent across tumour 
types and that it frequently occurs early in tumour evolution in colorectal cancer. A 
cancer cell-line system was used to demonstrate that rare cells that survive 
genome-doubling display increased tolerance to chromosome aberrations and a 
genome-doubling event was found to be independently predictive of reduced 
relapse-free survival in two independent cohorts.  
Finally, the clinical impact of intra-tumour heterogeneity was explored in the context 
of cancer neo-antigens and immune-modulation. The number of clonal neo-
antigens was associated with survival outcome in lung adenocarcinoma patients 
and T cells reactive to clonal neo-antigens were identified. Sensitivity to anti-PD-1 
therapy was dependent on neo-antigen clonal burden and intra-tumour 
heterogeneity. Thus, immunotherapeutic strategies targeting clonal neo-antigens in 
combination with checkpoint-blockade may provide a tractable approach to tackling 
lung adenocarcinomas. 
This thesis demonstrates how analyses of genomic data can shed light on the 
biology and clinical relevance of cancer evolution and intra-tumour heterogeneity.
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Chapter 1. Overview of the literature  
1.1 Introduction 
Cancer represents a disease of the genome and epigenome, and tumours have 
been found to harbour widely varying numbers and types of somatic aberrations. 
While the vast majority of these mutations are likely to be passenger events that do 
not provide any selective benefit to the cancer cell, a subset will represent cancer 
driver events, conferring a selective advantage to the tumour (Stratton et al., 2009) 
Emerging evidence – much of which has accumulated since the start of this PhD - 
suggests that not every somatic mutation, whether a driver or a passenger, will 
necessarily be found in every cancer cell within the tumour population. While the 
types and distribution of somatic mutations across the tumour genome can be used 
to decipher the mutational processes that have been active during its evolutionary 
history, the degree of heterogeneity in space and over time can reveal a tumour’s 
life history. 
In this chapter, I explore our current understanding of the processes shaping the 
cancer genome and place these in the context of intra-tumour heterogeneity and 
cancer genome evolution. In addition, I outline some of the clinical implications of 
intra-tumour heterogeneity. 
The work presented in this chapter builds upon reviews I have published (as first 
author, or joint first author) concerning heterogeneity and tumour evolution (see 
Appendix 1, and (McGranahan and Swanton, 2015, McGranahan et al., 2012, 
Burrell et al., 2013b, Gerlinger et al., 2014b)).  
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1.2 Cancer as an evolutionary system 
Darwinian evolution by natural selection can be summarised by the requirement of 
three key tenets: 
1. Phenotypic variation – individuals within a population exhibit different 
phenotypes, e.g. different physiologies, behaviours and morphologies 
2. Differential fitness – phenotypes are associated with different fitness as 
measured by rates of survival and reproduction   
3. Heredity – fitness is heritable and can be passed from parents to offspring  
Although originally framed in relation to the evolution of individual organisms within 
a population, these principles of evolution can be viewed as a powerful predictive 
system for changes at multiple levels of biological organisation (Lewontin, 1970).  
An evolutionary synthesis of cancer progression, whereby the cancer cell is the unit 
of selection, was first outlined in 1976 by Peter Nowell (1976). Nowell posited that 
cancers arise from a single founder cell and tumour progression occurs through a 
process of clonal evolution, involving genetic instability and the sequential 
acquisition and selection of more aggressive subclones (Nowell, 1976).  
While our models of tumour evolution have become more nuanced since the 
original postulations of Nowell (1976), the notion of cancer as an evolutionary 
disease involving clonal selection is now supported by an overwhelming body of 
evidence (Greaves, 2015, Greaves and Maley, 2012, Yates and Campbell, 2012). 
This evidence is underpinned by a number of key findings. First, selection of 
specific somatic events has been observed across tumour types (Stratton et al., 
2009, Lawrence et al., 2014). Second, clonal populations of cancer cells have been 
demonstrated both through copy number and next generation sequencing studies 
(Greaves and Maley, 2012, Greaves, 2015). Third, exogenous and endogenous 
genomic instability processes, providing the fuel for somatic evolution, have been 
documented across a wide variety of cancers (Alexandrov et al., 2013a).  
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1.2.1 Types of cancer-causing mutations: drivers and passengers 
In keeping with the evolutionary synthesis of cancer, somatic genomic aberrations 
in cancer cells – ranging from single nucleotide substitutions to chromosomal 
aberrations – can broadly be classified as either drivers or passengers, reflecting 
their relative contribution to the fitness of cancer cells (Stratton et al., 2009). Driver 
aberrations increase cellular fitness, and thus are thought to play a significant role 
in promoting tumourigenesis and tumour progression, while passenger mutations 
confer a negligible benefit to the cancer cell (Stratton et al., 2009). Throughout this 
thesis, the terms cancer gene and driver gene will be used interchangeably, while 
recognising the fact that it is necessarily a somatic driver event that confers driver 
or cancer status to a gene. 
This binary classification of somatic aberrations as either drivers or passengers is 
underpinned by the multi-stage model of cancer development, which posits the 
existence of a number of rate-limiting steps in tumour progression – possibly 
equating to a number of key driver events – that punctuate cancer development 
(Armitage and Doll, 1954, Foulds, 1958, Hahn and Weinberg, 2002). On the basis 
of age-incidence statistics, it has been suggested that the number of rate limiting 
steps in common solid tumours is approximately 5-7 (Miller, 1980), and such 
estimates are supported by recent next-generation sequencing efforts (Vogelstein 
et al., 2013, Kandoth et al., 2013, Tamborero et al., 2013). For example, a study of 
3,053 sequenced tumour exomes from 12 major cancer types, including lung, 
breast and colorectal cancers, found that the vast majority of tumours (93%) 
harboured at least one non-synonymous mutation in a cancer gene, and the 
average number of somatic aberrations in cancer genes per tumour was generally 
low, with most tumours harbouring between 2-6 (Kandoth et al., 2013).  
Given the extensive number of tumours that have already been sequenced 
(>10,000) it is likely that the most common cancer genes have already been 
identified. Indeed, it has been estimated that cancer genes mutated in >20% of 
tumours are approaching saturation (Lawrence et al., 2014, Vogelstein et al., 2013). 
However, genes mutated at frequencies of <20% are still thought to be rising, 
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particularly those at <5% frequency (Lawrence et al., 2014). Conceivably, the tail of 
cancer genes, present at lower frequencies across the cancer population, may 
contain a large number of cancer genes that confer relatively minor fitness effects, 
aptly named ‘mini-drivers’ (Leedham and Tomlinson, 2012).  
It is also worth considering that the selective advantage of a mutation is context 
dependent - it is intrinsically linked to the environment it enters, both in terms of the 
genomic and epigenetic landscape, as well as the external ‘microenvironment’. As 
such, it is theoretically possible that a passenger mutation may become elevated to 
driver status later in tumour evolution, or, alternatively, the selective advantage of a 
particular mutation may eventually become negligible, demoting it to passenger 
status. The importance of context is illustrated by the fact that mutations to certain 
cancer genes are more prevalent in certain cancer types compared to others, for 
example, while mutations to VHL occur in the majority of clear cell renal cell 
carcinomas (Cancer Genome Atlas Research, 2013), they are infrequent in ovarian 
cancers, which almost all (96%) harbour mutations to TP53 (Cancer Genome Atlas 
Research, 2011). Furthermore, particular combinations of somatic mutations co-
occur more than expected by chance, such as mutations in TP53 and IDH1 in GBM 
while other combinations of somatic mutations, such as mutations in TP53 and 
CDH1 in breast cancer, are generally mutually exclusive (Kandoth et al., 2013).  
1.2.2 Approaches to identifying cancer genes 
The search for cancer genes remains an active area of research and many 
different methods have been proposed (Ding et al., 2014, Raphael et al., 2014). 
Broadly, three distinct, yet complementary, approaches can be distinguished, 
based on their underlying strategies: identifying cancer genes based on recurrence 
and evidence of positive selection; predicting functional impact of somatic variants; 
and pathway or network analysis.  
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1.2.2.1 Identifying drivers based on recurrence and or evidence of positive 
selection 
Most methods used to identify cancer genes are underpinned by the notion that 
these genes are likely to harbour a higher burden of coding variants than expected 
by chance. Thus, a key requirement of such methods is to determine the 
background mutation rate and what constitutes a higher mutation burden than that 
expected by chance (Figure 1:1).  
 
Figure 1:1 Identifying cancer genes from mutational catalogues 
Cancer genes can be identified based on: exhibiting a mutation rate higher than 
expected; showing evidence of selection whereby a higher proportion of non-
synonymous or functional mutations are observed compared to expected; or, 
based on mutation clustering, indicating particular amino-acid residues are being 
targeted.  
In evolutionary biology, a common approach for identifying signatures of selection 
involves comparing the ratio of non-synonymous to synonymous mutations, under 
the assumption that synonymous mutations are selectively neutral and can be used 
to approximate the background mutation rate (Hurst, 2009). Such methods have 
been adapted to the search for cancer genes (Greenman et al., 2006, Gonzalez-
Perez and Lopez-Bigas, 2012, Hua et al., 2013). Greenman et al. (2006) developed 
a hypothesis test in a Poisson regression framework to explore evidence of 
selection in genomes, accounting for differences in the mutation spectrum, and this 
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method has since been extended and used to identify cancer genes in a catalogue 
of over 7,651 cancer genomes (Murtaza et al., 2013). Similar approaches are also 
adopted in DrGAP (Hua et al., 2013) and FM-bias (Gonzalez-Perez and Lopez-
Bigas, 2012), where the main evidence for driver mutations is a signal of positive 
selection based on the ratio of damaging to benign mutations. An advantage of 
these approaches is that, in theory, they automatically adjust for gene length and 
genomic features, which may influence mutation rate. A drawback, however, is that 
they generally require large mutational catalogues or tumours with high mutation 
rates to accurately estimate the background mutation rate.  
Other approaches attempt to use the genomic features that may influence the 
background mutation rate as part of a model to identify cancer genes. MuSiC for 
instance, takes into account many of the covariates that affect the background 
mutation rate, such as gene expression, to estimate per-gene and per-patient 
mutation rate and identify genes mutated at a high rate (Dees et al., 2012). 
MutSigCV also estimates gene-specific background mutation rates from multiple 
genomic features, including replication timing and expression of genes, as well as 
coverage and the rate of non-synonymous mutations (Lawrence et al., 2014). 
These two methods have been used extensively in large scale sequencing studies 
(Lawrence et al., 2014, Kandoth et al., 2013, Cancer Genome Atlas, 2012, 
Govindan et al., 2012, Cancer Genome Atlas Research, 2014).  
An alternative, complementary, approach has been to consider the types of 
mutations and whether these cluster at specific sites within the gene sequence. 
Vogelstein proposed the 20/20 rule, postulating that a gene could be classified as a 
driver if either at least 20% of its missense mutations are located at a particular 
residue, or if at least 20% of the mutations are inactivating (for example, nonsense, 
frame-shift, splice site or stop codon mutations) (Vogelstein et al., 2013). A similar 
notion underpins OncodriverCLUST, which identifies genes harbouring a significant 
clustering of mutations as compared to a background model using synonymous 
mutations (Tamborero et al., 2013).  A clustering component is also incorporated 
into the analysis of MutSigCV.  
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In general, the identification of cancer genes based on copy number analysis is 
also based on the notion that segments of the genome harbouring driver events are 
likely to be altered at higher frequencies relative to genomic segments containing 
only passengers (Weir et al., 2007). Recent approaches, such as GISTIC2 (Mermel 
et al., 2011) and JISTIC (Sanchez-Garcia et al., 2010), also incorporate 
sophisticated background models to enable the statistical significance of 
overlapping copy number segments of variables lengths to be estimated.  
1.2.2.2 Predicting functional impact of somatic variants 
A number of tools have been developed that seek to determine the functional 
impact of somatic variants, thereby providing clues as to which may be involved in 
cancer development. Determining which amino acid substitutions are likely to affect 
protein function can, for example, be assessed by presuming that important amino 
acids in a sequence are more likely to be conserved in the protein family than less 
well conserved amino acids, and SIFT (sorting intolerant from tolerant) (Ng and 
Henikoff, 2003), PolyPhen (Adzhubei et al., 2010), MutationAssessor (Reva et al., 
2011) and Condel (Gonzalez-Perez and Lopez-Bigas, 2011) are commonly used 
approaches. Other tools, such as ActiveDriver (Tamborero et al., 2013), have been 
developed to predict effects that are related to protein aggregation, protein stability 
and alterations of residues targeted by post-translational modification. 
1.2.2.3 Pathway or network analysis 
Somatic mutations can also be considered together, enabling an examination of 
whether collections of genes linked to particular pathways are disrupted.  
A straightforward approach is to determine whether a catalogue of coding 
mutations occurs more frequently in a particular gene set than expected by chance, 
as determined by a Fisher’s exact test (Ding et al., 2014). Indeed, such an 
approach is incorporated into the MuSic analysis suite (Dees et al., 2012). However, 
while overcoming some of the limitations of exploring individual genes, such 
methods ignore the fact that pathways do not act in isolation and can only ever be 
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as useful and informative as the gene sets they use, thus restricting identification of 
novel combinations of genes. Other approaches therefore either rely on curated 
pathways to identify genes involved in cancer development or progression, or 
identify pathways de novo from the data itself (Ding et al., 2014).  
Notably, with the exception of a recent study by Sakoparnig and colleagues (2015), 
approaches to identify cancer genes generally do not make use of evolutionary 
timing or heterogeneity to disentangle drivers from passengers. As such, in general, 
current methods are likely biased to detect clonally dominant recurrent driver 
events, as these events will necessarily be present in all tumour cells and will likely 
exhibit a stronger signal of selection. Estimates for the number of cancer genes 
operating in an advanced tumour may rise considerably when one considers the 
possibility that each subclonal population in a tumour may harbour a driver 
mutation (Gerlinger et al., 2014a).   
1.3 Heterogeneity within tumours  
1.3.1 A brief history of heterogeneity research 
Within tumours, diversity can occur across multiple different biological scales, from 
genomic and epigenetic differences between single cells to macroscopic diversity 
and morphological differences between tumour regions. The biological scales at 
which heterogeneity can occur to a large extent reflect the history of research into 
intra-tumour heterogeneity itself, from macroscopic to single nucleotide, from past 
to present.  
Macroscopic intra-tumour heterogeneity has likely been evident ever since tumours 
were first excised thousands of years ago (Mukherjee, 2011). Many solid tumours, 
for example, often display distinct regions of growth, necrosis and hypoxia. As early 
as the 1800s pathologists such as Rudolf Virchow, with the aid of microscopes, 
documented morphological diversity between tumour cells within individual tumours 
(reviewed in (Brown and Fee, 2006)). Today, in recognition of its clinical 
Chapter 1. Overview of the literature 
 
 29 
importance, the pathologist’s grading system of breast tumours incorporates an 
element of heterogeneity (Russnes et al., 2011).  
The notion of clonal heterogeneity and the possibility of distinct tumour subclones 
within a single tumour gained prominence in the 1980s and 1990s as tools were 
developed to investigate intra-tumour heterogeneity at the chromosomal level. 
Chromosome G-banding and karyotyping methods have permitted detailed 
analysis of the chromosomal complements of cancer cells, revealing extensive 
clonal heterogeneity and multiple distinct subclones in many cancer types. For 
example, an in-depth study of multiple regions (one from each tumour quadrant) 
from 10 breast carcinomas revealed shared clonal chromosomal abnormalities in 
the majority of samples (89%), as well as private abnormalities, not detected in all 
tumour regions, in seven out of the 10 carcinomas (Teixeira et al., 1996). Similarly, 
a study in pancreatic cancer found nineteen of 25 pancreatic carcinomas 
harboured at least two detectable subclones, with one tumour exhibiting a total of 
58 clones (Gorunova et al., 1998).  
Fluorescence in situ hybridisation (FISH) techniques have been used extensively to 
explore heterogeneity of specific genomic loci (Zojer et al., 1998, Maley et al., 
2006), and, more recently, comparative genomic hybridization (CGH) microarrays 
have been used to dissect the extent to which copy number events may diverge in 
distinct tumour subpopulations (Navin et al., 2010, Benetkiewicz et al., 2006, 
Torres et al., 2007b). An analysis of chromosome 22 array-CGH profiling of 
multiple tumour regions in 15 breast tumours found four out of 15 exhibited 
evidence of intra-tumour heterogeneity for this chromosome (Benetkiewicz et al., 
2006), while in depth array-CGH profiling across the tumour genome of 34 tumour 
samples from 9 breast carcinomas revealed extensive intra-tumour heterogeneity 
and a median of 17.4% of genetic alterations identified as heterogeneous across 
the cohort (Torres et al., 2007b). Sector-ploidy-profiling has also been used to 
dissect the clonal heterogeneity of high-grade ductal breast carcinomas (Navin et 
al., 2010). In this case two classes of tumour were observed: monoclonal, where 
only one single major clonal population was detected within the tumour, and 
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polyclonal, in which multiple subclonal populations were observed (Navin et al., 
2010).  
Similarly, in GBM, multi-region copy number profiling revealed extensive 
heterogeneity, with different GBM subtypes identified within the same tumour 
(Sottoriva et al., 2013).  
1.3.1.1 Next generation sequencing to explore heterogeneity and clonal 
architecture 
The advent of next-generation sequencing has permitted analysis of heterogeneity 
at the single-nucleotide level across the genome and revolutionised the ability to 
dissect clonal heterogeneity in tumours, both from multi-region sequencing and 
single sample analysis. Notably, the majority of studies adopting next generation 
sequencing analysis, and development of associated methods, were undertaken 
after the start of the work for this thesis (i.e. post 2011). 
One of the first studies to use next-generation sequencing to dissect the clonal 
architecture of a tumour explored whether mutations identified in the metastasis of 
a lobular breast tumour were also present in the primary tumour, which arose 9 
years earlier (Shah et al., 2009). Consistent with previous work demonstrating 
heterogeneity at the karyotypic level (Torres et al., 2007b), only five of 32 mutations 
identified in the metastasis were also present at likely clonally dominant levels 
within the primary tumour, with 19 not detected and six present at allele 
frequencies indicative of subclonal prevalence.  Similarly, an analysis of seven 
prostate cancer tumours with paired metastatic samples revealed that on average 
36% (range 17-52%) of mutations identified were present in one or more of the 
metastatic samples exampled, but not in the primary region (Yachida et al., 2010).  
In contrast to these data, which demonstrate a high degree of divergence between 
metastasis and primary tumour, one report documented that 48 out of 50 mutations 
were shared between a primary basal-like breast cancer and a brain metastasis 
(Ding et al., 2010). Similarly, in colorectal adenocarcinoma cancer, sanger-
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sequencing revealed that only a minority of mutations (~3%) identified in the 
metastasis were not present in the primary tumour (Jones et al., 2008).  
While these studies shed light on the extent to which metastatic samples differed 
from their matched primary, the extent of heterogeneity within the primary tumour 
was not fully considered. To further elucidate the extent of heterogeneity in solid 
tumours, a study from our lab in KIRC (clear cell renal cell carcinoma) performed 
whole exome sequencing, SNP chromosome aberration analysis, and DNA ploidy 
profiling to multiple spatially separated biopsy samples and their associated 
metastatic sites in four patients (Gerlinger et al., 2012). Of all non-synonymous 
somatic mutations identified through multi-region sequencing, 63 to 69% of variants 
were heterogeneous. In every tumour region, inactivation of the tumour suppressor 
gene VHL was identified as a ubiquitous event, while mutations in other genes, 
such as SET2D and BAP1, were often subclonal.  
The analysis of KIRC has since been extended to 10 tumours, revealing 
heterogeneity in each case (Gerlinger et al., 2014a), and multi-region sequencing 
has also been performed in relatively small cohorts of patients in high-grade serous 
ovarian (Bashashati et al., 2013), bladder (Nordentoft et al., 2014), colorectal 
(Sottoriva et al., 2015), glioma (Johnson et al., 2014, Suzuki et al., 2015), 
glioblastoma (Favero et al., 2015b),  prostate (Cooper et al., 2015, Gundem et al., 
2015), and, more recently, breast tumours (Yates et al., 2015). In every case 
heterogeneity has been observed, with subclonal driver events present in only a 
subset of cancer cells. However, given that each study has performed different 
types of analysis, with different numbers of regions sequenced, different tumour 
stage, different depth etc., it is difficult to directly compare the extent of 
heterogeneity across tumour types, and further studies are required to identify 
patterns of heterogeneity across and within cancer types.  
1.3.1.2 Analysis of single tumour samples to reveal heterogeneity 
Deep analysis of single biopsies has also been used to shed light on the clonal 
architecture of tumours and extent of intra-tumour heterogeneity.  
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Exome sequencing and deep re-sequencing of somatic variants in 54 triple 
negative breast cancer tumours, coupled with a clustering process (see 
Computational tools to dissect clonal architecture, below), enabled estimates of the 
number of subclones in single breast tumour biopsies to be made (Shah et al., 
2012). The majority of tumours were found to harbour multiple subclones, with 
known driver mutations in cancer genes such as TP53 tending to occur in the 
dominant clone (Shah et al., 2012). Applying a similar clustering method, but 
leveraging data from whole genome sequencing, a contemporaneous study found 
that for the majority of 21 breast cancer tumours, the number of subclonal 
mutations exceeded the number of clonal mutations (Nik-Zainal et al., 2012b). 
However, in each case a dominant clone, representing 50-95% of tumour cells, 
was detected (Nik-Zainal et al., 2012b). Heterogeneity analysis from exome 
sequencing has also been performed in chronic lymphocytic leukaemia (Landau et 
al., 2013), and multiple myeloma (Lohr et al., 2014, Bolli et al., 2014), where most 
tumours were found to be composed of multiple subclones. Whole genome 
sequencing of single biopsies from non small-cell lung cancer (NSCLC) uncovered 
evidence for subclonal mutations in ten out of 17 cases (Govindan et al., 2012). 
Taken together, these studies demonstrate that heterogeneity has been observed 
across a wide variety of cancers, with both clonal and subclonal driver mutations. 
However, the majority of studies considering heterogeneity in detail have been 
limited to a small number of patients, or only investigated heterogeneity based on 
one sample from each tumour, thereby potentially underestimating the true extent 
of diversity within tumours.  
1.3.2 Computational tools to dissect clonal architecture 
Data available from next-generation sequencing experiments are particularly suited 
to statistical analysis and clonal dissection given that they represent a random 
sample of DNA molecules, and by extension cancer cell genomes, within a given 
tumour cell population. As such, the advent of next-generation sequencing has 
seen a surge in computational tools to explore the clonal architecture of tumours.  
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The fraction of reads reporting a point mutation is dependent upon the copy 
number at that locus, the level of tumour purity (or normal cell contamination) and 
finally, the cancer cell fraction, describing the fraction of cancer cells that harbour 
the mutation (Figure 1:2). The majority of tools to dissect clonal architecture rely on 
the relationship between these variables (see equation 1), to estimate whether 
mutations are likely clonal or subclonal.  
VAF = p*CCF / (CPNnorm*(1-p) + p*CPNmut)     (equation 1) 
Where VAF=variant allele frequency; p= tumour purity; CCF = cancer cell fraction; 
CPNnorm = local copy number in normal genome; CPNmut = local copy number in 
tumour genome.  
A first step in dissecting the clonal architecture of a tumour involves estimating its 
genomic copy number profile and also its purity. Both of these variables can be 
obtained from methods to estimate copy number across the genome, such as 
ASCAT (Van Loo et al., 2010), ABSOLUTE (Carter et al., 2012), OncoSNP (Yau et 
al., 2010), PICNIC (Greenman et al., 2010) or Sequenza (Favero et al., 2015a). 
These methods utilize mathematical frameworks to model the observed copy 
number array data as an amalgamation of measurements from a population of 
different cell types present at different proportions:  tumours cells that contain an 
unknown amount of DNA, as well as an unknown proportion of normal cells, which 
have a known amount of DNA per cell. While the system of equations is 
undetermined, only a few combinations of purity and ploidy result in biologically 
meaningful solutions. For instance, ploidy cannot be negative or infinitely large and, 
in the absence of subclonal events, copy numbers must be positive integers. 
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Figure 1:2 Estimating cancer cell fraction  
The cancer cell fraction of each mutation reflects both the local copy number and 
the variant allele frequency. 
Once the local copy number and purity of a sample has been determined, the 
cancer cell fraction and mutational multiplicity, describing the number of 
chromosome copies a mutation has, can be estimated from equation 1. A simple 
approach to assess whether a given mutation is subclonal is to assume the 
mutation reflects a binomial distribution and to calculate the probability that the 
observed variant allele frequency differs from what would be expected given a 
clonal mutation (Carter et al., 2012, Stephens et al., 2012).  
More sophisticated methods utilize the fact that multiple mutations with similar 
variant allele frequencies may correspond to a clonal or subclonal cluster of 
mutations. For example, PyClone (Shah et al., 2012, Roth et al., 2014) pioneered 
the integration of variant allele frequencies with allele specific copy number and 
purity estimates in order to define the subclonal composition of individual biopsies. 
The method uses a Bayesian Dirichlet clustering process to jointly group deeply 
sequenced  (>100x) mutations, and infers posterior density estimates over the 
cancer cell fraction (CCF) for each mutation. Indeed, modelling the number of 
subclones as coming from a Dirichlet process does not require knowledge of the 
number of subclones a priori, thus allowing both mutations to be assigned to 
clusters and the number of clusters to be inferred as part of the model (Roth et al., 
2014). A limitation of PyClone, however, is that it assumes all copy number events 
are clonal, and deep sequencing is required (Roth et al., 2014). The method 
adopted by Nik-Zainal (2012b) leverages data from whole genome sequencing to 
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circumvent the need for deep sequencing and allows mutations to reside on 
subclonal copy numbers. By contrast, SciClone (Miller et al., 2014) - which also 
applies a Bayesian clustering method - focuses exclusively on single-nucleotide 
variants (SNVs) in copy-number neutral, loss of heterozygosity (LOH)-free portions 
of the genome. Although this feature of SciClone circumvents issues associated 
with clonal and subclonal copy number aberrations, it means not every mutation 
can be associated with an SNV cluster. All these methods have also been 
extended to allow multiple samples over space or time to be included in subclonal 
clustering and this may considerably improve the accuracy of subclonal 
reconstruction.   
Importantly, in the absence of multi-region data, it may be impossible to accurately 
de-convolve the subclonal structure in a tumour. For example, if two clonal 
populations have similar cancer cell fractions in one tumour region, they will appear 
as one clone. Analysis of another tumour region may enable their separation.  
Alternatively, further information regarding the clonal composition of tumours can 
be inferred based on the mutual exclusivity or co-occurrence of mutations in cancer 
cells, either from single cell sequencing or from ‘phasing’. Phasing involves 
determining whether mutations co-occur or are mutually exclusive, allowing 
different subclones to be delineated; if two mutations never occur together they are 
likely to represent distinct subclones, whereas if two mutations can be phased in 
the same cancer cell they are necessarily present in the same lineage (Nik-Zainal 
et al., 2012b). However, such approaches are currently limited to analysis of 
mutations in regions of hyper-mutations or high mutation burden.  
The majority of computational tools focus on dissecting the heterogeneity of SNVs. 
More recently, tools have also been developed to explore heterogeneity at the copy 
number level (Ha et al., 2014, Oesper et al., 2014). For example, THetA (Tumour 
Heterogeneity Analysis) is an algorithm that seeks to estimate tumour, purity and 
clonal and subclonal copy numbers directly from DNA sequencing data (Oesper et 
al., 2014), while TITAN uses a hidden Markov model (HMM) framework to estimate 
clonal and subclonal clusters of copy numbers (Ha et al., 2014).  
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1.4 Types and patterns of tumour evolution 
1.4.1 Branched and linear tumour evolution 
Traditionally, tumourigenesis has been thought to proceed in a linear fashion, 
involving the sequential accumulation of mutations, accompanied by successive 
clonal sweeps where ancestral clones are replaced by fitter progeny. However, 
evidence of intra-tumour heterogeneity has led to a more complex view of tumour 
evolution (Greaves and Maley, 2012).  
While linear evolution can give rise to heterogeneity if, for example, a daughter 
clone fails to outcompete its ancestral clones, the presence of multiple subclones 
with distinct sets of mutations is incompatible with linear progression (Figure 1:3).  
Indeed, distinct subclonal populations are indicative of branched tumour evolution 
and can be represented as phylogenetic trees, reminiscent of Darwin’s iconic 
speciation tree (Figure 1:3). In this case, mutations present in all cancer cells 
represent the trunk of the tumour phylogenetic tree, while distinct subclones reflect 
branches (Figure 1:3).  
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Figure 1:3 Branched versus linear evolution 
Heterogeneity can be observed during linear evolution; however there will always 
be one subclone that harbours all the mutations in the tumour. In this case the 
green subclone carries all mutations that have occurred during tumour evolution. 
By contrast, during branched evolution distinct subclones evolve simultaneously, 
and at least two clones exist that harbour different private mutations.  
Notably, the subclonal structure identified by sequencing a single tumour sample at 
one point in time is almost always compatible with linear evolution, as without 
information on mutual exclusivity of mutations in tumour populations (from multi-
region sequencing, single cell or phasing information) it is always possible to nest 
subclones within each other, like Russian dolls. It is perhaps not surprising; 
therefore, that evidence for branched evolution has largely accumulated as a result 
of multi-region, serial sampling or single cell analysis.  
One of the first studies to unequivocally demonstrate the presence of branched 
tumour evolution used FISH to explore driver copy number differences in single 
cells of 30 ETV6-RUNX1 positive acute lymphoblastic leukaemias (ALL). Twenty-
four malignancies were found to exhibit clonal architectures only compatible with 
branched evolution, while six cases followed a linear progression model (Anderson 
et al., 2011).  
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In keeping with these findings, multi-region and single-cell sequencing of tumours 
has also predominantly uncovered branched tumour evolution across different 
cancer types, including KIRC (Gerlinger et al., 2012, Gerlinger et al., 2014a), 
ovarian (Bashashati et al., 2013), breast (Yates et al., 2015, Wang et al., 2014), 
bladder (Nordentoft et al., 2014), glioma (Johnson et al., 2014, Suzuki et al., 2015), 
colorectal (Sottoriva et al., 2015) and prostate (Cooper et al., 2015, Gundem et al., 
2015).  
Despite accumulating studies documenting branched evolution, it is worth bearing 
in mind that the majority of studies exploring intra-tumour heterogeneity have 
generally been limited to a handful of tumours studied at depth. Thus the 
prevalence and extent of intra-tumour heterogeneity and branched tumour 
evolution in many cancers remains unclear. The observations that some tumour 
types can develop in either a linear or branched manner (Anderson et al., 2011, 
Navin et al., 2010) demonstrates that branched evolution is not necessarily a 
prerequisite for tumour development and, moreover, intra-tumour heterogeneity 
may not be a universal phenomenon.  
Notably, the underlying reasons for branched or linear evolution remains unclear in 
almost all cases. In colorectal cancer it has been proposed intra-tumour 
heterogeneity results from clonal sweeps at early stages of evolution, followed by 
neutral evolution (Sottoriva et al., 2015). Conceivably, a greater understanding of 
patterns in tumour evolution may shed light on the mechanisms underpinning 
branched tumour evolution and the mechanisms driving intra-tumour heterogeneity 
across cancers.  
1.4.2 Recurrent patterns in tumour evolution 
A long-standing and contentious debate in evolutionary biology concerns whether 
macro-evolutionary rules and trends can be deciphered, and the veracity of Gould’s 
famous assertion that if the tape of life were rewound and played again a different 
evolutionary outcome would result (Gould, 2000). Examination of rules and 
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patterns in evolution is an emerging theme in cancer research and has important 
clinical implications.  
A seminal study in colorectal cancer used the frequency of somatic events across 
independent colorectal tumours at different stages of tumour development to infer 
their likely temporal order (Fearon and Vogelstein, 1990). According to this model, 
there are two routes resulting in colorectal cancer, one through inactivation of APC, 
and the other through mis-match repair deficiency.  Methods that rely on (and 
assume) common patterns across tumours have since been extended and 
developed into more sophisticated mathematical models (for a review, see 
(Beerenwinkel et al., 2014)).  
The timing of mutations can also be dissected based on their copy number. For 
example, if a mutation precedes a regional duplication, its copy number will be 
doubled. Conversely, if a mutation occurs after the duplication it will be present at 
only one copy (Figure 1:4). Application of such a procedure revealed mutations in 
TP53 mutations are early events in cutaneous squamous cell carcinomas (Durinck 
et al., 2011). In breast cancer, mutation data was used to time copy number events 
suggesting that large-scale chromosomal gains did not arise across the genome 
until at least 15-20% of somatic point mutations had accumulated, but 
subsequently were an on-going process (Nik-Zainal et al., 2012b).  
 
Figure 1:4 Using copy number to time mutations 
Mutations occurring in regions of copy number gain can be timed based on their 
mutational multiplicity. Mutations occurring prior to an amplification or doubling 
event will be present at multiple copes (red circles), whereas those occurring after 
amplification will only be present at one copy (blue stars).   
Finally, heterogeneity itself can also illuminate the temporal sequence of somatic 
events in cancer. Clonal mutations, occurring on the trunk of a tumour’s 
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phylogenetic tree, are by definition early events, whereas subclonal events, 
occurring on the branches, reflect later events (summarised in Table 1-1).  
Multi-region sequencing of 10 KIRCs revealed that mutations in VHL, together with 
loss of chromosome 3p, appear always to occur as early events in this cancer type 
(Gerlinger et al., 2014a). Conversely, mutations in TP53, SETD2, BAP1, PTEN and 
KDM5C were only ever found to be subclonal, suggesting these are often later 
events in KIRC evolution. In other cancer types, however, TP53 mutations have 
been found generally to be early events (Shah et al., 2012, Nik-Zainal et al., 2012b, 
Bashashati et al., 2013, Weaver et al., 2014, Yachida et al., 2010). Indeed, 
mutations in TP53 were found to be the only somatic events that could predict 
progression from Barrett’s oesophagus to oesophageal adenocarcinoma (Weaver 
et al., 2014), while in breast cancer and ovarian cancer, mutations in TP53 were 
found to occur as clonal events (Shah et al., 2012, Bashashati et al., 2013). In 
prostate cancer and type one low-grade glioma tumours, mutations to TP53 were 
often found to be subclonal (Hong et al., 2015, Suzuki et al., 2015). In combination, 
this implies that in many cancers mutations in TP53 may be one of the founder 
events during tumour evolution, while in other cancers it may play a role in 
maintenance and progression, occurring after the emergence of the founding 
cancer clone.  
Analysis of paired primary tumour and metastasis in colorectal cancer consistently 
identified driver mutations in KRAS, NRAS and BRAF in both contexts, suggesting 
these somatic events are generally early and are maintained through the metastatic 
dissemination process in this cancer type (Brannon et al., 2014). Conversely, in 
myelodysplastic syndrome (MDS), clonal analysis of single biopsies revealed that 
mutations in NRAS were often a later event while mutations in genes involved in 
splicing, such as U2AF1, were often the earliest (Papaemmanuil et al., 2013).   
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Table 1-1 Summary of truncal and branched driver events across cancer types  
Tumour type Trunk Drivers1 Branch Drivers References 
Acute myeloid 
leukemia (AML) 
DNMT3A, TET2, 
t(15;17),t(8;21), 
t(16;16), inv(16) 
WT1, KRAS, NRAS, 
KIT 
(Welch, 2014)  
Breast TP53, PIK3CA BRCA2 {Martins,2012; Nik-
Zainal ,2012.; Shah, 
2012; Yates, 2015) 
Chronic lymphocytic 
leukaemia (CLL) 
MYD88 SF3B1, TP53 (Landau et al., 2013) 
Colorectal2  KRAS, NRAS, 
BRAF 
TP53, PIK3CA (Brannon et al., 2014, 
Vakiani et al., 2012)  
Ewing Sarcoma 
 
EWSR1–ETS 
fusion 
STAG2 {Tirode, 2014) 
 
Follicular  
lymphoma 
BCl2-IGH (14;18), 
MLL2, CREBBP, 
EZH2 
MYD88, TNFAIP3, 
MYC, TP53 
(Okosun et al., 2014) 
Glioma IDH1 SMARCA4, BRAF, 
TP53, ATRX 
(Johnson et al., 2014) 
Myelodysplastic 
syndrome (MDS) 
SF3B1, SRSF2, 
U2AF1, DNMT3A 
NRAS (Papaemmanuil et al., 
2013)  
Melanoma BRAF NRAS, MEK1 (Van Allen et al., 2014) 
Myeloma IgH rearrangement KRAS, NRAS, BRAF, 
FAM46C 
(Bolli et al., 2014, Lohr 
et al., 2014, Melchor et 
al., 2014) 
Non-small cell lung 
cancer (NSCLC) 
EGFR, KRAS, 
TP53  
HGF (Govindan et al., 2012)  
Oesophageal 
adenocarcinoma 
TP53, SMAD4 
 
MYO18B, TRIM58, C
NTNAP5, 
ABCB1, PCDH9, UN
C13C, SEMA5A , 
CCDC102B 
(Weaver et al., 2014) 
Ovarian TP53 PIK3CA, CTNNB1, 
NF1 
(Bashashati et al., 
2013, Schwarz et al., 
2015) 
Prostate ERG 
rearrangements, 
21q22 deletion, 
NKX3-1 deletion  
FOXP1, SPOP 
CDKN1B, 
AR amplification 
(Baca et al., 2013, 
Haffner et al., 2013, 
Gundem et al., 2015) 
Pancreatic KRAS, CDKN2A, 
TP53, SMAD4 
OVCH1 (Yachida and 
Iacobuzio-Donahue, 
2013)  
Renal VHL, PBRM1*, 3p 
LOH 
SETD2, BAP1, 
KDM5C, MTOR, 
TSC1, TSC2, TP53 
(Gerlinger et al., 
2014a, Gerlinger et al., 
2012) 
1 Genes with * have also been found to be subclonal in multi-region samples. LOH refers to Loss of 
Heterozygosity. 2 Comparative sequencing analysis was used between matched primary and metastatic 
colorectal lesions to define potential branched status. 
In multiple myeloma (MM) known driver events, such as BRAF mutations, were 
found to be clonal in some tumours and subclonal in others, suggesting these 
alterations can contribute to either tumour initiation or maintenance and 
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progression (Lohr et al., 2014, Bolli et al., 2014). Similarly, in chronic lymphocytic 
leukaemia (CLL), mutations in TP53 were identified as subclonal in approximately 
50% of tumours, and only mutations to MYD88 were almost always present in the 
founding cancer clones when identified (Landau et al., 2013). 
Taken together these data suggest rules for tumour evolution can be deciphered 
but are often specific within tumour types and cannot necessarily be applied across 
different cancers.  
1.4.3 Epistatic interactions inform temporal order 
Epistatic interactions, whereby the action of a gene is influenced by the genetic 
background, may play a key role in dictating the order in which mutations are 
acquired. For example, in the presence of P53, loss of BRCA results in acute cell-
cycle arrest, thus it is likely that TP53 mutations usually occur before BRCA loss-of-
function (Ashworth et al., 2011). This is supported by observations that in breast 
cancer, loss of wild-type BRCA1 often occurs after loss of TP53 (Martins et al., 
2012). Moreover the evolutionary trajectory of breast tumours reflects their subtype, 
with the majority of luminal tumours displaying early mutations to TP53, while loss 
of PTEN is observed as the first event in basal-like subtypes 
 
Figure 1:5 Epistatic interactions influence order of mutation acquisition 
The temporal order of mutation acquisition may be influenced by epistatic 
interactions; for example, if gene X is mutated before gene Y, this results in a 
subclonal expansion, whereas if gene Y is mutated before gene X, this results in 
cell death. 
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In myelodysplastic syndrome (MDS), it was found the type of early driver mutations 
could play a role in dictating the future evolutionary trajectories of the disease 
course (Papaemmanuil et al., 2013), suggesting that certain somatic events may 
lead to a form of genetic canalization, in which a tumour is forced down a particular 
evolutionary path.  
Evidence from myelo-proliferative neoplasms has reinforced this notion and further 
demonstrated the importance of gene order influencing the biology and outcome of 
tumour development (Ortmann et al., 2015). Sequencing of 246 neoplasms 
harbouring mutations in JAK2V617F found that 24 also carried a mutation in TET2. 
Clonal analysis in these neoplasms revealed that twelve were characterized by 
early TET2 mutations, followed by JAK2 mutations (TET2-first), while in the 
remaining twelve neoplasms, mutations in JAK2 were acquired first (JAK2-first). 
Intriguingly, patients harbouring JAK2-first mutations were significantly younger at 
disease diagnosis than their TET2-first counterparts and, moreover, the JAK2-first 
patients were characterized by an increased propensity for developing 
polycythaemia-vera, a condition in which red blood cells are overproduced. 
Moreover, in JAK2-first neoplasms the JAK2 mutations increased proliferation of 
stem and progenitor cells, while a JAK2 mutation did not have the same impact in 
neoplasms that first acquired a TET2 mutation (Ortmann et al., 2015).  
1.4.4 Parallel evolution 
In evolutionary biology, parallel evolution is defined as the development of similar 
traits in related but distinct species, descending from the same ancestor. In tumour 
evolution, observations of distinct subclones converging upon disruption or 
deregulation of identical sets of genes or signalling pathways provide evidence for 
parallel tumour evolution (Figure 1:6). Parallel evolution may reflect epistatic 
interactions and suggest the presence of potentially recurrent patterns in tumour 
evolution.   
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Figure 1:6 Parallel tumour evolution 
Parallel evolution can occur during tumour development, in which, for example, a 
particular gene is mutated independently in different subclones.  
In metastatic pancreatic cancer, distinct metastatic sites have been found to 
harbour multiple independent out of frame deletions of exon 6 of PARK2 (Campbell 
et al., 2010), suggesting convergence upon inactivation of PARK2, while in acute 
lymphoblastic leukaemia (ALL), deletions in ETV6, PAX5 and CDKN2A were found 
to occur independently in distinct subclones from the same tumour (Anderson et al., 
2011). Our lab found evidence of parallel evolution in six out of ten KIRC tumours, 
with distinct somatic events in different tumour regions affecting the same gene 
(e.g. SETD2, KDM5C), pathway (PIK3CA, PTEN, mTOR) or protein complex 
(PBRM1, ARID1A and SMARCA4) (Gerlinger et al., 2014a). Moreover, an analysis 
of four tumours occurring in the kidneys of a patient with Von Hippel Lindau 
syndrome uncovered independent clonal origins in different tumours, with distinct 
chromosome 3p LOH events, resulting in bi-allelic inactivation of VHL. However, 
despite distinct tertiary driver events in every tumour, convergence for functional 
activation of the mTOR pathway was observed in all four tumours (Fisher et al., 
2014).  
In keeping with these studies, in glioma, multiple distinct somatic mutations in TP53 
and ATRX have been observed (Johnson et al., 2014, Suzuki et al., 2015), while in 
Chapter 1. Overview of the literature 
 
 45 
glioblastoma, a single cell sequencing approach, leveraging data from bulk 
genomic sequencing, documented parallel evolution with additional somatic 
alterations to EGFR following its amplification (Francis et al., 2014). Finally, in 
myeloma, independent subclones within the same tumour driving RAS/MAPK 
pathway activation through distinct RAS mutations have been observed (Melchor et 
al., 2014).  
Ultimately, evidence for parallel evolution and patterns in the temporal acquisition 
of mutations emphasizes the existence of constraints to tumour development. 
However, the extent to which these constraints can be predicted a priori remains 
unclear.   
1.5 Cancer as an ecosystem 
The evolutionary synthesis of cancer can be extended to viewing cancer as an 
evolving ecosystem. Thus, cancer cells interact with the plethora of different cells in 
their microenvironment and can compete and cooperate for the resources available 
in order to proliferate and survive (Tabassum and Polyak, 2015).  
1.5.1 Cooperation and competition between tumour subclones 
The interactions between different species have been explored extensively in 
ecology and evolutionary biology. More recently, the concepts developed to study 
ecosystems have been applied to investigate cancers, in recognition of the fact that 
reductionist view of cancer is too simplistic and subclones may act in a mutualistic 
or a competing fashion (Tabassum and Polyak, 2015).  
Co-operation, and potential mutualism, between tumour subclones has been 
documented in both mouse Wnt-driven mammary tumours (Cleary et al., 2014), 
and in Drosophila melanogaster where distinct tumour clones harbouring RASV12 
and scribbled loss of function somatic aberrations have been found to cooperate to 
induce JNK signalling and activation of growth promoting cytokines (Wu et al., 
2010). Likewise, co-operation has been observed in a glioblastoma tumour, where 
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a low frequency subclone bearing an EGFRvIII mutation contributed to the growth 
of the dominant subclone through paracrine mechanisms (Inda et al., 2010). 
Consistent with this, evidence from a zebra-fish melanoma xenograft suggested 
subpopulations with limited invasive potential acting in isolation could co-invade in 
a symbiotic fashion (Chapman et al., 2014).   
In a mouse model of small cell lung cancer, evidence was found of crosstalk 
between two histopathologically distinct populations of neuroendocrine and 
mesenchymal cells, sharing the same genetic origin (Calbo et al., 2011). 
Intriguingly, the neuroendocrine cells only acquired metastatic potential when the 
two cellular populations were engrafted together (Calbo et al., 2011). Similarly, in 
colorectal cancer it was found that low frequency KRAS mutant subclones – that 
are resistant to cetuximab – can support the survival of KRAS wild type, drug 
sensitive, subclones through the paracrine release of TGF beta and amphiregulin 
(Hobor et al., 2014).  
Potentially clonal cooperation may apply to many aspects of tumour growth and 
progression, as well as emergence of resistance phenotypes. However, it is worth 
noting that tumour populations with a reliance on clonal cooperation must maintain 
a dynamic equilibrium and disruption of this may lead to tumour collapse through 
clonal interference, an example being if a non-cell-autonomous driver subclone is 
outcompeted by a subclone with higher proliferative potential that cannot survive 
independently (Marusyk et al., 2014).  
Taken together, these data suggest tumours represent a complex dynamic 
ecological system where heterogeneity is not only a substrate for evolution, but can 
also promote or even be a requirement for continued tumour development and 
progression.  
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1.5.2 Cancer and the immune system 
The view of cancer as an ecosystem also encourages an appreciation of the 
microenvironment of tumours and the interaction between cancer cells and the 
immune system.  
Cancers can only arise if they can avoid predation by the immune system, and 
successfully achieve immune escape (Schumacher and Schreiber, 2015).  Just as 
organisms have evolved a wide variety of mechanisms to avoid predation, tumour 
cell escape can also occur through a multitude of different methods (reviewed in 
(Schreiber et al., 2011)) which are not necessarily mutually exclusive. For instance, 
a tumour cell may acquire alterations resulting in reduced immune recognition 
(such as loss of tumour antigens) or alterations leading to enhanced resistance to 
the cytotoxic effects of the immunity may be acquired (for example, through 
activation of anti-apoptotic mechanisms) (Schreiber et al., 2011). In addition, 
escape may be achieved by creating an immunosuppressive state within the 
tumour microenvironment by effectively modulating the immune system (Quezada 
and Peggs, 2013). For example, stimulation of regulatory T cells, such as CD4+ T 
cells, can result in the inhibition of tumour specific T lymphocytes through, for 
example, expression of the negative co-stimulatory molecules CTLA-4, PD-1, and 
PD-L1 (Quezada et al., 2011).  
1.5.2.1 Neo-antigens and immune escape 
Although a large proportion of all somatic variants may ultimately be silent, 
occurring in genes that are transcriptionally dormant or not yielding altered amino 
acid sequences, a subset of all somatic variants will result in altered protein 
products that are expressed.  If processed in a specific way, peptides, harbouring 
the mutated allele, may encounter HLA molecules present within a cell. Depending 
on the binding affinity of the peptide to the HLA molecule, some of these may be 
presented to a patient’s T-cell compartment. Given that peptides resulting from 
mutated amino acid sequences are necessarily different from their wild-type 
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counterparts, these ‘neo-epitopes’ have the potential to give rise to an immune 
response, and thus may be considered ‘neo-antigens’.  
The clinical importance of the neo-antigenic repertoire contained within a tumour 
will depend on the inflammatory environment and, moreover, whether immune-
regulatory checkpoints are permissive for T cell function (Quezada and Peggs, 
2013). A recent study, using a B16 murine melanoma model, identified tumour 
specific HLA-binding neo-antigens and found that cytotoxic T lymphocyte 
responses were induced in mice immunized with the mutated peptide but not the 
wild-type equivalent, and disease could be controlled therapeutically and 
prophylactically (Castle et al., 2012). An analysis of five cancer types found 
tumours with predicted neo-antigens exhibited an improved prognosis compared to 
tumours without neo-antigens (Brown et al., 2014). However, given that only a 
limited number of cancers were investigated, it was not possible to reliably assess 
the applicability of these findings within individual cancer types, and moreover, 
whether the number of neo-antigens a tumour harbours is clinically significant. 
More recently, a pan-cancer found the number of neo-antigens correlated with 
cytolytic activity – as measured by expression of granzyme A (GZMA) and perforin 
(PRF1) – and neo-antigen load was lower than expected in colorectal cancer, 
indicative of immune-editing (Rooney et al., 2015).  
The relevance of modulating the immune system is underscored by the interest in 
and success of trials that attempt to remove the immunological brakes that block 
the induction of anti-tumour responses, for example through inhibition of CTLA-4 or 
PDL-1 (Quezada and Peggs, 2013, Soria et al., 2015). Moreover, in support of the 
importance of immune modulation and neo-antigens, in both melanoma and 
NSLCC a relationship between number of predicted neo-antigens and progression 
free survival in the context of immune blockade has been observed (Snyder et al., 
2014, Rizvi et al., 2015).  
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1.6 Genome instability processes 
The substrate for tumour evolution is heritable somatic aberrations. These 
aberrations can occur at multiple genomic levels, from single nucleotide 
substitutions through to whole doubling events, and may be genetic or epigenetic in 
origin. Thus, a key component of understanding cancer evolution involves 
understanding the processes that give rise to somatic events, and their 
evolutionary importance.  
The prevalence of the different possible types of mutations identified within a 
cancer genome can shed light on the mutational processes that have been active 
during a tumour’s evolution. Indeed, the characteristic mutations associated with a 
particular genome instability process can be considered a “mutational signature”, 
reflecting the imprint of the type of DNA damage that has occurred. 
 
Figure 1:7 Mutational signatures in cancer evolution 
Multiple different mutational processes give rise to the mutational signature 
observed in the cancer genome. These processes may differ in their strength and 
temporal decomposition.  
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1.6.1 Genome instability processes at the single nucleotide level 
While there are twelve possible single-base changes (C>A; G>T; C>G; G>C; C>T; 
G>A; T>A; A>T; T>C; A>G; T>G; A>C), these effectively reduce to six types 
(C:G>A:T; C:G>G:C; C:G>T:A; T:A>A:T; T:A> C:G; T:A>G:C) as, given the double 
stranded nature of DNA, it is impossible to distinguish on which strand the mutation 
occurs. The nomenclature used to describe mutations varies considerably. Within 
this thesis, mutations will be described from the context of the purine base that is 
mutated, for example, a C:G>A:T mutation will be described as a C>A transversion, 
despite the fact that this necessarily also defines a G>T transversion.  
Historically, the exploration of mutational spectra has been restricted to analysis of 
targeted sequencing of established cancer genes (DeMarini et al., 2001, Giglia-
Mari and Sarasin, 2003, Schwemmle and Pfeifer, 2000). Using the catalogue of 
mutation documented in the tumour suppressor gene TP53, clear differences in the 
mutational spectra between lung carcinomas and other cancers were observed, 
with C>A transversions more prevalent in tumours from smokers (Schwemmle and 
Pfeifer, 2000). Furthermore, even at codons that are common hotspots across a 
variety of cancer types, a preponderance of C>A transversions in lung cancers of 
smokers was identified compared to other tumours and never-smokers. The C>A 
transversions derived from smokers’ tumours have been found to exhibit a strong 
transcriptional strand bias with fewer G>T transversions on the transcribed than the 
non-transcribed strand, likely reflecting the past activity of transcription-coupled 
nucleotide excision repair on bulky adducts of guanine caused by tobacco 
carcinogens (Hainaut et al., 2001). Ultraviolet (UV) light associated damage has 
been shown to induce C>T and CC>TT transitions in melanoma genomes, and 
also exhibited transcriptional strand bias, with fewer C>T mutations on the 
transcribed compared to the non-transcribed strand, probably due to the action of 
transcription-coupled repair on impaired pyrimidines (Pfeifer et al., 2005).  
While informative, a limitation of these single gene studies is that they rely on 
mutations in driver genes, making it difficult to disentangle the effects of selection 
with the mutational signatures operating. Moreover, aggregate signals from 
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thousands of samples are required, meaning only strong exposures or dominant 
repair processes operating across the majority of tumours can be accurately 
deciphered.  
1.6.1.1 Whole-genome and whole-exome analysis of mutational catalogues 
Analyses of mutational catalogues obtained from whole-genome sequencing of 
tumours with high mutation rates can provide a detailed picture of the processes 
operating. For example, two studies involving sequencing of a malignant melanoma 
and a single lung cancer were some of the first to illustrate the power of this 
approach (Pleasance et al., 2010a; Pleasance et al., 2010b). These two studies 
identified the characteristic mutational spectra of ultraviolet light and tobacco 
carcinogens respectively within single tumours. Since these seminal studies, 
further analysis of a large series of sequenced lung tumours has revealed that 
smokers on average exhibit a 10-fold increase in the burden of somatic mutations 
in their cancer genomes compared to never-smokers (Govindan et al., 2012; 
Imielinski et al., 2012). Moreover, consistent with previous findings and 
experimental evidence, this elevation is mainly due to the increase in the number of 
C>A transversions.  
In depth examination of the mutational spectra within cancers has also highlighted 
key differences in mutational processes within different tumours. For example, 
examination of hyper-mutated endometrial and colorectal tumours has revealed 
preponderance of C>A and C>G mutations at TpCpT sites specifically in tumours 
harbouring mutations in POLE-E (Palles et al., 2013), demonstrating somatic 
aberrations can result in the preponderance of a particular mutational signature.  
More recently, algorithms have been developed to quantify the number and 
contributions of mutational signatures operating within cancers at the single-
nucleotide level (Alexandrov et al., 2013b, Fischer et al., 2013). These approaches 
assume recurrent processes operate across different cancers, and make use of 
mathematical frameworks to de-convolve the different processes operating within 
each cancer. Application of NMF (non-negative matrix factorization) and model 
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selection to over 30 cancer types, represented by more than 7000 tumours, 
identified 20 distinct mutational signatures (Alexandrov et al., 2013a).  
In the majority of cancer samples analysed, at least two mutational processes were 
identified, consistent with an elevated mutation rate in most cancers (Alexandrov et 
al., 2013a). The most widespread mutational signature, identified in 25 cancer 
types, was characterized by C>T transitions at CpG sites, probably reflecting 
deamination of 5-methylcytosines at CpG sites. This signature correlated with 
patient age (Alexandrov et al., 2013a), consistent with a large proportion of these 
mutations having been acquired prior to tumourigenesis.  
Another pervasive mutational signature, identified in 15 cancer types, was 
characterized by C>T and C>G mutations at TpC sites. Orthogonal analysis, 
adopting a simpler method that used the prevalence of mutations with this motif 
compared to what would be expected given random mutagenesis, also identified 
the presence of this signature across multiple cancer types (Burns et al., 2013, 
Roberts et al., 2013). This signature has been linked to the family of apoliprotein B 
mRNA editing enzyme catalytic polypeptide-like (APOBEC) enzymes, involved in 
cytosine deamination. Cell line studies have demonstrated that APOBEC1, 
APOBEC3A, and APOBEC3B are capable of mutating DNA by the deamination of 
cytosine flanked by a 5’ thymine and thus result in C>T mutations at TpCpN tri-
nucleotides (Harris et al., 2002, Hultquist et al., 2011, Suspene et al., 2011, Taylor 
et al., 2013), consistent with their role in facilitating tumour mutagenesis. 
Furthermore, it has been shown that the activation of enzymes APOBEC3A and 
APOBEC3B in yeast can also lead to in C>G at TpCpN tri-nucleotides (Taylor et al., 
2013). This mutational pattern was attributed to replication over an abasic site, 
formed when an APOBEC deaminated cytosine is excised by uracil-DNA 
glycosylase, which is catalysed by REV1 (Taylor et al., 2013). 
Certain mutational signatures were also identified exclusively in specific cancer 
types. For instance, in oesophageal carcinomas (including both adeno and 
squamous cell-carcinomas), a signature characterized by T>G and T>C mutations, 
particularly at CpTpT sites, was identified, which has been linked to gastric acid 
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exposure (Dulak et al., 2013, Weaver et al., 2014). Similarly, the previously 
characterized smoking signature, involving C>A transversions, was also identified 
in lung and head-and-neck cancers.  
In combination these studies demonstrate that many of the mutational processes 
underlying cancer genome evolution are beginning to be elucidated. Importantly, 
however, the underlying processes responsible for many of the observed 
signatures still remain unclear, and in general their temporal decomposition is 
unknown. 
1.6.2 Therapy as an exogenous mutational process 
Therapy may also act as an exogenous source of genome instability (Hunter et al., 
2006, Johnson et al., 2014, Cahill et al., 2007, Ding et al., 2012). Examination of 
the clonal evolution of primary and relapsed acute myeloid leukaemia (AML) found 
an increase in transversion mutations, and in particular C>A mutations, following 
cytotoxic therapy at relapse (46%) compared with mutations prior to therapy 
(30.7%) (Ding et al., 2012). Consistent with this, in Caenorhabditis elegans, 
cisplatin treatment has been found to lead to a striking, dose-dependent, increase 
in base substitutions - predominantly C>A transversions - as well as an elevated 
rate of dinucleotide substitutions, indels, and structural variants (Meier et al., 2014). 
However, the mutational context of C>A transversions was not explored in the 
analysis of Ding (2012).  
Temozolomide, an alkylating agent, has also been found to leave a somatic imprint 
in the cancer genome in the form of an elevated rate of C>T transitions - primarily 
at CpC and CpT sites (Alexandrov et al., 2013a, Johnson et al., 2014). Analysis of 
primary gliomas revealed that recurrent tumours exhibited evidence of hyper-
mutation, and mutations that could be linked to temozolomide included those in 
RB1 and CDKN2A (Johnson et al., 2014).  
Thus, in these examples, conceivably therapy was not simply acting as an 
exogenous source of mutations, but also as a selection barrier, influencing the 
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evolutionary trajectory of a tumour and its progression to a more aggressive phase. 
Consistent with this notion, in NSCLC, chemotherapy has been found to be 
associated with reduced prevalence of mutations in EGFR (Bai et al., 2012), and 
treatment of colorectal cancer clones with oxaliplatin resulted in the outgrowth of 
previously dormant, resting clones (Kreso et al., 2013).  
1.6.3 Genome instability processes at copy number level 
Genome instability processes and mutational signatures can also be deciphered 
through copy number analysis. Chromosomal instability (CIN), a driving force of 
intercellular genetic heterogeneity, occurs at high frequencies across many 
different cancer types and describes an increased rate of change in chromosome 
number or structure, resulting in a range of karyotypic abnormalities, including 
whole-chromosome and segmental aneuploidies, as well as translocations, 
inversions and deletions.  
A study from our lab found the weighted genome instability index (wGII) – a 
measure capturing the extent of the genome that differs from ploidy – can 
discriminate between chromosomally unstable and stable colorectal cancer cell-
lines (Burrell et al., 2013a). A signature of CIN can also be deciphered from gene 
expression data. Indeed, the CIN70 signature, which encompasses a set of 70 
genes that correlate with an aberrant transcriptional profile (Carter et al., 2006), has 
been found to correlate with structural complexity (defined from SNP microarrays) 
and numerical CIN (as assessed by DNA image cytometry) (Birkbak et al., 2011).  
Chromosomal instability likely arises through multiple mechanisms including both 
pre-mitotic and mitotic defects (Bakhoum et al., 2009, Crasta et al., 2012, Burrell et 
al., 2013a, Janssen et al., 2011, Giam and Rancati, 2015), and is often categorized 
as either numerical CIN or structural CIN. Numerical CIN occurs following the 
missegregation of whole chromosomes at mitosis. Conversely, structural CIN 
results in the disordered integrity of parts of chromosomes. While traditionally 
considered in isolation, recent studies have revealed that both types of 
chromosomal instability can be mechanistically related and reciprocally causative.  
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Gross changes in chromosome structure arising from erroneous DNA repair render 
them susceptible to missegregation (Burrell et al., 2013a, Pampalona et al., 2010), 
and conversely, whole chromosome missegregation due to mitotic defects 
including merotelic attachments, alterations of the spindle assembly checkpoint 
(SAC) and centrosome number and positioning defects (Bakhoum et al., 2009, 
Silkworth et al., 2009, Sotillo et al., 2007), expose chromosomes to mechanical 
stress, DNA damage and erroneous repair, engendering structural CIN (Crasta et 
al., 2012, Janssen et al., 2011). 
The mechanisms underpinning CIN may also leave specific genomic imprints in the 
genome, which can be deciphered from sequencing or SNP6.0 analysis. For 
example, a key source of DNA damage is homologous recombination (HR) 
deficiency, which has been shown to result in a specific copy number profile 
involving loss of heterozygosity (Birkbak et al., 2012, Popova et al., 2012, Abkevich 
et al., 2012). As such, the telomeric imbalance score, assessing the number of sub-
chromosomal regions with allelic imbalance extending to the telomeres is thought 
to be indicative of impaired DNA repair (Birkbak et al., 2012). The clinical 
importance of this HR signature is underscored by the observations that it predicts 
cisplatin sensitivity in vitro and response to preoperative cisplatin treatment in 
patients with triple-negative breast cancer (Birkbak et al., 2012). 
Another likely source of much of the DNA damage in tumours is DNA replication 
stress. DNA replication stress is also thought to lead to a specific copy number 
profile involving enrichment of chromosome breakpoints and loss of heterozygosity 
in cancer genomes at fragile sites (regions of the genome that are particularly 
susceptible to replication stress) (Dereli-Oz et al., 2011). In keeping with the 
importance of replication stress, in general, copy number aberrations are enriched 
around fragile sites, in large genes and often display loss of heterozygosity.  
These studies demonstrate the presence of a number of different mutational 
signatures at the copy number level and highlight the importance of chromosomal 
instability. However, copy number data has not been subject to the same level of 
analysis as SNV data. Moreover, from a biological perspective, it is important to 
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recognise that cellular adaptations are likely to be required for cancer cells to 
tolerate the gross genome remodelling associated with CIN (Mcclelland et al., 2009, 
Gordon et al., 2012), and without such tolerance these signatures would not be 
observed in cancer genomes. Thus, for example, a signature of chromosomal 
instability may not only indicate the presence of karyotypic instability, but also that 
the cancer cell can tolerate it.  
One of the most frequently studied tolerance mechanisms is disruption to TP53, the 
so-called ‘guardian of the genome’ (Lane, 1992). Indeed, it has been found p53 can 
limit the proliferation of cells with an abnormal chromosome complement and it is 
up-regulated in response to an unstable karyotype (Giam and Rancati, 2015). Thus, 
disruption of p53 may facilitate chromosomal instability, permitting cancer genome 
evolution at the chromosomal level. However, it is likely additional tolerance 
mechanisms, beyond TP53 disruption, remain to be elucidated.  
1.6.4 Tetraploidy and whole genome doubling 
Whole genome doubling events have been crucial in the development of many 
different complex traits during organismal evolution, and a number of 
tetraploidisation events have been thought to occur early in vertebrate evolution 
(Huminiecki and Conant, 2012). Moreover, genome-doubling events are thought to 
facilitate the rise of novel gene functions, allowing functional divergence of 
duplicated genes (Huminiecki and Conant, 2012, Adams and Wendel, 2005).  
Whole genome doublings have been documented to occur frequently across a 
range of cancers and can be estimated from allele specific copy number data 
(Carter et al., 2012, Zack et al., 2013). Across common epithelial tumours, 
including colorectal, breast, lung, ovarian and oesophageal, it was estimated that 
genome doubling occurs in approximately 50% of tumours. In this case tumours 
were classified as genome doubled if over 50% of the genome exhibited a major 
allele copy number of at least two.  
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It has been posited that a genome-doubling event may be important as an 
intermediate stage leading to aneuploidy and CIN in cancers (Shackney et al., 
1989, Galipeau et al., 1996). In a seminal study comparing tetraploid and diploid 
cancer cells, it was found that tetraploid cells formed tumours in p53-null nude mice, 
exhibiting both numerical and structural chromosome aberrations, while their 
diploid counterparts did not (Fujiwara et al., 2005). Moreover, tetraploid cells 
generated through cell fusion events resulted in karyotypically diverse tumours in 
mice (Duelli et al., 2007, Nguyen et al., 2009). Likewise, the continual passage of 
tetraploid mouse ovarian cells results in aneuploid progeny (Lv et al., 2012).  
Tetraploid cells have also been observed following telomere crisis, and it has been 
shown that tumours that are initiated by tetraploid cells exhibit more complex 
aneuploidy karyotypes in vivo (Davoli and de Lange, 2012). More recently, 
mathematical modelling of tumour progression in neuroblastomas, combined with 
karyotypic analysis of tumours suggested that an early genome-doubling event was 
the most parsimonious explanation for the chromosomal complement observed in 
neuroblastoma tumours (Lundberg et al., 2013).  
Taken together, these studies suggest genome doubling may be a frequent event 
across cancers. However, the relationship between genome doubling and 
chromosomal instability remains unclear, and the timing of genome doubling across 
cancers is unknown.  
1.7 Clinical implications of intra-tumour heterogeneity  
1.7.1 Tumour sampling bias  
Given that therapeutic decision-making is frequently based on archival tumour 
material or, in cases where patients present with advanced disease, a single 
metastatic sample, tumour sampling bias may present a significant clinical 
challenge (Swanton, 2012). Indeed, if different regions of the same tumour are 
genetically distinct, one sample will not be representative of the tumour and, by 
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extension, if biomarkers are not clonal, sampling bias may confound clinical 
decision-making. 
In support of difficulties associated with validating clinical biomarkers, potentially 
due to sampling bias, it has been documented that while over 150,000 biomarkers 
have been proposed in the literature, approximately only 100 of these are used in 
clinical practice (Poste, 2011). Moreover, evidence for multiple distinct prognostic 
biomarkers within single tumours can be found in KIRC, where seven out of ten 
tumours were found to harbour distinct gene expression signatures, one associated 
with good prognosis, and the other associated with poor prognosis (Gulati et al., 
2014). Likewise, an analysis of 11 glioblastomas revealed that most patients 
harboured multiple different subtypes within the same tumour (Sottoriva et al., 
2013).   
Sampling bias may also lead to underestimates for the prevalence of particular 
mutations in cancers. Notably, in KIRC, an analysis in our lab found that single 
sample analysis suggests the prevalence of mutations in TP53 is only 10%, while 
multi-region analysis, with more complete sequencing of cancer cells, identified 
mutations in TP53 in approximately 40% of tumours (Gerlinger et al., 2014a).   
1.7.2 Heterogeneity and outcome 
1.7.2.1 Clinical relevance of chromosomal instability 
It has long been established that chromosomal instability – resulting in cell-to-cell 
genetic heterogeneity – is associated with poor prognosis across a wide range of 
cancers (see Table 1). For instance, multiple studies in NSCLC using FISH and 
gene expression signatures to measure CIN have found an association between 
CIN status and overall survival, independent of conventional risk factors, including 
tumour stage (Carter et al., 2006, Mettu et al., 2010, Choi et al., 2009). In breast 
cancer, CIN has been linked to poor prognosis and also is enriched in more 
aggressive subgroups of breast cancer, such as ER-negative and triple-negative.  
Chapter 1. Overview of the literature 
 
 59 
Furthermore, evidence has suggested that this form of genomic instability is 
associated with multi-drug resistance in colorectal cancer (Lee et al., 2011a). 
The potential benefits of chromosomal instability, and intra-cellular genetic 
heterogeneity, must be balanced against its potentially deleterious consequences. 
An abnormal chromosome number in yeast and murine systems has been 
demonstrated to be deleterious to normal cells, reducing proliferation (Torres et al., 
2007a, Williams et al., 2008). However, other studies have suggested 
chromosomal instability may redress imbalances in the stoichiometry of protein 
complexes which can result from an abnormal chromosome complement and CIN 
may effectively allow proliferation genes to be hardwired to the genome (Ozery-
Flato et al., 2011). It has thus been proposed there is an optimal level of CIN in 
tumours, beyond which it becomes unfavourable (Swanton, 2012, Cahill et al., 
1999). The notion of extreme CIN being deleterious for tumour development may 
be analogous to ‘mutational meltdown’ in bacteria, or error catastrophe in viruses 
(McGranahan et al., 2012). 
Consistent with excessive levels of CIN having adverse consequences for tumour 
progression, excessive CIN, induced by inactivation of spindle assembly 
checkpoint components, leads to excessive aneuploidy and cell death in human 
cancer cells, and multipolar cell divisions generate non-viable cells that are highly 
aneuploid (Giam and Rancati, 2015). Similarly, mice with reduced levels of CENP-
E – involved in spindle elongation – develop tumours with CIN. However, if CIN is 
increased through depletion of CENP-E in tumours that already had a pre-existing 
level of aneuploidy, the depletion can have tumour-suppressive abilities (Sotillo et 
al., 2007).   
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Table 1-2 Clinical significance of chromosomal instability 
Cancer Type Method of measuring 
CIN 
CIN associated with  Reference 
Lung cancer 
(NSCLC) 
 
FISH  (n=63) Poor prognosis (OS & DFS) (Choi et al., 2009) 
FISH (n=47) Poor prognosis (OS) (Yoo et al., 2010) 
FISH (n=50) Poor prognosis (OS) (Nakamura et al., 2003) 
12-gene signature (n=647) Poor prognosis (OS) (Mettu et al., 2010) 
CIN70 signature (n=62) Poor clinical outcome (Carter et al., 2006) 
Breast cancer SSI (n=890) Poor prognosis (OS) (Kronenwett et al., 
2004) 
SNP (n=313) Poor prognosis (MFS)  (Smid et al., 2011) 
12-gene signature (n=469) Poor prognosis (DFS & 
RFS) 
(Habermann et al., 
2009) 
CIN70 signature (n=1866) Poor clinical outcome (Carter et al., 2006) 
FISH (n=31) Lymph-node metastasis and 
ER negativity.   
(Takami et al., 2001)  
Myelodysplastic 
syndrome 
FISH (n=65) Poor prognosis (DFS)  (Heilig et al., 2010) 
Endocrine 
pancreatic 
tumours  
CGH (n=62) Metastasis  (Jonkers et al., 2005) 
Colon cancer 12 gene genomic instability 
signature (n=92) 
Recurrence of colon cancer (Mettu et al., 2010) 
Flow cytometry/ image 
cytometry (n = 10 126) 
Poor prognosis.  (Walther et al., 2008)  
Ovarian cancer 12-gene genomic instability 
signature  (n=124) 
Poor prognosis (RFS).  (Mettu et al., 2010) 
Endometrial 
cancer 
SNP (n=31) Poor prognosis (OS).  (Murayama-Hosokawa 
et al., 2010) 
Synovial 
sarcoma  
CGH (n=22) Poor prognosis (OS) (Nakagawa et al., 2006) 
Oral cancer 
(SCCs) 
FISH (n=77) Poor prognosis (OS & DFS)  (Sato et al., 2010) 
FISH (n=20) (Loco) regional 
tumour outgrowth  
(Bergshoeff et al., 2008) 
Diffuse Large B-
cell Lymphoma 
Anaphase segregation 
errors(n=54) 
Poor prognosis (RFS) (Bakhoum et al., 2011) 
Cervical cancer CIN70 signature (n=79) Para-aortic nodal relapse (How et al., 2015) 
Abbreviations: NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; FISH, fluorescence in 
situ hybridization; SSI, stem line scatter index; CGH, comparative genome hybridisation; SNP, single-
nucleotide polymorphisms, OS, overall survival; DFS, disease-free survival; MFS, metastasis-free survival; 
RFS, relapse free survival 
Evidence substantiating this hypothesis has been found when further dissecting the 
relationship between CIN and cancer outcome. Specifically, patients who harbour 
tumours with extreme CIN, defined as tumours in the upper quartile of CIN70 
expression, exhibit significantly better prognosis, in terms of recurrence-free or 
distance metastasis-free survival, compared to patients harbouring tumours in the 
third CIN70 expression quartile (Birkbak et al., 2011). This association has been 
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observed in ER negative breast, ovarian, gastric, breast and non-small cell lung 
cancers, but not in ER positive breast cancers (Birkbak et al., 2011).  
1.7.2.2 Clonal heterogeneity and outcome 
One of the first studies to specifically evaluate the clinical relevance of clonal 
heterogeneity adapted diversity measures from ecology and evolution to explore 
whether these could predict progression to adenocarcinoma in the premalignant 
condition Barrett’s oesophagus (Maley et al., 2006). Using the Shannon diversity 
index to capture both the number and abundance of clones, it was found that using 
multiple different types of somatic alterations, clonal diversity was predictive of 
progression to cancer in a large cohort of patients (Maley et al., 2006). These 
results have since been confirmed in an independent cohort of tumours, 
encompassing 239 patients (Merlo et al., 2010).  
More recently, in CLL, it has been found that the presence of subclonal drivers is 
associated with a shorter time to retreatment or death (Landau et al., 2013) while in 
head-and-neck cancer, a measurement capturing the clonal diversity – termed 
mutant allele tumour heterogeneity (MATH) – was found to correlate with poor 
prognosis (Mroz and Rocco, 2013). However, in MDS, the number of driver events 
was the key determinant of outcome, regardless of their clonal status; i.e. the 
presence of a driver was more critical than whether it was subclonal or clonal 
(Papaemmanuil et al., 2013).  
Clonal heterogeneity may also impact upon the efficacy of therapeutic treatments, 
through the presence of subclones harbouring resistance mutations, which may be 
barely detectable at diagnosis. In NSCLC with activating mutations in EGFR 
presence of subclonal gatekeeper T790M resistance mutations are associated with 
shorter progression free survival (Maheswaran et al., 2008, Su et al., 2012). In a 
small cohort of high grade serous ovarian cancers (n=14) treated with platinum-
based chemotherapy a copy number based clonal heterogeneity index was found 
to have predictive value for survival after chemotherapy treatment (Schwarz et al., 
2015). 
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Evidence in colorectal cancer (Diaz et al., 2012), as well as melanoma (Van Allen 
et al., 2014, Shi et al., 2014) suggests that multiple resistance events can occur 
independently in the same tumour. For instance, following BRAF inhibitor therapy 
in BRAF V600 mutant melanoma, resistance mutations in both NRAS and MEK1 
were identified in one tumour while another patient presented with a tumour 
harbouring two distinct NRAS mutations (Van Allen et al., 2014). It has also been 
demonstrated that resistance to BRAF inhibitors can occur through both MAPK 
pathway dependent and PI3K-AKT dependent mechanisms in the same tumour 
simultaneously (Shi et al., 2014). Likewise, in one patient with colorectal cancer, 
through longitudinal tracking of cell free tumour DNA, four distinct KRAS mutations, 
that increased in frequency during the acquisition of resistance to panitumumab 
therapy (targeting EGFR), were detected (Diaz et al., 2012).  
1.8 Summary 
In this chapter, I have provided a literature review of studies exploring cancer 
evolution and heterogeneity in cancer. I have situated this by considering the 
mutational processes that mould the cancer genome at both the single nucleotide 
and whole genome level.  
Taken together, this work demonstrates that clonal diversity and branched tumour 
evolution is an emerging theme across studies. However, a pan-cancer analysis 
exploring the extent of diversity across tumours in a unified way is lacking. 
Additionally, the extent to which a single biopsy may underestimate the extent of 
heterogeneity remains unresolved. Moreover, while mutational processes at both 
the single nucleotide and copy number level have been deciphered, their temporal 
decomposition is unresolved. Finally, while studies have started to shed light on the 
clinical importance of neo-antigens – especially in the context of immune 
modulation – the impact of intra-tumour heterogeneity on this relationship has not 
been investigated.  
In the subsequent chapters of this thesis, I will build upon the work outlined here to 
explore the extent of heterogeneity in human cancers, focussing in depth on 
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NSCLC and oesophageal adenocarcinoma, and how this information can be used 
to understand tumour evolution. I will perform a pan-cancer analysis of somatic 
intra-tumour heterogeneity, exploring the extent to which tumours harbour 
subclonal mutations in driver genes, and, moreover, whether temporal dissection 
can assist in the identification of cancer genes. I will explore the incidence and 
timing of genome doubling across cancers, and systematically investigate the 
effects of a whole genome-doubling event on chromosomal instability and tumour 
evolution in colorectal cancers. Temporal dissection of mutations will be further 
used to shed light on the timing of mutational processes in cancer, revealing which 
likely occur as early events, and which represent later processes. Finally, I will 
investigate the clinical implications of heterogeneity in the context of immune 
modulation.  
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Chapter 2. Experimental procedures 
2.1 Introduction 
While the heterogeneous nature of tumour populations may confound treatment 
success, it may also serve a role in shedding light on tumour evolution.  As 
discussed in the previous chapter, an understanding of the extent of diversity within 
individual tumours can both be used to temporally dissect mutations, and, 
moreover, reveal the type of evolution that has occurred. Thus, an understanding of 
how to dissect the extent of heterogeneity and the evolutionary history of tumours 
is crucial.   
In this chapter, I outline the bioinformatics and experimental methods adopted 
throughout the thesis. First, I briefly describe the main datasets used throughout 
the proceeding chapters.  Second, I explain how heterogeneity is determined and 
measured using both single and multi-region samples. I also provide details 
regarding the analysis of mutational signatures and their temporal decomposition, 
and in addition, I explore how copy number data can be used to infer genome 
doubling. Finally, I provide brief details regarding the analysis of neo-antigens and 
the wet-lab experimental procedures performed.  
2.2 Data used in this thesis 
2.2.1 Multi-region NSCLC data 
The multi-region NSCLC tumours for sequencing were obtained from six patients 
diagnosed with NSCLC who underwent definitive surgical resection prior to 
receiving any form of adjuvant therapy, such as chemotherapy or radiotherapy. 
These samples were collected from University College London Hospital, London 
(UCLHRTB 10/H1306/42) and informed consent had been obtained. Details 
regarding patient characteristics can be found in Table 3-1.  
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2.2.2 Multi-region oesophageal adenocarcinoma data 
Pre-treatment tumour regions were obtained endoscopically from a single tumour 
mass and post-chemotherapy tumour regions were obtained from the surgical 
tumour resection. Patients were treated with neo-adjuvant combination 
chemotherapy and did not receive any concurrent radiation treatment. Details 
regarding patient clinical characteristics can be found in Table 3-2 
2.2.3 TCGA data 
TCGA data was obtained from the TCGA data portal, or, alternatively from the 
broad maf dashboard (https://confluence.broadinstitute.org/display/GDAC/ 
MAF+Dashboard). Information about TCGA and the investigators and institutions 
that constitute the TCGA research network can be found at 
http://cancergenome.nih.gov/. 
2.2.4 Additional lung single sample data 
To explore the mutational spectrum of lung cancer genomes, data was obtained 
from the supplementary tables of Imielinksi et al. (2012).  
2.2.5 Validation data for Genome Doubling 
Validation cohort data was kindly provided by Dr Oliver Sieber, and colleagues at 
the Victorian Cancer Biobank (Australia). Patients were recruited from the Royal 
Melbourne Hospital, Western Hospital Footscray and St Vincent's Hospital Sydney 
in Australia. The study was ethics approved, and patients gave informed consent. 
2.2.6 NSCLCs treated with pembrolizumab 
Samples obtained from Rizvi and colleagues (2015) reflected a patient cohort of 
stage IV NSCLC, and detailed clinical characteristics of this cohort are provided in 
Table 8-11.  
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2.3 Bioinformatics analyses 
All bioinformatics analysis was carried out in the R statistical environment, unless 
otherwise specified.  
2.3.1 SNV calling for TCGA tumours 
For TCGA samples, SNV calling was performed by individual sequencing centres. 
To ensure consistency, further filtering was also applied. Specifically, every SNV 
was filtered to ensure that each variant had at least five tumour reads and 
coverage of ≥30. Only single nucleotide variants were used for analysis (insertions 
and deletions were excluded due lower validation rates). 
2.3.2 SNV calling from multi-region NSCLC WES and WGS data  
The pipeline for multi-region SNV calling was developed by Richard Mitter and 
Gareth Wilson. For multi-region NSCLC tumours, raw paired end reads in FastQ 
format generated by the Illumina pipeline (WES or WGS) were aligned to the full 
hg19 genomic assembly (including unknown contigs), using bwa 0-5.9 (Li and 
Durbin, 2009) with a seed length of 72bp for data sequenced on the GAII and 
100bp for data sequenced on the HiSeq. Up to 3 or 4 mismatches were allowed per 
read for the GAII or HiSeq respectively, and all other settings were left as default.  
Picard tools v1.8 was used to both merge samples from the same patient region 
and to remove duplicate reads (http://picard.sourceforge.net) prior to determining 
sequence coverage (Table 8-1). 
Variant calling was performed between tumour and matched germ-line using the 
“somatic” tool from VarScan2 v2.3.3 (Koboldt et al., 2012). SAMtools mpileup 
output from combined tumour and normal samples generated by skipping bases 
with a phred score of <20 or reads with a mapping-quality <2 was used as input for 
VarScan2.  SAMtools BAQ computation was disabled and the coefficient for 
downgrading mapping quality was set to 50. VarScan2 somatic was run with 
default settings, except for the following: minimum coverage was set to 10 for 
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germline and 6 for tumour regions, the minimum variant frequency for calling a 
heterozygote was set to 0.01 and tumour purity was set to 0.5. Calls were 
subsequently filtered for false positives using Varscan2's fpfilter.pl script, run with 
the settings outlined by Ding (2012). Additionally, variants were only accepted if 
present in ≥ 5% of reads in at least one tumour region and present with ≤2 reads in 
germ-line and ≥ 2 reads in at least one tumour region.  
Small insertions and deletions (indels) were identified using pindel version 0.2.4 
(Ye et al., 2009) in paired tumour-normal mode. Variants were annotated using 
both ANNOVAR (Wang et al., 2010) and dbNSFP (Liu et al., 2011). Each variant 
identified as non-silent was manually reviewed by Elza de Bruin, using Integrated 
Genomics Viewers (IGV) (Robinson et al., 2011).  
Variants not subjected to ultra-deep orthogonal validation were further filtered using 
an in-house filter, VarSLR, developed by Max Salm, which models strand-bias, 
mapping-quality, base-quality and position-in-read in a stepwise logistic regression 
framework. Any substitution identified in dbSNP Build 132 was removed. For the 
WGS data, variants detected in repetitive regions (RepeatMasker, USCS 
genomicSuperDups tracks) or blacklisted by the Encode Mappability were also 
removed from downstream analysis.  
2.3.3 SNV calling from multi-region oesophageal adenocarcinoma tumours 
and NSCLC tumours from Rizvi et al. (2015)   
SNV calling for multi-region oesophageal adenocarcinoma and NSCLC tumours 
obtained from Rizvi et al. (2015) was carried out as described above, with a 
number of modifications. Specifically, bwa mem (bwa-0.7.7) (Li and Durbin, 2009) 
was used for genome alignment. Picard tools v1.107 was used to clean sort and 
merge files from the same patient region and to remove duplicate reads 
(http://broadinstitute.github.io/picard). Quality control metrics were obtained using a 
combination of picard tools (1.107), GATK (2.8.1) and FastQC (0.10.1) 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  
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For those variants not subjected to Ion Torrent validation, further filtering was 
applied whereby variants were only accepted if present in ≥ 5 reads and ≥ 5% 
variant allele frequency (VAF) in at least one tumour region with germ-line VAF ≤ 
1%. If a variant was found to meet these criteria in a single region, then the VAF 
threshold was reduced to ≥ 1% in order to detect low frequency variants. VarSLR 
was not applied to filter mutations.  
All variants were annotated using ANNOVAR (Wang et al., 2010). Variants 
identified as non-silent were manually reviewed using Integrated Genomics 
Viewers (IGV) (Robinson et al., 2011). 
2.3.4 Copy number analysis from multi-region NSCLC 
Copy number processing was performed by Max Salm. For exome data, relative 
copy number was estimated using VarScan2 (v2.2.11) (Koboldt et al., 2012) with 
default parameters, excluding the sex chromosomes and low mapability regions 
(ENCODE 'DAC blacklisted' regions) and adjusting for GC-content. To identify 
genomic segments of constant copy number, logR values were quantile normalized, 
winsorized using the Median Absolute Deviation, and jointly segmented at the 
patient level (gamma = 1000). Integer copy numbers were calculated from relative 
copy numbers using ABSOLUTE (v1.0.6) (Carter et al., 2012). Minimum/maximum 
ploidy was set to within +/-0.5 of the prior ploidy estimate, calculated from the 
sample's FACS-based DNA-index. The top 5 ABSOLUTE models (ranked by log-
likelihood) were retrieved for each exome, and a set of inter-sample models was 
identified that minimized the total pairwise distance derived from the segments' 
expected modal copy-number, whilst maximizing the model’s posterior log 
likelihood. Final model solutions were manually reviewed.  
For multi-region WGS regions ASCAT was used for allele specific copy number 
estimation (Van Loo et al., 2010). Subclonal copy number analysis was performed 
using the Battenberg algorithm and was used as the input for the mutation 
clustering (Nik-Zainal et al., 2012b). 
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2.3.5 Copy number analysis from multi-region oesophageal 
adenocarcinoma 
Processed sample exome SNP and copy number data from paired tumour-normal 
was generated using VarScan2 as described above. Output from VarScan was 
processed using the Sequenza R package 2.1.1 (Favero et al., 2015a) to provide 
segmented copy number data as well as purity and ploidy estimates. The following 
settings were used: breaks.method = 'full', gamma = 40, kmin = 5, gamma.pcf = 
200, kmin.pcf = 200. 
Manual verification was performed on the automatically selected models for ploidy 
and cellularity, and for 6 cases the model fitting was re-run using the second most 
optimum solution returned by Sequenza.  
2.3.6 Copy number analysis from NSCLC exomes from Rizvi et al (2015) 
Processed sample exome SNP and copy number data from paired tumour-normal 
was generated using VarScan2 as described above. Output from VarScan was 
processed using the ASCAT v2 (Van Loo et al., 2010) to provide segmented copy 
number data as well as purity and ploidy estimates The following setting was 
altered from its default value: Threshold for setting ACF to 1 was adjusted from 0.2 
to 0.15 and the package was run with gamma setting of 1. 
2.3.7 Estimating allele specific integer copy numbers in TCGA samples 
Affymetrix SNP6 data from paired tumour-normal samples were normalized and 
pre-processed to obtain logR and B-allele fractions (BAF) using the Aroma 
Affymetrix CRMAv2 algorithm (in the allele-specific setting) (Bengtsson et al., 2009). 
The BAF was subsequently further adjusted using the CalMaTe and TumourBoost 
algorithms (Ortiz-Estevez et al., 2012, Bengtsson et al., 2010). Tumour copy 
number aberrations, ploidy and normal cell contamination was then determined 
using either ASCAT (Van Loo et al., 2010) or OncoSNP (Yau et al., 2010) with 
normal samples as references and hg19 coordinates. Sex chromosomes were 
Chapter 2. Experimental procedures 
 
 71 
excluded from all analysis. Samples that failed ASCAT processing due to poor 
model fit were discarded from all subsequent analysis. 
Cell-lines were also analysed with Affymetrix SNP6.0 arrays.  In this case, PICNIC 
(Greenman et al., 2010) was used for both normalization and integer copy number 
estimation.  
Validation cohort for COAD analysis was performed on Illumina 610 Quad arrays.  
LogRs and BAFs were obtained using GenomeStudio V2011.1 and Genotyping 
Module V1.9.4. For QC, samples with moving standard deviation >0.28 were 
discarded. Integer copy numbers were estimated using OncoSNP (Yau et al., 
2010). 
Ploidy was estimated for each tumour sample by summing the weighted median 
integer copy for each chromosome and dividing by number of chromosomes 
analysed (n=22). The number of chromosomes in each sample was estimated by 
summing the modal copy numbers from the segmented copy number profile of 
each chromosome. Each segment was weighted according to the number of base 
pairs it covered. Copy number segments of loss and gain were defined relative to 
ploidy. wGII was calculated as in (Burrell et al., 2013a), by calculating the 
proportion of each chromosome that different from the genome median ploidy, and 
calculating the average across chromosomes.  
2.3.8 Estimating the cancer cell fraction of TCGA mutations 
As discussed in the Introduction, the variant allele frequency of a mutation is 
dependent on the copy number at the mutated site in the cancer cells, the copy 
number at the mutated site in the normal cells, the number of copies of the 
mutation itself, the purity of the cancer sample (i.e. the stromal contamination) and, 
finally, the fraction of cancer cells that harbour the mutation. If the variant allele 
frequency (obtained from VarScan2), the purity and local copy number (estimates 
from ASCAT) are known, the cancer cell fraction can be estimated.  Specifically, 
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the relationship between copy-number, purity and variant allele frequency can be 
described by the following formula: 
Expected VAF (CCF) = p*CCF / CPNnorm (1-p) + p*CPNmut. 
Where CPNmut corresponds to the local copy number of the tumour, p is the tumour 
purity and CPNnorm  is the local copy number of the matched normal sample. For a 
given mutation with ‘a’ alternative reads, and a depth of ‘N’, the probability of a 
given CCF can be estimated using a binomial distribution P(CCF) = binom(a|N, 
VAF(CCF)). CCF values can then be calculated over a uniform grid of 100 CCF 
values (0.01,1) and subsequently normalized to obtain a posterior distribution over 
the CCF. The 95% confidence intervals of the cancer cell fraction can be obtained 
from this distribution. Given that sex chromosomes were excluded from this 
analysis CPNnorm was assumed to be 2. 
Similarly, the mutation copy number, nmut, (the number of chromosomal alleles 
harbouring the mutation) can be calculated as follows: 
nmut = (VAF/p)*((p*CNt)+CNn*(1-p)) 
To ensure the number of subclonal mutations was not overestimated, a 
conservative method for subclonal classification was utilized for TCGA samples. 
Any mutations was classified as clonal (present in all tumour cells sequenced) if the 
upper band of the 95% cancer cell fraction confidence interval was ≥1 and 
subclonal otherwise.  
2.3.9 Estimating the cancer cell fraction of multi-region NSCLC 
For multi-region NSCLC, the cancer cell fraction was estimated using a multi-
dimensional Dirichlet process. This process was implemented by David Wedge.  
In brief, subclonal clusters were identified using a Markov Chain Monte Carlo 
(MCMC) implementation of the Dirichlet process. Based on the MCMC assignment 
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of mutations to clusters, the most likely configuration was obtained using a 
stepwise, greedy expectation-maximization (EM) algorithm. The best set of clusters 
was chosen using the Bayesian information criterion. Clusters containing less than 
1% of mutations identified in a tumour were excluded from further analysis.  
2.3.10 Estimating the cancer cell fraction of multi-region oesophageal 
adenocarcinoma and NSCLC from Rizvi et al. (2015) 
For each mutation, reference read counts were first corrected for copy number and 
purity using a modified version of the methods described above. In brief, the 
mutation copy number, nmut, was first calculated for each mutation using the 
formula described above. The expected copy number, nchr was then determined 
using maximum likelihood. Notably, the expected copy number could take the form 
of a subclonal copy number. An estimate of the cancer cell fraction was obtained 
by dividing nmut by nchr. This therefore yielded cancer cell fraction estimates 
corrected for clonal and subclonal copy number and purity  
Next, cancer cell fraction estimates were grouped using the PyClone Dirichlet 
process clustering (Roth et al., 2014). Mutations were clustered based on modified 
total read depth as well as the observed alternative read depth. The modified read-
depth was set such that the alternative read depth divided by the total read depth 
was equal to the cancer cell fraction calculated. Given that copy number and purity 
had already been corrected, integer copy numbers were set to 1 and purity to 1, 
allowing clustering to simply group clonal and subclonal mutations. PyClone was 
run with 10,000 iterations and a burn-in of 1000, and default parameters.  
2.3.11 Identification of SNV heterogeneity driven by copy number alterations  
For multi-region NSCLC mutation heterogeneity that could be driven by copy 
number heterogeneity was evaluated by visual inspection of copy number profiles. 
However, for oesophageal adenocarcinoma tumours a more systematic approach 
was devised.  
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For each tumour any SNV residing in a genomic segment of copy number 
heterogeneity across multiple tumour regions was identified, with minor and major 
copy number aberrations considered separately. For each chromosome, mutations 
were grouped into non-contiguous genomic segments with consistent copy number 
states within tumour regions and within SNV clusters defined above.  
In order to restrict the analysis to mutations lost in at least one tumour region, the 
median CCF value of each SNV group was then determined, and only SNV groups 
where the median CCF value was <=0.25 in at least one tumour region were 
considered. Whether copy number loss coincided with lower CCF levels was 
assessed using a one-sided Wilcoxon test or, if more than two copy number states 
were present across tumour regions, a one-sided Cochrane-Armitage trend test. To 
ensure the lower CCF value was driven by copy number and not simply which 
tumour region harboured the mutation, a regression analysis was also 
implemented, including both copy number and region in the model. In total, across 
all oesophageal tumour regions, 100 mutations were filtered as being driven by 
copy number change. 
2.3.12 Phylogenetic tree analysis of NSCLC multi-region tumours 
The phylogenetic relationships between tumours subclones were inferred using 
Maximum Parsimony as implemented in the MEGA5 package (Tamura et al., 2011). 
For each tumour, every identified mutation (both non-silent and silent) was used as 
input. In cases where subclonal analysis of given tumour region revealed 
considerable subclonal diversity, this region was divided into a major and a minor 
subclone based on the mutation clusters described above. In addition, in cases 
where there was evidence for ubiquitous mutations becoming heterogeneous due 
to regional copy number losses, mutations were considered ubiquitous prior to tree 
reconstruction.  
Maximum parsimony trees were inferred using the max-mini branch-and-bound 
algorithm calculating branch lengths with the average pathway method. The 
germline sample was designated as the outgroup, and, in the event of multiple 
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optimal topologies, a consensus tree was constructed by collapsing branches 
reproduced in less than 50% of the trees.  
2.3.13 Phylogenetic tree analysis of oesophageal adenocarcinoma multi-
region tumours 
Two types of phylogenetic trees were constructed for oesophageal 
adenocarcinoma tumours, region-trees and subclones trees. Region trees were 
constructed above using a Maximum Parsimony approach, treating each region as 
a separate species.  
For subclonal cluster trees, the pigeonhole principle was used (Nik-Zainal et al., 
2012a). That is, in each region if two subclonal clusters have a combined cancer 
cell fraction greater than 100% the smaller subclonal cluster must be nested within 
the larger. For each region, each possible subclonal structure was delineated, and 
this was compared across tumour regions to give a final subclonal relationship 
based on all tumour regions. Subclones that were incompatible with the 
phylogenetic relationship were removed. To illustrate this process, consider the 
following four clusters identified in three tumour regions. Cluster 1 is present in 
100% of cells in all tumour regions. Cluster 2 is present in 90% of cells in region R1 
and R2, and present in region 20% of cells in region R3. Conversely, cluster 3 is 
present in 80% of cells in region R3, but not present regions R1 and R2. Cluster 4 
is present in 70% of cells in region R1 and R2 and 15% of cells in R3. Given that a 
tumour region cannot contain more than 100% of cells, and cluster 1 is present at 
100% in all tumour regions, this cluster must represent the trunk node, with all 
other clusters contained within it. Cluster 2 and cluster 3 when combined never 
exceed 100% and so may represent separate branches of the phylogenetic tree. 
Cluster 4 must be contained within cluster 3 as their combined sum exceeds 100% 
in regions R1 and R2, yielding a complete phylogenetic relationship.  
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2.3.14 Classification of known driver mutations in multi-region NSCLC 
In order to identity putative driver mutations, all genes harbouring non-silent 
mutations were compared with lists of potential driver genes in NSCLC, containing 
all genes identified as frequently mutated by large-scale lung cancer sequencing 
studies (Ding et al., 2008, Govindan et al., 2012, Imielinski et al., 2012, The Cancer 
Genome Atlas Research Network, 2012) or large-scale pan-cancer analyses 
(Lawrence et al., 2014, Davoli et al., 2013) using q<0.05 as cut-off, or present in 
the COSMIC cancer gene census (downloaded February 2013). For genes with a 
non-silent mutation identified in the tumours by multi-region sequencing that were 
present in one of these lists, whether the amino acid substitution had been 
previously identified in COSMIC was explored. In addition, when available, 
functional prediction scores (SIFT, Polyphen2, LRT and MutationTaster) were used 
and a mutation was scored as ‘deleterious’ when at least two out of the four 
predictors classified the mutation as deleterious. Finally, all non-silent mutations 
were grouped into four distinct categories. Category 1, ‘high confidence driver 
mutations’, contained all disrupting mutations (nonsense, frameshift, splicing or 
‘deleterious’ missense) in tumour suppressor genes or activating amino acid 
substitutions in oncogenes as described in the literature. Category 2, ‘putative 
driver mutations’, on the other hand, represented all other amino acid substitutions 
located at the same position or up to 5 amino acids away from a substitution 
present in COSMIC. Category 3, ‘low confidence driver mutations’, contained all 
other non-silent mutations in genes that were present in the lists of cancer-related 
genes described above. Finally, category 4, ‘unknown significance’, contained the 
remaining non-silent mutations. 
2.3.15 Identification and classification of driver mutations in oesophageal 
adenocarcinoma 
Driver mutations in oesophageal adenocarcinoma were identified as above, with 
the substitution of lung specific genes with those identified in previous oesophageal 
sequencing studies (Dulak et al., 2013).  
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2.3.16 Classification of known driver mutations in TCGA tumours  
Driver mutations were classified as non-silent mutations residing in genes 
representing the intersection of genes identified by the recent Lawrence analysis 
(Lawrence et al., 2014) and those residing in the cancer gene census (Futreal et al., 
2004).  
2.3.17 Identification of novel cancer genes using temporal analysis 
To identify novel cancer genes, for each cancer type, MutSigCV was applied to all 
mutations as well as to ‘early’, ‘late’, clonal and subclonal mutations separately. A 
q-value threshold of 0.05 was adopted. For each run of MutSigCV only samples 
with at least 5 mutations within a given category were used and only genes with at 
least 10 non-silent mutations were considered.  MutSigCV was implemented using 
default settings, using hg19 coordinates and the covariates and coverage tables 
provided (assuming full exome coverage).  
2.3.18 Intra-tumour heterogeneity index in NSCLC and oesophageal 
adenocarcinoma 
An intra-tumour heterogeneity index was calculated for each tumour. The index 
was calculated by firstly calculating for each tumour the proportion of 
heterogeneous mutations, relative to total number of mutations, for each possible 
pairwise comparison of tumour regions. The index was then determined by 
assessing the mean value across each pairwise comparison.  
2.3.19 Permutation testing to assess clonal enrichment 
In order to assess whether a specific gene had an enrichment or depletion of 
clonal/subclonal mutations a permutation test was devised. Consider a cancer 
gene with 50 non-silent mutations across 500 separate samples. Of these 50 
mutations, 35 are clonal and 15 subclonal. To assess whether this gene exhibits an 
enrichment or depletion in clonal mutation 50 non-silent mutations are randomly 
sampled from 500 samples 10,000 times to obtaining a background distribution 
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representing the expected proportion of clonal/subclonal mutations. A p-value can 
then be obtained by comparing the observed proportion of clonal/subclonal 
mutations with this background distribution.  
2.3.20 Temporal dissection of mutations of multi-region tumours 
For each multi-region sequenced tumours, each mutation was classified as ‘early’ 
or ‘late’ based on whether it was located on the trunk or branch of the phylogenetic 
tree, with all truncal mutations classified as ‘early’ and any branch mutation as ‘late’. 
Mutation copy number estimates calculated as described above were used to time 
mutations relative to genome doubling. Only regions with at least two copies of the 
major allele were used, whilst regions where the minor allele was equal to one 
were excluded. Any mutations that had an estimated mutation copy number >1 was 
considered to have occurred before doubling, and all copy number 1 mutations as 
after doubling. Chi-square tests were used to compare the mutation spectra of the 
six mutations types (C>A, C>G, C>T, T>A, T>C, T>G).  To compare the relative 
frequency of specific mutation types a two-sided Fisher’s exact test was used.  
APOBEC enrichment was assessed as described below. 
2.3.21 Temporal dissection of mutations in TCGA samples 
For each single-region TCGA sample, it was not possible in these to construct 
phylogenetic trees as described above. Therefore mutations were classified as 
early or late based on their clonal status and when possible mutations were timed 
relative to copy number events. 
In brief, for timing mutations relative to copy number events, analysis was restricted 
to mutations occurring in regions with at least two copies of the major allele. For 
any such region, mutations at mutation copy number >1 were classified as ‘before 
event’ and any mutations with a mutation copy number of 1 were classified as ‘after 
event’.  Combining this with cancer cell fraction estimates (see above), all clonal 
mutations that were not classified as ‘after event’ were aggregated as ‘early’, whilst 
all subclonal or ‘after event’ mutations were aggregated as ‘late’.  
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2.3.22 Estimating smoking strand bias 
Strand bias was calculated based on annotating each C>A mutation as to whether 
it fell on the transcribed or untranscribed strand in the UCSC hg19 gene track 
(available from http://genome.ucsc.edu/cgi-bin/hgTables). TCGA Samples, grouped 
according to histology and smoking status, were considered in aggregate. Two-
sided Fisher’s exact tests were used to determine significance. 
2.3.23 Detecting an APOBEC mutation pattern 
To detect an APOBEC mutation pattern the methods outlined by Roberts et al 
(2013) were utilized. In brief, the enrichment ETCW relating to the strength of 
mutagenesis at the TCW motif across the genome was calculated as follows:  
ETCT =
mutationsTCW × contextCorG
mutationsCorG × contextTCW
 
where mutationsTCW is the number of mutated cytosines (and guanines) falling in a 
TCW (or WGA) motif, mutationsC (or G) is the total number of mutated cytosines (or 
guanines), contextTCW is the total number of TCW (or WGA) motifs within a 41-
nucleotides region centred on the mutated cytosines (and guanines) and contextC 
(or G) is the total number of cytosines (or guanines) within the 41-nucleotides region 
centred on the mutated cytosines (or guanines). Only specific base substitutions 
were included (TCW to TTW or TGW, WGA to WAA or WCA, C to T or G, and G to 
A or C).  
Over-representation of APOBEC signature mutations in each sample was 
determined using a two-sided Fisher's exact test comparing the ratio of the number 
of cytosine-to-thymine or cytosine-to-guanine substitutions and guanine-to-adenine 
or guanine-to-cytosine substitutions that occurred in and out of the APOBEC target 
motif (TCW or WGA) to an analogous ratio for all cytosines and guanines that 
reside inside and outside of the TCW or WGA motif within 41-nucleotide region 
centred on the mutation cytosine (and guanine). P-values were corrected using 
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Benjamin-Hochberg multiple testing correction, and a significance threshold of 
q<0.05.  For each sample, APOBEC mutation enrichment was determined for all 
mutations, ‘early’ mutations and ‘late’ mutations separately.  
2.3.24 Detecting a platinum mutation pattern 
As discussed in the Introduction, previous work (Meier et al., 2014) has 
demonstrated the propensity for platinum exposure to lead to C>A transversion 
mutations within a CpC context. To detect a platinum mutation pattern the methods 
outlined for APOPEC enrichment, described above, were adapted. The enrichment 
ECpC relating to the strength of mutagenesis at the CpC motif across the genome 
was calculated as follows: 
E = (mutationsCpC * contextC) / (mutationsC * contextCpC) 
where mutationsCpC is the number of mutated cytosines (and guanines) falling in a 
CpC (or GpG) dinucleotide, mutationsC (or G) is the total number of mutated 
cytosines (or guanines), contextCpC is the total number of CpC (or GpG) 
dinucleotides within a 41-base region centred on the mutated cytosines (and 
guanines) and contextC (or G) is the total number of cytosines (or guanines) within 
the 41 base region centred on the mutated cytosines (or guanines). A two-sided 
Fisher’s exact test was used to determine if an overrepresentation of platinum 
signature mutations was present in each sample. The test compared the ratio of 
the number of cytosine-to-adenine and guanine-to-thymine substitutions that 
occurred in and out of the CpC (GpG) platinum target dinucleotide to an analogous 
ratio for all cytosines and guanines that reside inside and outside of the CpC or 
GpG dinucleotide within 41 base region centred on the mutation cytosine (and 
guanine), representing the genomic background. P-values were adjusted using 
Benjamin-Hochberg multiple test correction. A two-tailed Fisher’s exact test was 
performed to compare for platinum enrichment between the pre- and post-
chemotherapy samples. 
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2.3.25 Mutational signature analysis in TCGA tumours 
For each cancer type, mutational signature analysis was implemented separately 
on early and late mutations, as well as on all mutations. To ensure sufficient 
statistical power, mutations classified as ‘early’ or ‘late’ rather than simply clonal 
and subclonal were used.  
Hierarchical clustering was used to ensure the same signatures were identified in 
early, late mutations and all mutations. Each signature identified was then 
hierarchically clustered together with the signatures identified in Alexandrov et al. 
(2013a) and visually inspected to ensure a good fit. Tumours were classified as 
harbouring a mutational signature if at least 25% of mutations or over 100 
mutations were found to belong to a given signature (as in (Alexandrov et al., 
2013a)).  
Finally, to compare the prevalence of mutational signatures in early and late 
mutations a paired Wilcoxon test was used, comparing, for each tumour, the 
proportion of mutations that corresponded to a given signature in their early and 
late mutations. Only samples that harboured at least 10 early and 10 late mutations 
were considered. A small number of samples with outlier mutation signatures were 
identified and discarded so as to avoid biasing mutational signature interpretation 
(e.g. one HNSC sample with a prevalent UV-signature).   
2.3.26 Mutational signature analysis in TCGA oesophageal tumours 
The deconstructSigs package for R, which determines the contributions from a 
given set of mutational signatures to an individual tumour sample, was used to 
explore mutational signatures in TCGA oesophageal tumours. As above, for each 
tumour sample, the package was applied separately to all, early and late mutations. 
Comparisons between signatures were also performed as described above.    
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2.3.27 Genome doubling algorithm 
A modified version of a published algorithm (Carter et al., 2012) was used to 
estimate the prevalence of genome doubling. Each sample, s, was represented as 
an aberration profile of major and minor allele copy numbers at chromosome arm 
resolution. From this profile, Ns, the total number of aberrations (relative to diploid) 
and Ps, the probabilities of loss/gain for each allele at each chromosome arm were 
calculated. 10,000 simulations were then run for each sample s. In each simulation, 
Ns sequential aberrations, based on Ps, were applied to a diploid profile. A p-value 
for genome doubling was obtained by counting the percentage of simulations 
where the proportion of chromosome arms with a major allele copy number ≥2 was 
higher than that observed in the sample. Different p-value thresholds were used 
depending on the ploidy of the tumour. For samples with ploidy ≤3, a p-value 
threshold of 0.001 was used. A p-value ≤ 0.05 was used if ploidy=4, and all 
samples where ploidy≥5 were classified as genome-doubled.  
2.3.28 Estimating timing of genome Doubling 
Each genome-doubled sample was represented as an array of genotype 
proportions reflecting copy numbers ranging from zero to eight. Sixteen possible 
genotypes were discriminated: zero copies, A|B (1 copy); AA|BB and AB (2 
copies); AAA|BBB and AAB|ABB (3 copies)…. (where A and B represent the two 
parental alleles).  
To explore the timing of genome doubling, only losses to two copies (AA, BB, AB) 
were used as these can either reflect losses before (AA or BB) or after genome 
doubling (AB). Samples with a higher proportion AB compared to AA/BB were 
classified as having genome doubled before the majority of losses, whereas those 
where AA/BB > AB were classified as having genome doubled after the majority of 
losses  
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2.3.29 Significance of correlation between wGII and copy number loss 
Based on the observed probability for loss, given by the percentage of genome that 
was identified as lost relative to the ploidy in that sample, an aberration state (loss 
or no loss) was calculated for each sample separately. A point-biserial correlation 
between aberration state and wGII was then calculated across samples. This 
process was repeated 10,000 times and a p-value was obtained for each gene by 
counting the percentage of simulations showing a greater correlation coefficient 
than that observed for that gene.  
2.3.30 Shannon diversity index in genome-doubled and non-genome doubled 
colonies 
Based on data from clonal FISH data from chromosome 2 and 8, the Shannon 
diversity index was calculated using the following formula: 
SD =  −  𝑝! ln 𝑝!!!!!  
where pi is the proportion of colonies with a mode i. The Shannon diversity index 
quantifies the uncertainty in predicting the chromosome complement from a colony 
that is taken at random from the population. For example, if the colony modes of 
chromosome 2 and 8 are always diploid the SD will be 0. Conversely, if the colony 
modes differ greatly, the SD will be a larger number.  
2.3.31 HLA typing of patient samples 
The 4-digit HLA type of each TCGA patient was determined using POLYSOLVER 
(POLYmorphic loci reSOLVER)(Shukla et al., In press). Patients L011 and L012 
were serotyped and simultaneously genotyped using Optitype (Szolek et al., 2014), 
which produced concordant results. 
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2.3.32 Identification of putative neo-antigens 
Identified non-silent mutations were used to generate a comprehensive list of 
peptides 9-11 amino acids in length with the mutated amino acid represented in 
each possible position. The binding affinity of every mutant peptide and its 
corresponding wild-type peptide to the patient’s germline HLA alleles was predicted 
using netMHCpan-2.8 (Hoof et al., Nielsen et al., 2007).  Candidate neo-antigens 
were identified as those with a predicted binding strength of < 500 nM. 
2.3.33 Survival analyses 
Survival curves were plotted according to the Kaplan Meier method. Log-rank test 
statistics were used to assess significance for univariate analysis. Cox proportional 
hazards regression models were conducted for multivariate survival analysis (R 
package survival). 
2.4 Experimental work 
While I carried out the bioinformatics work described in this thesis, unless 
otherwise indicated, Elza de Bruin, Sally Dewhurst and Andrew Furness carried out 
the experimental work.  
2.4.1 Cell culture  
Cell culture was performed by Sally Dewhurst. HCT-116 was obtained from the 
Cancer Research UK cell services facility. STR DNA fingerprinting for HCT-116 
was carried out in October 2010. The HCT-116_MLH1.3 was STR fingerprinted in 
February 2010 and was a gift of Françoise Praz, with similar results to HCT-116 
except at vWA. Cell lines were maintained at 37°C in 5% CO2 in Dulbeco’s 
Modified Eagle medium (DMEM) media (1X), High Glucose with L-Glutamine 
(Gibco, Invitrogen), with 10% foetal bovine serum (FBS) and 1xPenStrep (Sigma). 
During long-term culture, clones were passaged approximately once a week, and 
clones were always split at the same dilution. All passage numbers described 
within the thesis are within <4 passages of the numbers represented in figures. 
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CellTiter-Blue® (Promega) assays were performed following the manufacturers 
instructions. Cloning efficiency was estimated using the Poisson distribution as 
follows: Efficiency =  (-100) * ln(#of wells with no colony / total number of wells)%. 
Under the assumptions that the expected proportion of colonies accurately 
approximates the true efficiency and that the observed proportion of failures 
approximates the probability of zero growth in a single well (as described in (Leight 
and Sugden, 2001)). 
2.4.2 Fluorescence Activated Cell Sorting (FACS) 
FACS analysis was carried out by Sally Dewhurst. Cells were stained with 10µg/ml 
Hoescht 33342 (Sigma) for 1hr at 37°C. A MofLo (Beckman Coulter) cell sorter was 
used, with a 100mW JDS Uniphase XCyte pulsed UV laser, emitting at 355nm. 
Single cells were sorted into 96 well plates containing 20% FBS media. Genome 
doubled clones were expanded before assessment of DNA content by flow 
cytometry using either Propidium Iodide (Sigma) with RNase (Life Technologies), 
or Hoescht 33342, after fixation in 70% Ethanol. 
2.4.3 Clonal FISH, metaphase spreads & immunofluorescence of genome 
doubled and non genome doubled clones 
FISH was performed probing for chromosomes 2 (CEP2 D271, SO), and 8 (CEP8, 
D872, SGn, both Abbott Molecular probes) and was carried out as previously 
described (Burrell et al., 2013a). Slides were either scored semi-automatically 
using the Ariol system (Leica Microsystems). After a low magnitude scan (5x) 
discrete colonies were selected and scanned at a higher magnification (40x). Nine 
stacks of 0.7µm were taken through each colony. Analysis was performed utilizing 
the automated SPOT assay before manual curation. An Olympus DeltaVision RT 
microscope (Applied Precision, LLC) equipped with a Coolsnap HQ camera with an 
Olympus ×100, ×60 or x40 1.4 numerical apertures UPlanSApo oil immersion 
objective was used to score slides. As previously described (Burrell et al., 2013a), 
metaphase spreads were prepared and probed with an all-human centromere 
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probe (Posiedon)]. Finally, immunofluorescence and segregation error 
classification were performed as previously described (Burrell et al., 2013a).  
2.4.4 H2B-mRFP transfection and live-cell imaging analysis 
H2B-mRFP cells: cells were transfected with pH2B-mRFP (gift from A. Straube) 
using Fugene 6.0 (Promega), and selected in 1 mg ml−1 G418 (Life technologies) 
before flow-sorting for mRFP expression. Cells were maintained in 
500µg ml−1 G418. Cells were imaged in an 8 well imaging chamber (LabTek). 
Fourteen-micrometre z-stacks were recorded using an Olympus ×40 1.3 numerical 
aperture UPlanSApo oil immersion objective using a DeltaVision microscope in a 
5% CO2 atmosphere at 37°C. Stills were captured every 3mins for 6hrs and every 
15mins thereafter, for approx. 60 hours. Analysis was carried out with Softworx 
Explorer (Applied Precision, LLC). Daughter cells were scored as arrested if they 
failed to undergo division within 48 hours of the first division. Multipolar divisions 
were excluded from analysis. 
2.4.5  APOBEC3B expression analysis 
Total RNA was isolated from tumour regions of which fresh frozen material was 
available (L001, L002, L003, L004 and L011), using the AllPrep DNA/RNA kit from 
Qiagen according to the manufacturer’s instruction, and used to synthesize cDNA. 
The cDNA was then amplified using APOBEC3B Taqman Assay (Applied 
Biosystems) on a 7500 FAST Real Time PCR machine (Applied Biosystems). 
Taqman Assays for the housekeeping gene TBP. APOBEC3B expression was 
normalised towards TBP, and the fold-change in expression was determined 
against the expression in the adjacent normal lung. 
2.4.6 MHC multimer generation and combinatorial encoding-flow cytometry 
analysis  
MHC-multimers holding the predicted neo-antigen were produced in-house at 
Technical University of Denmark, in the laboratory of Sine R. Hadrup. HLA 
molecules matching the HLA-expression of L011 (HLA-A1101, A2402, and B3501) 
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and L012 (HLA-A1101, A2402, and B0702) were refolded with a UV-sensitive 
peptide, and exchanged to peptides of interest following UV exposure (Toebes et 
al., Bakker et al., Frosig et al., Chang et al.). Briefly, HLA complexes loaded with 
UV-sensitive peptide were subjected to 366-nm UV light (CAMAG) for one hour at 
4°C in the presence of candidate neo-antigen peptide in a 384-well plate. Peptide-
MHC multimers were generated using a total of 9 different fluorescent streptavidin 
(SA) conjugates: PE, APC, PE-Cy7, PE-CF594, Brilliant Violet (BV)421, BV510, 
BV605, BV650, Brilliant Ultraviolet (BUV)395 (BioLegend). MHC-multimers were 
generated with two different streptavidin-conjugates for each peptide-specificity to 
allow a combinatorial encoding of each antigen responsive T cells, enabling 
analyses for reactivity against up to 36 different peptides in parallel (Hadrup et al., 
Andersen et al.). 
2.4.7 Identification of neo-antigen-reactive CD8+ T cells 
MHC-multimer analysis was performed on in-vitro expanded CD8+ T lymphocytes 
isolated from lung tumour regions and adjacent normal lung tissue. 290 and 355 
putative epitopes (with predicted HLA binding affinity <500nM, including multiple 
potential peptide variations from the same missense mutation) were synthesized 
and used to screen expanded L011 and L012 tumour infiltrating lymphocytes (TILs) 
respectively. For staining of expanded CD8+ T lymphocytes, samples were thawed, 
treated with DNAse for 10 min, washed and stained with MHC multimer panels for 
15 min at 37°C. Subsequently, cells were stained with LIVE/DEAD® Fixable Near-
IR Dead Cell Stain Kit for 633 or 635 nm excitation (Invitrogen, Life Technologies), 
CD8-PerCP (Invitrogen, Life Technologies) and FITC coupled antibodies to a panel 
of CD4, CD14, CD16, CD19 (all from BD Pharmingen) and CD40 (AbD Serotec) for 
an additional 20 min at 4°C. Data acquisition was performed on an LSR II flow 
cytometer (Becton Dickinson) with FACSDiva 6 software. Cut-off values for the 
definition of positive responses were ≥0.005% of total CD8+ cells and ≥10 event 
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Chapter 3. Evidence and extent of intra-tumour 
heterogeneity 
3.1 Introduction 
Accumulating evidence suggests intra-tumour heterogeneity may be widespread 
across human cancers. The extent of this diversity within tumours has important 
clinical implications. For instance, in colorectal cancer, subclonal mutations in the 
oncogene RAS have been shown to precipitate resistance to cetuximab (Misale et 
al., 2012), while in NSCLC, subclonal EGFR T790M mutations are associated with 
resistance to EGFR-TKI (tyrosine kinase therapy) (Kobayashi et al., 2005). Further 
complicating the issue, the use of targeted therapy against a subclonal driver 
mutation, present in a subset of cancer cells within a tumour`, may lead to 
stimulation of wild-type subclones which lack the actionable alteration (Lohr et al., 
2014). 
Targeting clonally dominant somatic events, present in all tumour cells, or adopting 
combinatorial targeted therapy approaches, may therefore be necessary for optimal 
tumour control (Yap et al., 2012a). However, although the clonal status of driver 
mutations has received attention in certain cancers (Papaemmanuil et al., 2013, 
Bolli et al., 2014, Lohr et al., 2014, Shah et al., 2012, Nik-Zainal et al., 2012b, 
Landau et al., 2013, Gerlinger et al., 2012, Gerlinger et al., 2014a), a broad 
understanding of the heterogeneity of mutations in cancer genes, and deciphering 
their clonal and subclonal frequencies, is lacking.  
More generally, an understanding of the patterns of cancer evolution may begin to 
shed light on whether rules dictating progression of cancers can be discerned. 
Such rules may inform clinical practice, and reveal novel avenues for drug 
discovery and clinical trial design. Relatedly, there is a need to understand the 
impact of therapy itself on tumour evolution and the extent of diversity within 
tumours.  
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In this chapter I explore the degree of intra-tumour heterogeneity across ten major 
cancer types. I make use of next-generation sequencing data from both multi-
region sampling and single tumour sample data to quantify intra-tumour 
heterogeneity and tumour evolution. I investigate the extent to which both driver 
and passenger mutations are clonal or subclonal across cancers, focussing on 
heterogeneity at the single-nucleotide level. In addition, heterogeneity within 
tumours is used to time the acquisition of driver events in cancer evolution, 
revealing which events may be crucial for tumour transformation, whilst also 
shedding light on others which may play important roles in tumour progression and 
metastasis. Finally, I investigate the impact of neo-adjuvant platinum chemotherapy 
on tumour evolution and intra-tumour heterogeneity in oesophageal 
adenocarcinoma.  
The data presented in this chapter of the thesis largely forms sections of three 
separate publications (McGranahan et al., 2015, de Bruin et al., 2014, Murugaesu 
et al., 2015), which can be found in Appendix 2.    
3.2 Results 
3.2.1 Multi-region sequencing data to explore heterogeneity in NSCLC 
To determine the degree of heterogeneity in NSCLC, 27 regions from tumours 
derived from six patients were subject to whole-exome or whole genome 
sequencing, as well as matched germ-line blood or normal tissue. On average, 4 
tumour regions were sequenced per patient (range 3-6), to mean coverage depths 
of 107X for exome and 96X for whole genome (Table 8-1). Likewise, matched 
germ-line blood was sequenced to mean coverage depth of 98X for exome and 
38X for whole genome.  
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Table 3-1 Clinical characteristics of multi-region NSCLC 
Patient 
ID 
Age 
(years) 
Gender Histology Lymph 
node(s)/ 
location 
Stage 
(I-IV) 
Regions 
sequenced 
Smoking 
status 
(pack-
years*) 
L003 84 F LUAD 2/Station 4 IIIB R2 (RLL), R4 
(RUL), LN 
never- 
smoker 
L008 75 M LUAD 2/Hilar IIIA R1 (RUL), R3 
(RML), LN 
ex- 
smoker (25) 
L001† 59 F LUAD 3/Hilar IIA R1-R5, LN ex- 
smoker (10) 
L004‡ 73 M Undiff. 
NSCLC 
none IIB R1-R4 current 
smoker (50) 
L011 49 F LUAD none IB R1-R3 current 
smoker (45) 
L002 78 M LUAD/ 
LUSC 
2/Station 5 IIIA R1-R4 current 
smoker (>50) 
Abbreviations: LLL, lower lobe; LUL, left upper lobe; RLL, right lower lobe; RUL, right upper 
lobe; RML, right middle lobe; R, region; LN, lymph node; Undiff, undifferentiated. * a pack-year 
is defined as the number of packs of cigarettes smoked per day multiplied by the number of 
years the person has smoked. †L001 presented a synchronous MEN1 syndrome-associated 
tumour, classified as separate tumour based on histological morphology, biochemical profile 
and octreotide scan imaging. ‡L004 presented a synchronous oesophageal adenocarcinoma, 
classified as separate primary tumours based on histological morphology and 
immunohistochemistry marker profile. 
Patients represented a range of ages (49-84) and included a never-smoker (L003), 
as well as two former smokers (L008 and L001) and three current smokers (L004, 
L011, and L002) (Table 3-1). Four tumours were classified as lung 
adenocarcinoma (LUAD), one tumour classified as an undifferentiated NSCLC, and 
a final tumour as a mix of both LUAD and lung squamous cell carcinoma (LUSC) 
(Figure 3:1).  
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Figure 3:1 L002 Histology 
L002 histopathology staining. Sections from LUAD (upper) or LUSC (lower) regions 
are shown. Left section is taken from frozen material adjacent to material used for 
DNA extraction for sequencing. The remaining sections are taken from FFPE 
representing LUAD or LUSC tumour regions and stained with hematoxylin and 
eosin or with an antibody detecting CK5 or CK7, as indicated. 
Mutation calling was performed on individual tumour regions using VarScan2, as 
outlined in the Experimental procedures section.  To ensure heterogeneity was not 
overestimated, mutation calling leveraged data from all sequenced regions within a 
tumour. Thus, if a mutation was identified in any tumour region its presence was 
assessed in all other tumour regions. In total, 44,882 mutations were identified 
across the 6 tumours, of which 1,758 were non-silent. An average of 293 (range 
117- 476) non-silent mutations were identified per tumour, and 229 (range 42-403) 
per tumour region and, on average, 20% (range 3-87%) of each region’s mutations 
were only identified as a result of leveraging multi-region sequencing analysis 
(Figure 3:2). Use of leveraged mutation calling was most prominent in tumour 
region R4 in L002 - while only 31 non-silent mutations passed calling thresholds 
within that specific tumour region, multi-region sequencing was used to confirm the 
likely presence of an additional 212 non-silent mutations. These data highlight the 
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benefits of utilizing a multi-region approach to more fully capture the catalogue of 
mutations within a tumour.  
 
Figure 3:2 Mutations leveraged by multi-region sequencing 
Mutations identified as present within tumour regions are split into the proportion 
identified by leveraging multi-region sequencing (red) and the proportion identified 
regardless of multi-region sequencing.  
3.2.2 NSCLC exhibits extensive heterogeneity at SNV level 
To obtain a measure of heterogeneity, independent of the number of tumour 
regions sequenced, a heterogeneity score was devised, normalizing for the number 
of regions sequenced. In brief, for a given tumour, each tumour region was 
compared to each and every other tumour region and the mean proportion of 
heterogeneous non-silent SNVs between pairs of tumour regions was used to give 
an indication of the extent of heterogeneity at the non-silent mutation level.  
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Figure 3:3 NSCLC Multi-region heatmap 
Heatmap displaying non-silent mutations identified in NSCLC multi-region 
sequencing data. Tumours are grouped according to smoking status. The extent of 
heterogeneity and number of mutations is indicated below each heatmap. Category 
1-3 driver mutations are shown from black to light grey.  
Intra-tumour heterogeneity at the SNV level was evident in all six NSCLC tumours 
(Figure 3:3), with a median of 30% of non-silent mutations not present in all regions 
sampled within an individual tumour (range 4-63%), and a median heterogeneity 
score of 18% (range 3-41%).  
The extent of the heterogeneity varied considerably between tumours derived from 
different patients. The adeno-squamous cell carcinoma tumour, L002, displayed 
extensive intra-tumour heterogeneity, with 63% of non-silent mutations identified as 
heterogeneous and not present in all tumour regions, and a heterogeneity score of 
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41%. Although heterogeneous mutations showed regional separation, concordant 
with LUAD (regions R1 and R2) or LUSC (regions R3 and R4) histopathologies, a 
shared clonal origin was evident, with 37% of the non-silent mutations identified as 
present in all tumour regions sequenced (Figure 3:3). By contrast, L011 exhibited 
minimal heterogeneity at the SNV level, with only 4% of mutations identified as 
heterogeneous and a heterogeneity score of 3%.  
Both patient L003 and patient L008 presented with two tumours in separate lobes 
of the lung (Figure 3:3). Multi-region sequencing was therefore used to decipher 
the clonal origins of these tumours. In L008, 74% of non-silent mutations were 
ubiquitously identified in both tumour regions derived from the middle lobe and the 
upper lobe of the lung, suggesting a shared clonal origin between the two tumours. 
Thus, for L008 one of the tumours likely represents a metastasis of the other. 
Conversely, in L003 only a single mutation (EGFR-L858R) was identified as shared 
between the tumours from the upper and lower lobes of the lung. Given that EGFR-
L858R is a highly recurrent mutation, occurring in approximately 43% of EGFR 
mutated lung tumours (Mitsudomi and Yatabe, 2010), and no other mutations 
(silent or non-silent) were identified as shared, it is likely that the tumours were of 
independent clonal origin, converging upon identical EGFR activating mutations.  
3.2.3 Single sample analysis to explore heterogeneity across 9 major cancer 
types 
To further explore the level of heterogeneity at the SNV level across a range of 
cancer types, data from the TCGA was used. In total 2,694 tumour samples, 
representing 9 major cancer types, bladder (BLCA, n=130), breast (BRCA, n=903), 
colon adenocarcinoma (COAD, n=190), head-and neck squamous cell carcinoma 
(HNSC, n=250), glioblastoma mulitforme (GBM, n=289), kidney clear cell renal cell 
carcinoma (KIRC, n=303), lung adenocarcinoma (LUAD, n=257), lung squamous 
cell carcinoma (LUSC, n=131), and skin cutaneous melanoma (SKCM, n=241), 
were investigated.  
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For TCGA tumours, mutations were called by individual sequencing centres and 
further filtering was applied to ensure consistency within and across tumour types 
(see Experimental procedures). A total of 516,672 somatic mutations were used for 
downstream analysis, consisting of 326,918 missense, 145,009 silent, 24,236 
nonsense, 9867 RNA [5’ un-translated region (UTR) or 3’UTR], 9828 splice-site, 
341 nonstop and 473 translational start-site mutations.    
Sequencing coverage at mutated sites varied considerably both within and 
between tumour types, with a median coverage of 94.5X across the pan-cancer 
cohort (range 73-125). Notably, the read coverage across the genome will directly 
impact upon the ability to detect low frequency mutations. It is estimated that at a 
sequencing depth of 70, the probability of detecting mutations at a variant allele 
frequency (VAF) of 0.1 is 0.98; however, the probability is reduced to 0.69 when 
attempting to detect a variant with a VAF of 0.05 (Cibulskis et al., 2013). Thus, in 
this analysis, the number of low-frequency subclonal mutations may have been 
underestimated.  
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Figure 3:4 Purity and coverage in TCGA tumours 
A) Tumour coverage at mutated bases across different tumours. For each cancer 
type, each dot represents one TCGA tumour. B) ASCAT purity estimates across 
different tumours. 
Relatedly, the purity of the sample will also directly impact upon the ability to 
identify mutations, with low purity samples necessarily exhibiting mutations with 
lower VAF than their higher purity counterparts when matched for copy number. 
Encouragingly, the vast majority of TCGA samples (>90%) exhibited purity above 
35%, as estimated by ASCAT (Figure 3:4 B).  
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3.2.4 Deciphering heterogeneity and timing of SNVs within single tumour 
samples  
Next, the clonal status and timing of mutations was estimated by integrating variant 
allele frequencies with copy number and purity estimates (see Experimental 
procedures). The cancer cell fraction, describing the proportion of cancer cells 
harbouring a mutation, was calculated and mutations were classified as clonal if the 
95% confidence interval of the cancer cell fraction overlapped with 1. The subclonal 
fraction, describing the proportion of mutations classified as subclonal within a 
tumour, varied considerably within and across tumour types (Figure 3:5).  
 
 
Figure 3:5 Subclonal fractions across and within tumour types 
For each tumour type, each dot represents one tumour, and the proportion of the 
entire mutational burden that is classified as subclonal is depicted. Notably, the 
subclonal fraction varies considerably both between and within tumour types. 
To determine whether the observed differences in subclonal fraction was primarily 
driven by differences in tumour purity, ASCAT purity was directly compared to the 
subclonal fraction in all tumours. Reassuringly, the subclonal fraction was not 
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significantly different between high purity (purity>0.8) and medium purity (purity 0.6-
0.8) samples. Nevertheless, a lower subclonal fraction was observed for tumours 
with a purity lower than 40%, confirming that low purity levels likely hamper the 
ability to decipher clonal architecture, leading to underestimates of intra-tumour 
heterogeneity.  
 
Figure 3:6 Tumour purity in relation to subclonal fractions 
For the entire pan-cancer cohort, the subclonal fraction is depicted in relation to 
different ASCAT purity levels. Each blue dot represents one TCGA tumour. As can 
be seen, tumours with lower purity exhibit a lower subclonal fraction.  
Although it is difficult to directly compare different cancer types, given differences in 
tumour coverage and tumour purity as well as mutational calling strategies, it is 
interesting to note that SKCM was identified as the tumour type with, on average, 
the lowest subclonal fraction. Given that most SKCM samples in TCGA represent 
metastatic samples, these data potentially indicate a bottlenecking event occurring 
during metastatic dissemination in this tumour type.  
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3.2.5 Deciphering clonal heterogeneity of SNVs within multi-region tumour 
samples  
For multi-region sequencing samples, the clonal estimation was further refined 
using a Dirichlet clustering process extended into multiple dimensions (see 
Experimental procedures). This analysis was undertaken in collaboration with 
David Wedge at the Sanger Institute. As outlined in the Introduction, a Dirichlet 
clustering process can be implemented in order to cluster mutations within similar 
cancer cell fraction estimates. Mutation clusters likely represent subclones that are 
present, or have been present, during tumour evolution.  
For most pair-wise comparisons between tumour regions, a cluster at (1,1) was 
detected. Such mutation clusters represent mutations present in 100% of tumour 
cells within at least two tumour regions. Mutations present at (1,1) for each and 
every region comparison represent fully clonal mutations, identified as present in 
100% of tumour cells sequenced. These mutations likely occurred prior to the 
emergence of the most recent common ancestor. Conversely, mutations present at 
(0,1) or (1,0) reflect mutations giving the illusion of clonality. That is, such mutation 
clusters appear clonal within one tumour region but are not identified within another 
tumour region. For example, in L002, over 10,000 mutations were identified as 
clonal in region R1, but not present in region R3.  
As in TCGA data, subclonal mutations were also identified within single biopsies. 
For example, all private mutations within region R3 in L001 were classified as 
present in less than 100% of cancer cells within that tumour region, and in region 
R1 of L008, both a regionally clonal and regionally subclonal mutation cluster was 
identified, harbouring private mutations only identified in region R3.  
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Figure 3:7 2D Dirichlet plots for multi-region NSCLC tumours 
2D Dirichlet plots showing mutation clusters based on cancer cell fraction 
estimates. Clusters at (1,1) represent mutations present in 100% of cancer cells 
within at least two tumour regions. Conversely, mutation clusters at (1,0) or (0,1) 
represent mutations that give an illusion of clonality, appearing fully clonal within 
one tumour region, but not detectable within another tumour region.  
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3.2.6 Deciphering timing of SNVs and phylogenetic relationships of multi-
region tumour samples  
Next, for multi-region sequencing data, cancer cell fraction estimates for individual 
tumour regions were used to construct phylogenetic trees, to yield insights into the 
relationships between tumour regions and evolutionary histories of individual 
tumours. Phylogenetic trees were constructed using the maximum parsimony 
approach (see Experimental procedures).  
When constructing phylogenetic trees it is important to recognise that subclonal 
mutations, present in only a subset of cancer cells, are not necessarily later events, 
but may reflect copy number driven heterogeneity. For example, in L008 a segment 
of the genome on chromosome 7q was lost specifically in region R3 but not region 
R1. As a result, any mutations present on this chromosomal segment will only be 
found in region R1, despite the fact that many of these mutations likely occurred 
prior to the emergence of the common ancestor between region R1 and region R3.  
 
Figure 3:8 Copy number driven heterogeneity in L008 
A genomic segment on chromosome 7q was lost specifically in region R3, but not 
in region R1. Loss of this segment likely creates intra-tumour heterogeneity as 
mutations which were previously homogenous become heterogeneous, only to be 
found in one tumour region.  
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In addition, certain tumour regions were found to harbour multiple distinct 
subclones, such that the region tree, where each region is considered as a 
separate species, did not match the clonal dissection tree. For instance, in L004 
region R5 harboured three distinct mutations clusters (Figure 3:7). One cluster was 
present at 100% cancer cell fraction, thereby representing the ancestral clone. 
Another cluster was present at a cancer cell fraction of 80%, and was unique to 
region R5, thereby representing a leaf-node on the tree. The final, smallest cluster, 
present at 20%, contained mutations also present in regions R1, thereby 
suggesting a minor subclone within region R5.  
 
Figure 3:9 Phylogenetic trees of multi-region NSCLC tumours 
Phylogenetic trees generated by a maximum parsimony approach based on the 
distribution of all detected mutations. Scale is indicated for each sample next to the 
trunk with the number of mutations (silent and non-silent) indicated. GL indicates 
germ-line. Trees of L002 and L008 are based on WGS data, and the remaining 
ones on WES data. Categories 1 and 2 driver mutations (black and grey) are 
indicated next to the trunk or with an arrow pointing to the branches where they 
were acquired (see Experimental procedures).  
For each NSCLC, branched tumour evolution was observed, with distinct 
subclones observed in separate tumour regions. It is also notable that, in general, 
very few mutations that were subclonal in multiple regions were identified, 
suggesting that NSCLCs often harbour geographically distinct, regionally dominant, 
subclones, with little subclonal mixing. 
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3.2.7 Heterogeneity of SNVs in tumour suppressors and oncogenes 
To explore the regional heterogeneity of candidate tumour driver mutations in multi-
region NSCLC, non-silent mutations were classified into four categories, based on 
the confidence that it was a driver mutation (Table 8-2, see Experimental 
Procedures). Categories 1-3 contained all non-silent mutations that were present in 
genes that have previously been implicated as tumour driver mutations, with 
category 1 representing ‘high confidence’, category 2 ‘probable’ and category 3 
‘potential’ driver mutations. Conversely, category 4 represented all other non-silent 
mutations. Further details regarding mutation classification can be found in the 
Experimental procedures section.  
Within the multi-region sequenced samples a median of three ‘high confidence’ 
(category 1), six ‘putative’ (category 2) and six ‘low confidence’ (category 3) driver 
mutations were identified in each tumour (Table 8-2). Every tumour showed 
evidence for regional heterogeneity in driver mutations (Figure 3:9). Moreover, 
many of the heterogeneous driver mutations gave an illusion of clonality in one 
tumour region. For example, mutations in TGFBR1 and EP300 were clonally 
dominant in a subset of tumour regions but not detectable in other regions from the 
same tumour (Table 8-2). These data further imply that subclonal estimates based 
on single samples likely underestimate the true extent of heterogeneity.  
To investigate heterogeneity and clonal status of candidate driver mutations in the 
pan-cancer cohort, non-silent mutations were classified as occurring in established 
cancer genes based on the recent pan-cancer analysis by Lawrence et al. (2014), 
combined with the manually curated COSMIC gene census (Futreal et al., 2004). 
Consistent with multi-region results in NSCLC, non-silent subclonal mutations in 
known cancer genes were identified in every cancer type (Figure 3:10).  
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Figure 3:10 Pan-cancer cancer cell fraction of cancer genes 
Pan-cancer cancer cell fraction estimates for established cancer related genes. For 
each tumour type, clonal (red) and subclonal (blue) mutations in established cancer 
genes are shown. Each dot represents one mutation, with 95% confidence interval 
of the cancer cell fraction indicated. Mutations are classified as clonal if the 95% 
confidence interval overlaps with 1.   
3.2.8 Established driver mutations typically occur early in tumour evolution 
To explore whether certain genes had a tendency to be clonal or subclonal, beyond 
what might be expected by chance, permutation tests were performed. In KIRC, 
over 50% of non-silent mutations in PTEN were found to be subclonal (significantly 
more than the background rate, Figure 3:11 P=0.0116). These results are 
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consistent with observations from a smaller cohort of KIRC samples subject to 
multi-region sequencing (Gerlinger et al., 2014a), and support the role that 
inactivation of PTEN may play later in tumour evolution in this cancer type. In 
BRCA, mutations in CBFB were exclusively clonal, as were mutations in CDKN2A 
in LUSC and HNSC, and a similar trend was observed for mutations in ARID1A in 
BLCA.  
Within the multi-region NSCLC cohort, four tumours (L002, L011, L001, and L008) 
were found to harbour mutations in TP53 and, in each case, these were identified 
as fully clonal, occurring in every cancer cell sequenced.  Consistently, in TCGA 
LUAD and LUSC tumours and in the pan-cancer dataset as a whole, somatic 
mutations in TP53 were significantly more often clonal than the background rate 
(Figure 3:11, P<0.0001). Conversely, mutations in PIK3R1 and MLL3 were 
frequently subclonal across cancer types, such that a higher proportion of 
subclonal mutations was observed in these genes compared to the background 
rate (Figure 3:11).  
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Figure 3:11 Clonal status significance using permutations 
In the left panel, for each gene the proportion of mutations that are clonal (red) and 
subclonal (blue) are depicted. The significance is shown in the right panel, 
comparing the observed proportion of clonal mutations with the background 
distribution obtained from 10,000 randomizations, assuming the same mutation 
number. As can be seen, mutations in TP53 (across the pan-cancer cohort) and 
VHL (in KIRC tumours) are significantly more often clonal compared to 
background, whereas mutation in PTEN in KIRC and PIK3R1 as well as MLL3 in 
the pan-cancer cohort show a significant tendency to be subclonal. 
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Next, to determine whether mutations in established cancer genes had a tendency 
to be clonal or subclonal, all non-silent mutation in cancer genes were grouped 
together and compared to all non-silent mutations in non-cancer genes. In multi-
region NSCLC tumours, driver mutations were significantly more often truncal 
compared to non-driver mutations (P=0.016, Fisher’s exact test), indicating that 
established driver mutations tend to occur early in tumour evolution. This 
observation was confirmed across the pan-cancer cohort, where a clear tendency 
for mutations in driver genes to be clonal compared to mutations in non-cancer 
genes was observed (Figure 3:12). In every cancer type, with the exception of 
KIRC, mutations in driver genes (considered in aggregate) were enriched to a 
statistically significant degree for clonal mutations, compared to mutations in non-
driver genes. In KIRC, VHL was the only cancer gene that had a significantly higher 
proportion of clonal mutations than the background rate representing all non-silent 
mutations, consistent with multi-region sequencing results in KIRC (Gerlinger et al., 
2014a) and supporting the approach to distinguish clonal from subclonal somatic 
events used in this thesis (P = 0.0147, Figure 3:11). These results remained robust 
to multiple different cut-offs to define clonal/subclonal mutations.  
 
Figure 3:12 Clonal versus subclonal mutations in cancer driver genes 
Bar-plots showing the proportion of clonal versus subclonal non-silent mutations in 
driver genes and other genes across 9 cancer types. 
Taken together, these results suggest that many known cancer genes have a 
tendency to be clonal within single samples and corroborate the ‘driver’ capabilities 
of these genes. These data also suggest that mutations in known driver genes 
frequently occur before subclonal diversification, and are less likely to be subject to 
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sampling bias compared to non-driver genes. However, although a tumour may 
harbour a founder driver aberration, such as mutation to TP53, branched subclonal 
expansions can result in additional driver events, such as a mutation to PIK3R1, 
dominating only one region of the tumour, or a subset of tumour cells within a 
region.  
3.2.9 Recurrent patters in tumour evolution 
Across the pan-cancer cohort in a minority of cases multiple subclonal mutations 
occurring in the same cancer gene or in separate cancer genes whose function 
might be expected to be redundant were identified. 
For example, in KIRC-B0-5399, two distinct mutations in SETD2, one occurring in 
40% of cancer cells and the other in 19%, were observed. These observations are 
consistent with evidence for parallel tumour evolution, whereby the same genetic 
pathway, gene or protein complex is disrupted independently in distinct tumour 
subpopulations within one tumour (Gerlinger et al., 2014a). Likewise, in GBM-28-
2513, two subclonal mutations in genes involved in the PI3K signalling axis were 
identified, with one mutation in PIK3R1 present in 54% of cancer cells and a 
mutation in PTEN present in only 36% of cancer cells.  
In further support of parallel evolution, in general when multiple non-silent 
mutations were identified in the same cancer gene within one tumour sample, 
these mutations exhibited a significantly lower cancer cell fraction compared to 
mutations in cancer genes occurring only once in a cancer sample (Figure 3:13, 
P<0.001, Wilcoxon rank sum test).  
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Figure 3:13 Examples of parallel evolution 
A-B) Probability distributions over the cancer cell fraction for individual mutations 
are shown for specific tumours. In both cases, the cancer cell fractions are 
consistent with mutations occurring in independent tumour subclones. C) When 
multiple non-silent mutations were identified in the same cancer gene within one 
tumour sample these mutations exhibited a significantly lower cancer cell fractions 
compared to mutations in cancer genes occurring only once in a cancer sample 
(P=7.151e-07, Wilcoxon rank sum test). 
3.2.10 Identification of novel putative subclonal and clonal cancer genes 
using temporal and clonal dissection  
Given the observation that many clonal mutations likely occur before 
tumourigenesis and the fact that many branches of NSCLC phylogenetic trees did 
not harbour known driver genes, it seems reasonable to postulate that it might be 
possible to identify drivers of subclonal expansions by focusing exclusively on late 
or subclonal mutations (see Experimental procedures).  
The MutSigCV algorithm (Lawrence et al., 2014), a statistical analysis that takes 
into account nucleotide context, gene expression, replication timing, and the 
somatic background mutation rate to identify cancer genes, was therefore applied 
to temporally and clonally dissected mutations in the pan-cancer cohort. Given that 
MutSigCV requires a large number of tumour samples in order to identify putative 
cancer genes, multi-region NSCLC samples were not utilized for this part of the 
analysis.   
In total, 32 late putative driver genes were identified across the 9 cancer types 
(q<0.05, Table 8-3). Of these, 12 would have been missed in at least one cancer 
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type without temporally dissecting mutations. Temporal dissection was required to 
uncover the cancer gene PIK3CA in HNSC, suggesting that mutations in this gene 
may often lead to, or be permissive for, subclonal expansions in this cancer type.  
A number of putative cancer genes that were identified can be linked to tumour 
development, maintenance, and progression.  A notable example is cell adhesion 
gene CTNNA2, catenin (cadherin-associated protein) alpha 2, identified in LUAD. 
CTNNA2 has previously been implicated in laryngeal cancer as a tumour 
suppressor, and its inactivation in HNSC cells is associated with migration and 
invasion advantages, consistent with it playing a role at later stages of tumour 
development (Fanjul-Fernandez et al., 2013). In LUAD, mutations in NRXN3 were 
identified as a putative subclonal driver event.  A polymorphic site of this gene 
(rs10146997) has been associated with higher risk of breast cancer development 
(Kusinska et al., 2012), and low expression of NRXN3 is associated with reduced 
overall-survival in lung cancer (Figure 3:14).   
 
Figure 3:14 Overall survival and expression of NRXN3.  
High expression of NRXN3 in NSCLC is associated with significantly improved 
prognosis compared to low expression. High and low expression groups were 
defined relative to median expression level. Survival plot was generated using KM 
plotter (www.kmplot.com). 
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Another putative cancer gene, identified in COAD, was ATXN1. The ATXN1 protein 
family plays an important role in transcriptional control of extracellular matrix 
remodelling, and mutations in ATXN1 have been putatively linked to cancer 
metastasis, consistent with its occurrence as a later event in COAD (Lee et al., 
2011b). In LUSC, LRP1B, which encodes a member of the low-density lipoprotein 
(LDL) receptor gene family, was identified as a putative cancer gene.  It has been 
suggested that LRP1B acts as a tumour suppressor gene (Varela et al., 2010), and 
in KIRC its depletion results in increased anchorage-independent growth, cell 
migration, and invasion in vitro (Ni et al., 2013).  
By temporally separating mutations, driver genes that may be missed by the 
inclusion of late or subclonal mutations were also identified. For example, when 
focusing exclusively on clonal mutations it was possible to identify BRAF in COAD, 
consistent with BRAF playing an important role early in tumour evolution and the 
clonal nature of this event in published studies (Brannon et al., 2014). Likewise, in 
LUSC, BRAF, KRAS, and EGFR were only identified as drivers in this cancer type 
by focusing on early mutations.  
3.2.11 Mutations in genes with clinical relevance can be subclonal 
Mutations in genes and gene pathways for which therapeutics have been 
developed or are in development (Table 8-4), have received much attention in 
oncology given their appeal as targets for personalized medicine. For instance, the 
presence of mutations that activate the PI3K/AKT/mTOR pathway and contribute to 
carcinogenesis has engendered much interest in inhibitors of this signalling axis 
(Janku et al., 2011).  
It is therefore notable that, with the exception of CDKN2B and CDKN1B, for every 
gene that has been linked with a targeted therapy approach, a subclonal mutation 
was identified in at least one tumour in the pan-cancer cohort (Figure 3:15). Over 
10% of all non-silent PIK3CA mutations and over 20% of all non-silent mutations in 
PTEN were found to be subclonal and over 15% of mutations in genes in the 
PI3K/AKT/mTOR pathway overall were identified as subclonal (Figure 3:15 B). In 
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GBM, the use of IDH-targeted therapies has been proposed for tumours with IDH1 
or IDH2 mutations (Rohle et al., 2013), and yet over 20% of IDH1 mutations in 
GBM were identified as subclonal.  On the other hand, all IDH1 mutations detected 
in SKCM were clonal. In KIRC, mTOR inhibition is a common therapeutic option; 
however, over 30% of mutations in mTOR were subclonal within this disease type 
within single tumour samples.  
Clear differences between different cancer pathways were also observed; 
significantly fewer subclonal mutations in genes associated with cyclin dependent 
kinases (CDKN1A, CDKN1B, CDKN2B, RB1, CDKN2A, CDK6, and CDK5) and the 
RAS-MEK pathway were observed compared to mutations in the AKT/mTOR/PI3K 
pathway (P<0.05, Fisher’s exact test).  
Finally, in order to restrict the analysis to well-characterized mutations, some of 
which are considered ‘actionable’, the database of curated mutations (DoCM, 
docm.genome.wustl.edu) was used. Only mutations occurring in at least three 
tumour samples within the cohort were considered.  For the majority of these 
mutations, both clonal and subclonal mutations were identified in at least one 
cancer type (Figure 3:16).  Of particular clinical relevance, tumour samples with 
subclonal mutations in known sites with therapeutic relevance such as NRAS 
(Q61K, Q61R, Q61L); BRAF (V600E); KRAS (G12C, G12D, G12V); PIK3CA 
(E542K, 545K, H1047R); IDH1 (R132H), as well as many subclonal loss-of-function 
mutations in tumour suppressor genes such as PTEN (Figure 3:17) were observed. 
Identified subclonal driver mutations often occurred in tumours where clonal 
mutations in established cancer genes were also present (Figure 3:17; mean 45% 
across cancers [range 15-67%]). For example, in patient HNSC-CV-7177, a 
PIK3CA (E545K) mutation in the highly conserved helical domain was estimated to 
be present in only 36% of cancer cells, whereas a mutation in TP53 in the same 
tumour was found to be present in all cancer cells. Similarly, patient 
SKCM−ER−A2NE exhibited a clonal mutation in NRAS (Q61K), whereas a PTEN 
mutation (Y178*) was present only in 13% of cells. 
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Figure 3:15 Heterogeneity of mutations in genes linked with therapies 
(A) Heatmap showing the proportion of non-silent mutations that are subclonal for 
each potentially actionable gene across nine cancer types. For each mutation, the 
number of subclonal mutations identified is indicated for each cancer type and the 
combined pan-cancer data set. Grey indicates the absence of a mutation. (B) The 
clonality of actionable pathways is depicted for each cancer type and the combined 
pan-cancer data set. Pathways are ordered according to sub-clonality in the pan-
cancer data set, with pathways that have a higher proportion of subclonal 
mutations at the top of the heatmap. Genes related to CDKs (cyclin-dependent 
kinases) have very few subclonal mutations. RTK, receptor tyrosine kinases. For 
details of all the genes within each pathway, see Table 8-4. 
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Figure 3:16 Clonal and subclonal actionable mutations 
For each known ‘actionable’ site (http://docm.genome.wustl.edu/), the number of 
subclonal (numerator) and total mutations (denominator) is listed for each cancer 
type. Grey indicates absence of a mutation.  
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Figure 3:17 Clonal and subclonal actionable mutations across cancers 
A) For specific cancer genes, lollipop plots are shown depicting the frequency of 
clonal and subclonal mutations across the coding sequence. B) Probability 
distributions over the cancer cell fraction for individual mutations are shown for 
specific tumours.  
3.2.12 Multi-region sequencing in oesophageal adenocarcinoma 
Work in this chapter has thus far has focussed on predominantly primary tumours 
that have not received any treatment. In order to gain a deeper understanding of 
the clinical implication of intra-tumour heterogeneity, and, further, explore the 
impact of treatment on tumour evolution and tumour diversity, multi-region 
sequencing data from eight oesophageal adenocarcinomas pre and post-exposure 
to platinum chemotherapy was obtained. The clinical characteristics of these 8 
patients are shown in Table 3-2, and included patients with stage IIB to IIIC disease. 
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Table 3-2 Clinical characteristics of oesophageal multi-region tumours 
Sample ID Gender Pre-op 
TNM 
Staging 
Pre-op 
Stage 
Mandard 
Score 
Path TNM 
Stage 
Post-op 
Stage 
Response Outcome 
OG005 M T2N1 2B 5 pT3N2 3B Upstaged Poor 
OG015 M T3N1 3A 5 pT4aN3 3C Upstaged Poor 
OG001 M T3N0 3A 5 pT3N0 2B Same Intermediate 
OG006 M T1N0 1B 3 pT1N1 2B Upstaged Intermediate 
OG014 M T3N1 3A 4 pT1bN1 2B Down-staged Intermediate 
OG003 M T3N1 3A 3 pT3N1 3A Same Good 
OG017 M T3N1 3A 3 pT2N1 2B Down-staged Good 
OG009 M T4N2 3C 2 pT1bN1 2B Down-staged Good 
 
In total 40 tumour regions were sequenced at a median 90-fold coverage (range 
56-191), with matched germ-line samples also sequenced to a median depth of 
90X (range 42-132). As in NSCLC, mutation calling leveraged data from all tumour 
regions. The total number of mutations identified if only a single tumour region had 
been samples was significant lower than the number of mutations identified using 
multi-region sequencing (P<0.01, Wilcoxon test).  
3.2.13 Intra-tumour heterogeneity in oesophageal adenocarcinoma 
To determine the evolution and heterogeneity of oesophageal adenocarcinoma, 
mutations were first classified as either ubiquitously detected, if detected in all 
tumour regions, or heterogeneous, if identified in only a subset of tumour regions 
(Figure 3:18). Mutations were further grouped according to whether they were 
identified pre-chemotherapy or post-chemotherapy treatment.  
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Figure 3:18 Intra-tumour heterogeneity of oesophageal adenocarcinoma 
Heatmaps depicting the extent of intra-tumour heterogeneity of non-silent 
mutations in multi-region sequenced oesophageal adenocarcinomas. Pre- and 
post- chemotherapy tumour regions are indicated. Category 1-3 mutations in 
cancer genes are indicated, with black, bold, genes category 1, dark grey category 
2 and light grey category 3.   
All primary tumours exhibited intra-tumour heterogeneity, indicative of branched 
tumour evolution (Figure 3:18). A median of 55.63% of non-silent mutations were 
classified as heterogeneous (range 12.6% to 69.4%). The degree of intra-tumour 
heterogeneity was assessed in each tumour by the use of the heterogeneity index 
described above. In this small cohort, a strong correlation between the 
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heterogeneity index and response to neo-adjuvant chemotherapy was observed 
(Figure 3:19), suggesting a simple heterogeneity score may predict response to 
therapy in oesophageal adenocarcinoma. 
 
Figure 3:19 Intra-tumour heterogeneity and response in oesophageal 
adenocarcinoma 
Relationship of intra-tumour heterogeneity and response to neo-adjuvant 
chemotherapy treatment. Spearman rho is indicated.  
3.2.14 Clonal architecture pre and post chemotherapy treatment 
Next, to further resolve the clonal architecture of mutations both pre and post-
chemotherapy treatment, the cancer cell fraction of each mutation was determined 
and mutations were clustered using a multi-dimensional Dirichlet process (Figure 
3:20). As in NSCLC, the cancer cell fraction was determined by integrating copy 
number and purity estimates.  
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Figure 3:20 Clonal Architecture of oesophageal adenocarcinoma 
For each tumour region within each tumour, the clonal composition is shown, with 
the cancer cell fraction of each mutation indicated. Mutation clusters, as 
determined by a multidimensional Dirichlet clustering process are depicted.  
Category 1-3 mutations in cancer genes are indicated.  
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Analysis of the subclonal architecture of oesophageal adenocarcinoma revealed a 
multitude of subclones in each tumour, exceeding the number of regions 
sequenced in every case (Figure 3:20). The number of subclones identified was 
directly related to the number of tumour regions sequenced, highlighting the 
necessity of multi-region to resolve the clonal architecture of tumours. Indeed, 
many mutation clusters identified exhibited near-identical cancer cell fractions 
within the same tumour region, rendering their de-convolution intractable without 
multi-region sequencing.  
A fully clonal cluster was identified in every tumour, reflecting the mutations present 
in the most recent common ancestor, and the founding cancer clone. On average, 
this mutation cluster represented 51% of mutations in each tumour (range 28-69%). 
In general, the majority of mutation clusters present prior to adjuvant chemotherapy 
were found to be present in 100% of tumour cells within at least one tumour region, 
while sometimes absent or present in only subset of tumour cells within other 
tumour regions (Figure 3:21). Such clusters may reflect a clonal sweep within one 
tumour region. Mutation clusters identified exclusively after treatment with platinum 
chemotherapy were often subclonal, occurring in less than 100% of tumour cells 
within every tumour region, suggesting platinum chemotherapy may foster 
additional subclonal diversity. Further samples will be needed to confirm this 
observation, and it is difficult to assess fully without a control group that has also 
been serially sampled.  
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Figure 3:21 Clonal and subclonal clusters in tumour regions 
For each tumour region, the median cancer cell fraction of all mutations within each 
cluster identified is shown as a barplot. Number of mutations within each cluster is 
shown under plot. Clusters were heterogeneity may be driven by copy number loss 
were removed from analysis.   
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3.2.15 Phylogenetic trees for oesophageal adenocarcinoma 
In order to understand the evolutionary relationship between tumour subclones, 
and to further explore how chemotherapy may influence the subclonal architecture 
and tumour diversity, phylogenetic relationships between clonal and subclonal 
mutation clusters were investigated.  
First, for each mutation cluster identified, the possibility of copy number driven 
heterogeneity was determined (see Experimental procedures). In total the 
heterogeneity of 100 mutations was identified as potentially driven by copy number 
diversity. For instance, in OG015 a chromosomal segment harbouring 16 mutations 
was identified as deleted in tumour region R1, but present in all other tumour 
regions.  
Next, two types of phylogenetic trees were constructed, region trees, where each 
region was treated as a separate species and subclonal architecture trees, where 
the subclonal architecture of each tumour region was taken into account. To 
determine the subclonal evolutionary history of each tumour, the pigeonhole 
principle was adopted, such that any two branches of the evolutionary tree when 
summed could not exceed 100% of tumour cells and ancestral clones were 
necessarily at a higher or equal cancer cell fraction compared to their descendants 
(see Experimental procedures).  
Every oesophageal adenocarcinoma exhibited branched tumour evolution. In two 
of eight tumours, parallel evolution was observed. In OG005, multiple distinct 
mutations in NOTCH1 were observed on separated tumour branches and in 
OG001 distinct mutations in GNPTAB were identified in separate tumour regions.   
Two distinct modes of tumour evolution were observed following chemotherapy 
treatment.  In two tumours (OG005 and OG015) post-chemotherapy regions 
clustered separately as a monophyletic group (indicating a shared common 
ancestor). However, in the remaining tumours, paraphyly was observed whereby 
pre- and post- chemotherapy regions clustered together. Interestingly, in this small 
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cohort, tumours OG005 and OG015, which had a poor response to chemotherapy 
(Table 3-2), exhibited monophyly with clustering of post-chemotherapy tumour 
regions from a shared common ancestor, consistent with a common genomic event 
conferring resistance to therapy in these tumours.  
In six of eight subclonal architecture trees, at least one tumour region was found to 
harbour subclones from different nodes of the phylogenetic tree, highlighting the 
fact that these tumours exhibit a complex subclonal structure, and subclones can 
be shared between different tumour regions of oesophageal adenocarcinoma 
tumours (Figure 3:23).  
 
Figure 3:22 Oesophageal tumour region phylogenetic trees 
Phylogenetic trees generated by a maximum parsimony approach based on the 
distribution of all detected mutations. Trunk and branch lengths are proportional to 
the number of mutations acquired. Categories 1 -3 driver mutations are indicated 
next to the trunk or with an arrow pointing to the branches where they were 
acquired  
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Figure 3:23 Subclonal phylogeny in oesophageal adenocarcinoma 
Phylogenetic trees based on subclones. Relationships between subclones are 
computed based on pigeonhole principle. Tumour regions are depicted beneath 
tree, with lines indicating presence of subclone within tumour region. Number of 
SNVs is indicated.   
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3.3  Conclusions  
The results of this chapter demonstrate the presence of considerable intra-tumour 
across cancer types, and provide further evidence for branched tumour evolution, 
involving competing or cooperating subclones. Indeed, in both NSCLC and 
oesophageal adenocarcinoma, using multi-region sequencing, branched tumour 
evolution was observed.  
Subclonal driver mutations including known canonical hotspot mutations, such as 
IDH1 (R132H) and PIK3CA (E545K) were identified in every cancer type 
investigated. Further, almost every gene linked with a targeted therapy was found 
to harbour subclonal mutations in at least one tumour within the cohort. Moreover, 
certain pathways were found to be more likely to harbour subclonal mutations than 
others, and evidence for parallel evolution was identified, suggesting constraints to 
tumour evolution that may one day be therapeutically exploitable.  
Analysis of paired pre- and post- neo-adjuvant platinum chemotherapy 
oesophageal adenocarcinoma tumours suggested intra-tumour heterogeneity might 
facilitate development of resistance to therapy. However, additional samples are 
required to confirm this observation.  In addition, mutations detected post-
chemotherapy tended to be subclonal in all tumour regions.  
Nevertheless, despite extensive heterogeneity, the results presented here also 
demonstrate that mutations in established driver genes have a tendency to be 
clonal compared to mutations in non-driver genes, suggesting that these mutational 
events may often be required as early events in tumourigenesis and might 
represent suitable candidates for cancer screening approaches (Martinez et al., 
2013). The enrichment for clonal mutations in established driver genes is likely 
related to the fact that current methods for detecting driver genes are 
underpowered to detect subclonal drivers of tumour subclade expansions, present 
at low variant allele frequencies or spatially or temporally separated within tumours. 
Consistent with this, by focusing on later mutations, it was possible to identify 
cancer genes that may be responsible for subclonal clade expansions. Indeed, 
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genes such as ATXN1 and CTNNA2 have been linked to tumour metastasis and 
cell migration (Lee et al., 2011b).  
Importantly, comparisons of multi-region and single sample techniques to decipher 
heterogeneity revealed that sampling bias, which can create an illusion of clonal 
dominance, can render single sample analysis inaccurate and potentially 
misleading. However, further work is needed to characterize the optimum number 
of tumour samples required to accurately de-convolve the subclonal structure of a 
tumour. Moreover, current methods for deciphering intra-tumour heterogeneity are 
not without limitations and are heavily influenced by purity and sequencing depth. 
Future studies, such as TRACERX in NSCLC (Jamal-Hanjani et al., 2014), 
employing deep-multi-region sequencing on large cohorts of tumour may be 
required to gain a more complete picture of the genomic and clonal landscape of 
tumours.   
In summary, the evidence presented here highlights the need to understand the 
subclonal composition of tumours. Moreover, the results demonstrate that known 
driver mutations not only play a role in tumour initiation, but also likely influence 
tumour behaviour after tumour branching within distinct subclones. The next two 
chapters further explore the mechanisms generating this intra-tumour 
heterogeneity.  
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Chapter 4. Genome doubling in cancer evolution 
4.1 Introduction 
Chromosomal instability contributes to intra-tumour heterogeneity by creating a 
genomically diverse pool of tumour cells upon which selection can act. Consistent 
with providing a substrate for tumour evolution, CIN is associated with both poor 
prognosis and intrinsic multi-drug resistance across a wide range of cancers 
(McGranahan et al., 2012, Lee et al., 2011a, Duesberg et al., 2001).  
Another common feature of tumour cells is an abnormal chromosomal content. 
Polyploid cells have been observed in multiple cancer types, and genome doubling 
events have been proposed as an intermediate state en route to chromosomal 
instability (Carter et al., 2012, Davoli and de Lange, 2011, Shackney et al., 1989). 
However, the relationship between genome doubling and CIN, and the effect of a 
whole genome-doubling event on cancer genome evolution remains unclear.  
In this chapter, I explore the timing and impact of a whole genome-doubling event 
on genomic instability and cancer genome evolution. I make use of SNP6.0 copy 
number and mutation data from 10 major cancer types. In addition an isogenic 
colorectal cell-line system is used to explore the acute affects of a whole genome-
doubling event. Finally, I investigate the clinical implications of a genome doubling 
in colorectal cancer.  
The majority of the work presented in this chapter forms the basis of a publication 
in Cancer Discovery (see Appendix 2, Dewhurst and McGranahan et al. 2014). I 
undertook all the bioinformatics work presented in this chapter, while experimental 
work was performed by Sally Dewhurst.  
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4.2 Results 
4.2.1 Exploring chromosomal instability using copy number data 
As discussed in the introduction to this thesis, CIN represents a dynamic state in 
which cells gain or lose whole chromosomes, or parts of chromosomes, at an 
elevated rate, creating intercellular genetic heterogeneity. Allele specific copy 
number data can shed light on the average copy number state of a population of 
tumour cells, revealing the level of aneuploidy in a tumour population. However, 
given that the copy number state of a tumour genome does not necessarily reflect 
the underlying rate of copy number loss/gain, it is necessary to infer proxies of 
chromosomal instability from copy number data. 
A simple method to capture a gross level of instability, first proposed by Chin et al. 
(2007), involves measuring the extent of the genome that is subject to copy number 
change. This measure, termed genome instability index (GII), can broadly 
distinguish unstable from stable genomes. However, a drawback of this method is 
that it ignores the ploidy of a sample, and, moreover, is biased by the fact that 
larger chromosomes will necessarily contribute more to the score than smaller 
chromosomes.  
The wGII, the weighted genome integrity index, builds directly upon the GII by 
measuring gains and losses relative to the ploidy of a simple, and further, is 
weighted to ensure each chromosome contributes equally to the score, and thereby 
losses or gains affecting longer chromosomes will not bias the score (Burrell et al., 
2013a).  
4.2.2 Genome doubling can be inferred from allele specific copy number 
A tetraploid genome may result from successive gains of individual chromosomes 
and chromosome arms, or from a genome-doubling event. In order to distinguish 
between the two and identify genome-doubling events, allele specific copy-number 
information can be used. Starting from a diploid genome, a genome doubling will 
initially result in both major and minor alleles (i.e. the two homologous chromosome 
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segments at each locus) being even numbers. Following the genome-doubling 
event, specific chromosomes, or chromosome segments, may be lost, but the 
major allele would be expected to have a copy number ≥2 throughout the majority 
of the genome. Thus, the extent to which a tumour sample’s genome exhibits a 
major allele >=2 across multiple chromosome arms can be used to assess the 
probability of genome doubling (see Experimental procedures for full details).  
4.2.3 A relationship between ploidy and genomic complexity in COAD 
To explore the relationship between ploidy, CIN and genome doubling across a 
range of cancer types, including COAD, allele specific copy number was used. 
  
Figure 4:1 Genome doubling and chromosomal instability 
Relationship between weighted mean chromosome copy number and wGII. Each 
circle represents one TCGA COAD tumour sample. Red depicts genome-doubled 
(GD) samples; blue non–genome-doubled (nGD) samples (see Experimental 
Procedures). A histogram of weighted mean chromosome copy number for GD 
(red) and nGD (blue) is shown on top. 
In COAD tumour samples, significantly higher wGIIs were found in polyploid (ploidy 
≥3) compared to diploid tumours (P<0.0001, Student’s t-test, Figure 4:1), although 
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some stable (wGII <0.2) tetraploid tumours were also observed. Furthermore, 
significantly higher wGIIs were observed in tumours classified as genome-doubled 
compared to non genome-doubled (P<0.0001, Student’s t-test, Figure 4:1), 
suggesting a potential relationship between genome doubling and genomic 
complexity.  
The majority of tumours with a triploid karyotype appeared to have undergone a 
genome-doubling event (105/110 tumours), consistent with a genome-doubling 
event occurring en route to further genomic change (Carter et al., 2012, Davoli and 
de Lange, 2011, Shackney et al., 1989). However, near-diploid tumours with high 
wGIIs and no evidence of genome doubling were also observed within the cohort, 
suggesting that there exist multiple routes to an unstable genome in COAD tumour 
evolution. A small number of relatively stable genome-doubled tetraploid tumours 
were also observed; potentially indicating genome doubling may be an early event 
in COAD evolution.  
To explore whether these results were consistent across cancer types, both the 
prevalence of genome doubling and its association with the wGII was explored in a 
further 9 cancer types (Figure 4:2). The prevalence of genome doubling was found 
to vary considerably across cancers, with almost 80% of oesophageal carcinomas 
exhibiting evidence for genome doubling, in contrast to only 23% of GBM tumours. 
In all cancer types, wGIIs were found to be significantly higher in genome-doubled 
compared to non-genome-doubled tumours (P<0.001,all cancer types, Figure 4:2). 
Taken together, these results suggest genome doubling and chromosomal 
instability may be linked in a range of cancer types.  
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Figure 4:2 Genome doubling across cancer types 
wGIIs for genome-doubled (GD) and non-genome-doubled (nGD) tumours is 
shown for 9 different cancer types. In every case, wGIIs are significantly higher in 
GD tumours compared to nGD tumours.  
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4.2.4 Genome doubling is an early event in the majority of COADs 
To determine the timing of genome doubling in colorectal cancer evolution, the 
relative abundance of different copy number states can be used. Copy number 
losses occurring on the background of a diploid genome will necessarily result in 
loss of heterozygosity (LOH), as either the maternal or paternal allele will be lost. 
This LOH will leave a permanent footprint in the genome, persisting after a 
genome-doubling event and will be indelibly imprinted for the remainder of the life 
history of the tumour (Figure 4:3-2 A i). By contrast, losses occurring after genome 
doubling are less likely to exhibit LOH (Figure 4:3-2 A ii). The types of losses in a 
genome-doubled sample may thus shed light on the relative timing of a genome-
doubling event in cancer evolution.  
In the majority of genome-doubled TCGA COAD tumours, genome doubling likely 
occurred as a relatively early event, prior to the majority of copy number losses (Fig. 
1B). In almost two thirds (130/196) of genome-doubled tumour, a higher fraction of 
the genome was found to be present at heterozygous diploid compared to 
homozygous diploid. Further, in 20% of these samples, the proportion of the 
genome exhibiting LOH was less than is typical for stable tumours exhibiting 
microsatellite instability (MSI).  
These data not only suggest that genome doubling is frequently an early event in 
colorectal tumours, but importantly, also imply that CIN often occurs after genome 
doubling in vivo.  
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Figure 4:3 Timing genome doubling  
A) i) Copy number losses that occur on the background of a diploid genome, before 
genome doubling, will result in LOH. In tumours that harboured CIN before 
doubling, the majority of losses will be unbalanced, involving LOH. Unbalanced 
losses to two copies (AA or BB) are depicted with a purple box with purple dotted 
lines. ii), in tumours where genome doubling was an early event, before the onset 
of CIN, the majority of losses to two copies will be balanced without LOH. Balanced 
losses to two copies (AB) are depicted with an orange box with orange dotted lines 
around them. B) Timing of genome doubling estimated using copy number and 
LOH profiles. Each bar represents one genome-doubled TCGA tumour and its 
height corresponds to the proportion of AB − proportion AA or BB copy number 
states. Tumour genomes in which the majority of losses to two copies are likely to 
have occurred after genome doubling are shown in red (n = 130; proportion AB > 
proportion AA or BB), and those where the majority of losses are likely to have 
occurred before doubling are shown in blue ( n = 66; proportion AB < proportion AA 
or BB).  
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4.2.5 Timing of genome doubling varies across cancer types 
Applying the same reasoning to a further nine cancer types revealed that the timing 
of genome doubling is variable across cancer types. Interestingly, in BRCA, ESCA, 
LUSC and SKCM, there was a highly significant trend for the majority of deletions 
in genome-doubled tumours having occurred before a genome doubling, 
suggesting genome doubling may be a later event in these cancer types, occurring 
after the onset of CIN (Figure 4:4, P<0.001, paired Wilcoxon test). Conversely, in 
KIRC, like COAD, there was a significant trend for genome doubling occurring as a 
relatively early event (Figure 4:4).  
Taken together, these data suggest divergent patterns of genome doubling both 
within and across tumour types. 
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Figure 4:4 Timing of genome doubling across cancer types 
Timing of genome doubling across 9 cancer types. In each cancer type, the 
proportion of the genome that shows balanced losses to diploid (AB) is compared 
to unbalanced (BB or AA). P-values are indicated, reflecting the results of a paired 
Wilcoxon test.  
4.2.6 Genome doubling often occurs prior to the last clonal sweep at SNV 
level 
Using multi-region sequencing data from oesophageal and NSCLC (Table 3-1 and 
Table 3-2), it was possible to gain further resolution regarding the timing of genome 
doubling. Genome doubling events were observed in all 8 oesophageal 
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adenocarcinomas, in keeping with its high prevalence in TCGA data. In every case, 
the genome-doubling event was shared in all tumour regions, indicating it likely 
occurred on the trunk of the phylogenetic tree, prior to last clonal sweep and before 
the emergence of the most recent common ancestor. In addition, extensive LOH 
was observed in every tumour, suggesting the doubling may have occurred after 
the onset of chromosomal instability. These data corroborate the findings 
discussed above using TCGA copy number data, indicating genome doubling in 
oesophageal cancers often occurs after the onset of CIN. 
In the multi-region NSCLC cohort, four out of six tumours displayed evidence for 
whole-genome–doubling events. In three tumours (L001, L004, and L008), the 
genome-doubling event was identified in every tumour region, indicating it occurred 
on the trunk of the tumours’ evolutionary tree. In each of these cases, the majority 
of truncal mutations (84-88%) were present at ploidy >=2, consistent with a large 
mutational burden preceding genome doubling. Further, in these three tumours, all 
truncal driver mutations were found to exhibit mutation copy numbers >=2, 
suggesting these were present prior to doubling. 
These data are consistent with genome doubling being a relatively late event in 
NSCLC. In further support of this, in L002 the majority of heterogeneous mutations 
were found to be present at ploidy >=2, indicative of two independent genome-
doubling events: one in the LUAD region, region R1, and one in the LUSC region, 
region R3 (Figure 4:5).  Additional NSCLC multi-region sequencing data will be 
required to decipher the frequency of multiple independent genome doubling 
events during tumour evolution in this cancer type. 
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Figure 4:5 Genome doubling in L002 
2D-dirichlet process plot (upper) using mutation copy numbers; increasing intensity 
of red indicates the location of a high posterior probability of a cluster. Private 
mutations clustered at a copy number 2 are observed in both regions R1 and R3, 
suggesting two independent genome-doubling events. Copy number profiles of 
L002 regions R1 and R3 (lower). Trunk mutations are shown in blue, whilst private 
mutations are depicted in green. Total copy number is depicted as a black line, with 
minor allele as a red line.  
Chapter 4. Results 
 
 142 
In combination, these data suggest genome doubling is a common event across 
human cancers and that polyploid tumours often arise from a genome-doubling 
event, rather than through sequential gains of individual chromosomes. While, in 
COAD and KIRC tumours genome doubling appears to be a relative early event, 
potentially preceding CIN, in the majority of other cancer types, genome doubling 
appears to occur after the onset of chromosomal instability.  
4.2.7 Enrichment for mutations in TP53 in genome-doubled tumours 
Given the established associated between disruption of the tumour suppressor 
gene TP53 and chromosomal instability (Giam and Rancati, 2015), the relationship 
between genome doubling and mutations in TP53 was next explored.  
Across the pan-cancer cohort, a highly significant enrichment of TP53 mutations 
was observed in genome-doubled compared to non genome-doubled tumours 
(P<0.0001, Fisher’s exact test). Further, almost invariably (>90% cases), these 
mutations occurred prior to doubling, significantly more than the background rate, 
consistent with TP53 playing an important role in tolerance of genome doubling 
(Figure 4:6).  
Nevertheless, despite this strong association, a substantial majority of genome-
doubled tumours (831/1270) did not exhibit somatic mutation disruption to TP53, 
suggesting there are likely multiple routes to tolerance of genome doubling.  
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Figure 4:6 TP53 and genome doubling 
A) Association between mutations in TP53 and prevalence of genome doubling. B) 
Timing of mutations in TP53 compared to background randomizations. 92% of 
mutations in TP53 are classified as early, significantly more than expected given 
random mutations.  
4.2.8  An isogenic cell line system to study the effects of genome doubling 
To explore the impact of genome doubling on genome stability in colorectal cancer, 
an isogenic, p53 wild-type cell line system was used. The experimental work 
described in this section of the thesis was undertaken by Sally M. Dewhurst.  
HCT-116, a diploid micro-satellite unstable COAD cell line, was found to have a 
small sub-population (<2%) with >4N DNA content (Figure 4:7 A), reflecting a 
genome-doubled population. Single tetraploid (genome-doubled) and diploid (non 
genome-doubled) cells were isolated by flow cytometry. The cloning efficiency of 
genome-doubled cells was lower than non-diploid cells, suggesting a genome 
doubling event is poorly tolerated in HCT-116 cells under standard culture 
conditions (2N= 63%, 4N= 6%, Figure 4:7 B), 
One diploid clone (nGD 8) and two rare surviving genome-doubled, tetraploid, 
clones (GD 3, GD 4, Figure 4:7 C), were expanded in culture. It was also possible 
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to isolate a second generation of genome-doubled clones (GD-13, GD-16, GD-17, 
GD-35) as well as two diploid, non-genome-doubled, clones (nGD-14, nGD-25) 
from the diploid clone nGD 8 (Figure 4:7 D). Thus, all second-generation clones 
shared a common ancestor (nGD 8), and had arisen spontaneously within the time 
frame of the experiment. The ancestry of genome-doubled and non-doubled clones 
can be seen in Figure 4:7 E.  
To verify that any observed differences between genome-doubled and non-
genome-doubled clones were not impacted upon by MSI status, an MLH1 
competent clone, HCT-116_MLH, was also investigated. In this clone, a wild-type 
MLH1 allele was reincorporated into the genome, thus effectively rendering the 
clone micro-satellite stable.  Both genome-doubled (MLH-GD11 and MLH-GD16) 
and non-genome-doubled (MLH-nGD8) clones were isolated from this MLH 
competent cell-line (Figure 4:7 E).  
All genome-doubled clones were found to have a seemingly functional p53 
response to DNA damage, and no mutations were found in the coding regions of 
TP53 or CDKN1A (p21), suggesting that in these clones tolerance to genome 
doubling cannot be accounted for by direct disruption of p53.  
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Figure 4:7 Isogenic genome doubling cell-line system 
A) Flow cytometry shows a >4N population in the MSI colon cancer cell line HCT-
116, indicative of a genome-doubling event. B) Cloning efficiency of 2N and >4N 
cells is shown with mean and standard error of mean (three experiments). The 
cloning efficiency of the >4N, genome-doubled, population was significantly lower 
than cloning efficiency of the diploid, non genome-doubled, population  (P = 0.032, 
Student’s t-test). C) After single-cell sorting, DNA content was assessed by flow 
cytometry with Hoescht staining. Two genome-doubled clones (GD 3 and GD 4), 
one non genome-doubled, diploid, clone (nGD 8), as well as HCT-116 are 
depicted. D) Flow cytometry of the non genome-doubled clone nGD 8 also shows a 
small >4N subpopulation. Two further non-genome-doubled, diploid, clones (nGD-
14 and nGD-25) and four genome-doubled clones (GD-13, GD-16, GD-17, and 
GD-35) were isolated from nGD 8, and their DNA content, by flow cytometry with 
Hoescht staining. E) A family tree depicting the relationships between genome-
doubled and non genome-doubled clones. GD= genome doubled; nGD= non 
genome doubled.  
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4.2.9 Chromosomal instability in genome-doubled clones 
To explore the level of chromosomal instability in both genome-doubled and non-
doubled clones data from experiments conducted by Sally Dewhurst were analysed.  
A measure of numerical instability can be obtained by assessing the percentage of 
cells deviating from the modal chromosome number within individual cell colonies, 
using clonal fluorescence in situ hybridization (FISH). Within a given colony, a high 
degree of deviation from the mode is indicative of cell-to-cell variation in 
chromosome number, and the presence of chromosomal instability during the 
clonal expansion. By contrast, colonies exhibiting little deviation from the mode, 
and low cell-to-cell variation, suggest limited chromosomal instability during clonal 
expansions.  
Colonies from genome-doubled clones displayed significantly higher cell-to-cell 
variation than non-genome-doubled colonies (Figure 4:8 A: passage 5 non 
genome-doubled mean=7% (0-23%); genome-doubled mean=28% (5-57%), 
P<0.0001; passage 50 non genome-doubled mean=13% (3-34%); genome-
doubled mean=33%, (7-68%), P<0.0001, Student’s t-test). The results remained 
consistent in genome-doubled clones derived from a microsatellite competent clone 
of HCT-116.   
To further assess the level and extent of chromosomal instability, segregation 
errors occurring during mitosis were assessed on both a per-cell and a per-
chromosome basis using immunofluorescence. Specific segregation errors scored 
included lagging centric chromosomes, anaphase bridges, lagging acentric 
chromosome fragments, and joint lagging dicentric chromosomes.  
Genome doubled cells exhibited a significantly higher proportion of segregation 
errors compared to non-genome-doubled cells across three different passages 
(Figure 4:8 B). However, the segregation error rate on a per chromosome basis 
was not found to be significantly different between genome-doubled and non-
genome-doubled clones. These data suggest the elevated segregation error rate in 
Chapter 4. Results 
 
 147 
genome-doubled clones may simply result from the greater number of 
chromosomes that these cells harbour. In further support of this, the profile of 
segregation errors in genome-doubled and non-genome-doubled clones was not 
significantly different.  
The prevalence of structural chromosome aberrations in all clones was scored from 
metaphase chromosome spreads hybridised to an all-centromere fluorescent probe 
(Figure 4:8 C). Specifically, the presence of di-centric chromosomes, a-centric 
chromosomes as well as double strand breaks was scored. The number of 
structural abnormalities per cell was found to be significantly higher in genome-
doubled compared to non genome-doubled cells (Figure 4:8 C, non genome-
doubled mean: 0.39 (0.26-0.58) abnormalities; genome-doubled mean: 0.93 (0.60-
1.62) abnormalities, all passage P<0.05, Student’s T test). However, in keeping 
with the result from scoring segregation errors, on a per chromosome basis the 
number of structural abnormalities was not significantly different between genome-
doubled and non-genome-doubled clones (Figure 4:8, abnormalities per 
chromosome: diploid mean=0.0088 (0.0058-0.0130); tetraploid mean=0.0108 
(0.0073-0.0180), P=0.1093, Student’s t-test). 
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Figure 4:8 Chromosomal instability in genome-doubled clones 
A) Cell-to-cell variation in chromosome number. The average percentage deviation 
of chromosome 2 and 8 is shown for each clone at passages 5 and 50. Each point 
represents one colony. Median number of cells: at passage 5 = 2,479, passage 50 
= 2,105. B) Chromosome segregation errors on a per-cell and per-chromosome 
basis. Errors on a per-cell basis are shown on top graph and on a per-chromosome 
basis on bottom. C) Structural abnormalities on a per-cell and per-chromosome 
basis. Abnormalities on a per cell basis are shown on the top, and on per 
chromosome are shown below. Median number of spreads scored at each 
passage: passage 5 = 25, passage 25 = 29, passage 50 = 27, and HCT-116 = 37; 
ns, not significant. GD= genome doubled; nGD non-genome doubled 
Finally, to determine whether chromosomal instability was present in genome-
doubled clones prior to genome doubling, all clones were subject to SNP6.0 
analysis, and the proportion of the genome showing LOH was determined (Figure 
4:9). As discussed above, any losses occurring prior to a genome-doubling event 
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will necessarily result in LOH. Thus, if chromosomal instability were present prior to 
doubling one would expect to see genomic scars in the genome in the form of LOH. 
However, early passage genome-doubled clones showed limited to no LOH 
beyond that harboured by the diploid clones (diploid, non genome-doubled, mean: 
6.17% (5.96–6.36%) of genome; genome-doubled mean 6.46% (6.16-6.79%), 
P=0.181, Kolmogorov-Smirnov test). These data are in agreement with findings in 
TCGA COAD tumours, suggesting genome doubling often occurs prior to CIN in 
this cancer type.  
 
Figure 4:9 LOH in GD and nGD clones 
SNP6.0 data illustrating extent of LOH in genome-doubled and non genome double 
early passage clones. LOH is depicted in purple. Notably, little difference in 
genomic regions of LOH is seen between genome-doubled and non genome-
doubled clones. The barplot above displays the proportion of the genome exhibiting 
LOH. GD= genome-doubled, nGD = non genome-doubled.  
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4.2.10 Tolerance of chromosomal instability observed in genome-doubled 
clones 
A chromosomal instability phenotype requires not only a high rate of errors, but 
also a tolerance of errors, enabling propagation of aneuploidy (Thompson and 
Compton, 2010). As such, a high rate of both cell-to-cell variation and segregation 
errors in genome-doubled clones does not equate with tolerance to chromosomal 
instability. To explore whether genome-doubled clones exhibited enhanced 
tolerance to chromosomal instability, SNP6.0, clonal FISH experiments and live-cell 
imaging was performed.  
Given that SNP6.0 data provides a population measure of chromosomal content, 
any aberrations detected by SNP6.0 are suggestive of not only tolerance of errors, 
but also their propagation. Thus, to assess tolerance and propagation of 
chromosomal instability, all clones were subject to SNP6.0 analysis at multiple 
different passages over 18 months in culture.  
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Figure 4:10 Tolerance to CIN in GD clones 
A) wGIIs for nGD and GD clones from passage 5 to 75. Dashed line indicates wGII 
= 0.2, a threshold separating MSI and CIN cell lines (Burrell et al., 2013a). GD 
clones are depicted in red, nGD in blue. B) wGIIs for GD and nGD clones in 
relation to COAD tumours. Each grey dot represents one TCGA COAD tumour 
while red dots and blue dots represents GD and nGD clones respectively. C-D) 
Frequency of different colony modes from clonal FISH data is shown from all 
clones at passage 5 (C) and at passage 50 (D). Shannon diversity (SD) index is 
show above each colony. Median number of colonies scored: passage 5 = 44, 
passage 50 = 39. E) Live-cell imaging of H2B-mRFP–expressing cell reveals 
different daughter cell fates after segregation errors. GD= genome doubled; nGD 
non-genome doubled. 
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Early-passage non-genome-doubled clones exhibited wGII scores similar to stable 
COAD tumours.  Furthermore, non-genome-doubled clones remained stable over 
time, suggesting either a lack of tolerance of segregation errors, or, alternatively, 
no selection for an altered karyotype. Conversely, in genome-doubled clones, wGII 
significantly increased from passage 5 through to passage 75 clones (One way 
ANOVA test for passage 5, 25 and 50, GD P=0.0002, nGD P=0.5907,Figure 4:10 
A). By the late passage (approximately 18 months), genome-doubled clones had 
wGIIs similar to those of genomic complex polyploidy COAD tumours in the TCGA 
data set  (Figure 4:10 B). Changes in genome-doubled clones over time in culture 
are therefore in keeping with a model of genome doubling occurring as a precursor 
state to a complex triploid karyotype, commonly observed in COAD.  
To confirm the increased tolerance to chromosomal segregation errors observed in 
genome-doubled clones, clonal FISH data was further utilized. The presence of 
multiple colonies with distinct modal populations may be indicative of colony-to-
colony variation and tolerance of CIN. The extent of this variation can be quantified 
by the Shannon diversity index. This index, frequently used in ecology, integrates 
both the number and abundance of colonies with differing modes. In non-genome-
doubled, diploid clones, only a single aneuploid colony was observed in HCT-116 
(1.7% of colonies) and one tetraploid colony was observed in a non genome-
doubled clone, consistent with the observation that genome doubling is a rare and 
poorly tolerated event in diploid cells. Overall, genome-doubled clones exhibited 
significantly greater Shannon diversity indices than their non-doubled counterparts, 
both at passage 5 and passage 50 (Figure 4:10, P<0.01, Wilcox test).  HCT-
116_MLH1 genome-doubled clones also exhibited similar colony-to-colony 
variation in modal chromosome number.  
Finally, live-cell imaging was used to track the fate of both genome-doubled and 
non-doubled cells following a segregation error (Figure 4:10 D). In non-genome-
doubled clones, after a cell underwent a segregation error its daughter cells 
frequently died or underwent cell-cycle arrest. However, the majority of non 
genome-doubled cells that underwent a normal division (i.e. no detectable 
segregation errors) continued through a subsequent mitosis. By contrast, in 
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genome-doubled clones, after a cell exhibited a segregation error its daughter cells 
frequently continued through to a normal mitosis in the subsequent cell cycle. 
These data suggest that lack of aneuploidy karyotypes observed in non-genome-
doubled clones reflects a lack of tolerance of segregation errors and not a lack of 
selection for aneuploidy progeny.  
4.2.11 Genome doubled clones evolve specific chromosome losses 
Next, to explore whether convergent losses or gains were observed in genome-
doubled clones, copy number profiles were assessed over long-term culture.  
Chromosomal aberrations present in parental HCT-116 were observed in all 
analysed clones, confirming the ability of SNP6.0 data to identify clonal copy 
number aberrations, persisting through time and evolution of these clones. For 
example, chromosome 8q was identified as amplified in all early passage clones 
(Figure 4:11).  
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Figure 4:11 Specific losses in GD clones 
Genome-wide copy number losses and gains for all clones at passage 5, 25, and 
50 (and passage 75 for nGD-14, nGD-25, GD-13, GD-16, GD-17, and GD-35). 
Blue sections represent copy number losses and red sections represent copy 
number gains (relative to ploidy).  
As expected, no novel chromosomal gains or losses were observed exclusively in 
non-doubled clones. Likewise, in early passage genome-doubled clones no novel 
losses or gains were observed in every clone, indicating no single detectable 
genomic change at the copy number level can account for tolerance to a whole 
genome-doubling event. However, a non-contiguous segment of chromosome 4q 
containing 362 genes was lost to three copies in every genome-doubled clone by 
passage 50. This chromosomal alteration occurs after genome doubling as it does 
not display LOH and not occur before passage 25. This is indicative of selection for 
loss of this chromosomal segment during prolonged culture in every clone. A 
similar pattern of chromosome losses was also observed in HCT-116 MLH1 
genome-doubled clones, suggesting loss of this segment of the genome is 
independent of MIN status (Figure 4:12).   
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Figure 4:12 Specific losses in MLH GD and nGD clones 
Copy number losses and gains for one MLH1 diploid and two tetraploid clones 
compared to parental HCT-116. Clone and passage number is shown on x-axis. Y-
axis shows chromosomal position. Blue represents loss and red represents gain 
relative to ploidy. 
4.2.12 Losses in genome-doubled clones recapitulate losses in unstable 
COAD tumours 
Next, to explore whether loss chromosome of chromosome 4q was specific to the 
cell-line system or whether it recapitulates data observed in vivo, copy number data 
from COAD TCGA data was used.  
Loss of genes identified on chromosome 4q in the cell-line system was found to 
significantly correlate with increasing wGII (Figure 4:13 A) in COAD tumours. The 
relationship remained significant when controlling for the increased likelihood of 
chromosomal loss in unstable tumours (Figure 4:13 B). 
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Figure 4:13 Loss in genome-doubled clones mirror losses in COAD tumours 
A) Correlation between loss in COAD tumours and wGII. Notably, loss of genes on 
chromosomes 4q highly correlates with an unstable genome. B) Simulation to 
control for increased likelihood of chromosomal loss in unstable tumours. 
Correlation remained significant when taking into account the increased number of 
losses observed in tumours with high wGIIs.  
These data suggest the genome doubling cell-line system mirrors the evolution of 
genome-doubled COAD tumours in terms of large-scale copy number events.   
4.2.13 Genome doubling is associated with poor prognosis in CRC tumours 
Given the timing of genome doubling in COAD tumours, and moreover, the 
established relationship between genomic instability and poor clinical outcome 
across cancer types (McGranahan et al., 2012), the association between genome 
doubling and clinical outcome was explored.  
Clinical data, including information regarding both overall and relapse-free survival, 
was obtained for 150 stage 1-3 COAD patients from TCGA. In addition, a validation 
cohort, with relapse free survival, consisting of 189 stage 2-3 COAD patients was 
identified. Given that 80% of colorectal cancer recurrences occur within the first 2 
years, and the paucity of data beyond this time point for TCGA tumours, survival 
data was censored at 2 years.  
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A genome-doubling event, as predicted using allele specific copy number, was 
found to be significantly associated with relapse in both the TCGA and the 
validation cohort (P=0.019 Discovery; P=0.0022, Validation, log-rank test) (Figure 
4:14). When extending outcome to beyond 2 years, genome doubling remained a 
significant predictor of relapse in the validation cohort (P=0.00081, log-rank test), 
but not in the smaller TCGA cohort (P=0.099, log-rank test).  
 
 
Figure 4:14 Genome doubling and relapse free survival in COAD.  
Relationship between genome doubling and relapse free survival in A) TCGA data 
cohort (stage 1-3), censored at 2 years. B) Validation cohort (stage 2-3), censored 
at 2 years. C) TCGA data cohort (stage 1-3) not censored. D) Validation cohort 
(stage 2-3) not censored. E) Validation cohort (stage 2-3), not censored, diploid 
tumours only. In each case, the Kaplan Meier plots are shown, and p-values 
correspond to the log-rank test.  
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To determine whether genome doubling was predictive beyond classical predictors 
of survival in colorectal cancer a multivariate survival analysis was performed using 
a cox proportional hazard model, including tumour stage, age, and MSI status in 
the model. Genome doubling remained significant in multi-variate analysis in both 
cohorts (TCGA, P=0.045, Table 8-5; Validation, P= 0.028, Table 8-7). In the larger 
validation cohort, genome doubling was significant when restricting to just diploid 
tumours (Figure 4:14, P=0.001, log-rank test), and also when including polyploidy 
(ploidy ≥ 3) in a multivariate analysis (P=0.0209, Table 8-9).   
A genome-doubling event may therefore provide prognostic relevance with a 
greater sensitivity than aneuploidy to detect high-risk tumours. Indeed, while the 
wGII was found to be significantly associated with relapse in a univariate analysis 
using TCGA data, it was not a significant predictor using the validation cohort. 
Moreover, wGII was not significant in multi-variate analysis in either cohort.  
Furthermore genome doubling was significant in predicting overall 5-year survival 
when restricting to just early stage 1-2 tumours (available for the TCGA cohort only, 
Table 8-5).  
Finally, the relationship between chromosomal content, genomic complexity and 
tumour stage was considered specifically within genome-doubled tumours. 
Consistent with a model where genome doubling is an early event in COAD 
tumours, accelerating cancer genome evolution, tetraploid genome-doubled 
tumours were found to be genomically more stable and exhibited lower tumour 
stage than sub-tetraploid genome-doubled (ploidy <4) samples (Figure 4:15).  
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Figure 4:15 Tumour stage in genome doubled tumours 
Each circle represents one genome-doubled tumour. The stacked bar-chart shows 
the proportion of different tumour stages for tetraploid and sub-tetraploid samples. 
P = 0.0062, Cochrane– Armitage test for trend. 
4.3 Conclusions  
Analysis of allele specific copy number and mutation data revealed the presence of 
genome doublings in every cancer type, and an association between genome 
doubling and genomic complexity. However, both the prevalence and timing of 
doublings were found to vary across cancer types. In COAD tumours, genome 
doubling appears to be an early event, often occurring prior to detectable 
chromosomal instability. Conversely, in other tumour types, genome doubling often 
appears to occur after the onset of detectable CIN.   
In keeping with previous findings, a significant association between genome 
doubling and disruption to the tumour suppressor gene TP53 was evident across 
the pan-cancer cohort. Nevertheless, despite this association, a substantial 
majority of genome-doubled tumours were found to be TP53 wild-type, suggesting 
there are multiple routes to genome doubling and chromosomal instability, some of 
which may be independent of TP53 disruption.  
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CIN is a complex phenotype, requiring not only segregation errors to be made, but 
also tolerance of the genomic remodelling from one cell division to the next. Indeed, 
increasing segregation error rates in diploid MIN COAD cells does not lead to 
propagation of chromosomally unstable progeny (Thompson and Compton, 2010). 
Through long-term culture of naturally occurring, rare surviving tetraploid clones, 
the evolution of genomic complexity specifically was explored in TP53 wild-type 
colorectal cancer.  A year post genome doubling, the HCT-116 genome was 
considerably altered relative to its genomically stable diploid progenitors, 
suggesting that tolerance of genome doubling facilitates rapid genome evolution. 
Conceivably, a genome-doubling event may provide a permissive genetic 
background for selection of high-risk genomic copy number aberrations over time. 
Consistent with the impact of genome doubling upon genome instability, a 
tetraploidisation event was an independent predictor of reduced relapse-free 
survival time in COAD from the TCGA and in a larger validation cohort in both 
univariate and multivariate analyses. These data support studies that have linked 
aneuploidy with disease outcome in COAD (Araujo et al., 2007), and genome 
doubling with poor prognosis in ovarian cancers (Carter et al., 2012). Genome 
doubling may forecast the onset and tolerance of elevated CIN, which has 
previously been shown to be associated with both poor prognosis and intrinsic drug 
resistance (McGranahan et al., 2012, Lee et al., 2011a).  
Current methods for detecting genome doubling are not without limitation. 
Predicting genome doubling relies on accurate copy number calling, which in itself 
is influenced by tumour purity.  Future methods to define genome doubling and its 
timing may be improved by integrating SNV and copy number data.  
Nevertheless, taken together, these results suggest genome doubling may play a 
key role in driving diversity at the copy number-level. In the next chapter of this 
thesis I will consider how mutational processes at the SNV-level may contribute to 
intra-tumour heterogeneity and their dynamics during tumour evolution.  
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Chapter 5. Dynamics of mutational processes 
5.1 Introduction 
The mutational processes that have been active during the evolutionary life history 
of a tumour leave scars in the cancer genome in the form of somatic events, such 
as SNVs and copy number aberrations. A particular mutational process may result 
in a preponderance of a particular type of somatic event. UV irradiation damage, for 
instance, results in both C>T single nucleotide substitutions as well as CC>TT di-
nucleotide substitutions (Pleasance et al., 2010a). Similarly, chemicals contained in 
tobacco are thought to lead to an elevated number of C>A transversions (Govindan 
et al., 2012, Pleasance et al., 2009). As such, quantifying the types and abundance 
of different types of somatic events can reveal the processes that have been active 
during the evolutionary history of a tumour.  
Recently, mathematical frameworks have been developed to formally quantify the 
number and contributions of mutational signatures operating within cancers at the 
single-nucleotide level (Alexandrov et al., 2013b, Fischer et al., 2013). Application 
of NMF (non-negative matrix factorization) and model selection to more than 7000 
tumours from over 30 cancer types identified 20 distinct mutational signatures 
(Alexandrov et al., 2013a).  
However, although the mutational signatures present during tumour evolution are 
beginning to be characterized, little is known about their temporal decomposition. 
Understanding the dynamics of mutational signatures can reveal the importance of 
different mutational processes at different stages of a tumour’s life history. 
Moreover, these data may reveal whether patterns for tumour evolution can be 
deciphered. From a clinical perspective, this will inform whether mutational 
signatures can act as biomarkers and, further, whether certain processes can be 
considered as potential therapeutic targets.  
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In this chapter, I determine the presence and abundance of mutational processes 
and also explore their temporal decomposition in cancer genomes. I focus in-depth 
on NSCLC and oesophageal adenocarcinoma tumours, exploring the impact of 
both endogenous and exogenous mutational processes, and whether certain 
processes fuel intra-tumour heterogeneity and the acquisition of subclonal driver 
events.  
The work presented in this chapter forms sections of three first or joint first-author 
publications, (McGranahan et al., 2015, de Bruin et al., 2014, Murugaesu et al., 
2015), all of which can be found in Appendix 2.  
5.2 Results 
5.2.1 A signature of tobacco smoke in lung cancer genomes  
To shed light on the mutational processes operating in lung cancer genomes, the 
prevalence of the six types of base substitutions (C>A; C>G; C>T; T>A; T>C; T>G) 
was explored in the cohort of six multi-region NSCLC tumours (Table 3-1). The 
tumours exhibited marked differences in both their mutational load and their 
mutational spectra (Figure 5:1). L002, L004 and L011 were characterized by a high 
mutation burden, with 476, 450 and 387 non-silent mutations identified in these 
tumours respectively. By contrast, in L001, L008 and the two tumours from L003, 
only 195, 117, 76 and 87 non-silent mutations were respectively identified. The 
dichotomy between high and low mutation burden directly reflect the smoking 
status of patients (Table 3-1). L002, L004 and L011 were all current smokers, while 
L001 and L008 were reformed smokers and L003 was a never-smoker.  
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Figure 5:1 Mutational spectra and rate of multi-region NSCLC tumours 
A) Relative abundance of the six mutation types is shown for each tumour. B) 
Number of mutations per mega-base (Mb) with adequate coverage for the six 
mutation types. C) For mutations occurring in transcribed regions of the genome, 
the proportion of each mutation type that was on the transcribed versus 
untranscribed strand is shown.  All tumours are ordered with decreasing C>A 
transversion rate, from top to bottom.  
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The smoking status dichotomy also extended to difference in mutational spectra. 
L011, one of the heaviest smokers (45 pack-years – an average of 1.5 packets of 
cigarettes per day for 30 years), exhibited the greatest proportion of C>A 
transversions and highest rate of C>A transversions per megabase sequenced, 
with over 40% of base substitutions occurring as C>A transversion mutations, and 
a C>A transversion rate of over 3 substitutions per sequenced megabase (Figure 
5:1). Conversely, the two tumours in L003, a never-smoker, were characterized by 
predominantly by C>G and C>T mutations, and also exhibited a low mutation rate; 
indeed, the total mutation rate of all nucleotide substitutions was lower than that for 
L011 C>A transversions alone.   
To gain a deeper understanding of the types of base substitutions occurring in this 
cohort of tumours, mutations occurring in transcribed regions of the genome were 
considered further (Figure 5:1 B). While it is not possible to determine on which 
strand a mutation occurred, it is possible to assess whether a bias exists. Thus, it is 
possible to assess, for example, if C>T mutations preferentially occur on the 
transcribed strand relative to the non-transcribed strand or vice versa.     
A significant strand bias was observed specifically for C>A transversion mutations 
for every tumour (P<0.01, chi-square test), with the exception of L003 and L001. As 
discussed, while L003 was a never-smoker, L001 was a former smoker, who 
stopped smoking 25 years ago (Table 3-1). The bias observed was characterized 
by fewer C>A transversions on the non-transcribed compared to the transcribed 
strand. This is indicative of transcription coupled repair, and specifically nucleotide 
excision repair, which is thought to remove nucleotides with bulky adducts from the 
transcribed strands of genes. The presence of an elevated number of C>A 
transversions on the transcribed strand (at the expense of a reduced number of 
G>T transversions) suggest that bulky adduct damage to guanine may be the 
underlying cause of the observed base substitution.  These data are consistent with 
findings of Pleasance and colleagues (2009).  
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5.2.2 Smoking induced mutations are more likely to give rise to non-silent 
mutations than C>T transitions 
The degenerate nature of the genetic code results in a subset of base substitutions 
being synonymous, such that, despite a change in DNA nucleotide, no change in 
amino acid is observed. For example, both triplets AGC and AGT code for the 
amino acid serine, and, as such, a C>T transition in the 3rd codon position of 
ApGpC will be silent at the amino acid level.   
Given the different mutational spectra observed in different cancer genomes, and, 
by extension, the different mutational processes that have been active, it is worth 
considering that each mutation type, and associated mutational process, may be 
associated with a different likelihood of yielding a non-synonymous mutation.  
Comparing the ratio of C>T transition (the most prevalent nucleotide substitution in 
never-smokers) to C>A transversion mutations (the most prevalent in smokers), 
and the proportion of base substitutions that lead to amino acid substitutions 
reveals that a C>A transversion is more likely to result in non-synonymous 
mutations than a C>T transition (Figure 5:2). This suggests tobacco induced 
mutations may not only increase the mutation rate as a whole, but will also 
increases the proportion of the total mutational load that results in sequence 
changes at the amino acid level.  
An analysis of mutations at cytosine sites within the 3rd codon position, the position 
that is most likely to be degenerate, revealed a clear difference between heavy 
smokers and never-smokers, using data obtained from Imielinski et al. (2012) 
(Figure 5:2). Specifically, for heavy smokers, on average, over 30% of mutations 
occurring at the 3rd codon position result in non-synonymous mutations, yielding a 
change in coding sequence. Conversely, in never-smokers, on average, only 11% 
of mutations at the 3rd codon position result in a non-synonymous mutation. Thus, 
mutations at the 3rd codon position are, on average, 2.72 times more likely to be 
non-synonymous in smokers than never-smokers.  
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Figure 5:2 Likelihood of non-synonymous coding mutations  
The relationship between the ratio of C>A transversions compared to C>T 
transitions is shown for each tumour within the Imielenski cohort (2012). The line 
represents the expected relationship between the two given the genetic code. Each 
dot represents one tumour, with the colour indicating smoking status. Large circles 
represent the median value for each category. In each case, mutations in the 3rd 
codon position are considered.  Light smokers are defined by less than ten pack 
years of tobacco use), and heavy smokers more than ten pack years 
The effect of tobacco induced C>A transversions can also be considered in the 
context of specific DNA sequences or cancer genes. Across the coding sequence 
of the tumour suppressor gene TP53 over 80% of all possible C>A transversion 
mutations result in a non-synonymous amino acid substitution. By contrast, only 
63% of all possible C>T transition mutations are non-synonymous at the amino 
acid level. These data highlight the need to consider both the nucleotide 
composition and mutational spectra of genomes when attempting to identify cancer 
genes.  
It is also interesting to note that the majority of tumours exhibited an elevated rate 
of non-synonymous mutation acquisition compared to what would be expected by 
chance given the genetic code (Figure 5:2). This suggests positive selection may 
be pervasive during lung cancer genome evolution.  
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5.2.3 Temporal dissection of mutation spectra in NSCLC 
Mutational signatures may not only vary between different tumours, but also over 
time, reflecting the dynamics of mutational processes during the evolutionary 
history of a tumour. The temporal dynamics of these processes can be deciphered 
by comparing the spectrum of point mutations acquired on the trunk of a tumour’s 
phylogenetic tree with those acquired on the branches. 
Early (trunk) mutations likely reflect processes involved prior to and during tumour 
initiation and early development. Conversely, late (branch) mutations reveal 
mutational processes shaping the genome during tumour maintenance and 
progression, and may shed light on mechanisms driving diversity within tumours.  
Every multi-region NSCLC tumour, with the exception of L003, had sufficient 
numbers of branch mutations to permit temporal analysis. Given that L002 
represents two histologically distinct subtypes, each histological subtype was 
treated separately, allowing comparisons of LUAD (L002_R1) and LUSC 
(L002_R3) histologies within the same tumour.  
Statistically significant shifts in the mutation spectra were observed between early 
and late mutations in all five tested NSCLC tumours (Figure 5:3; P<0.05 all cases, 
chi-square test). As might be expected, the two ex-smokers both exhibited a 
statistically significant decrease in the proportion of C>A transversions, indicating a 
relative decrease in the mutational burden attributable to smoking in late mutations 
(Figure 5:3; P<0.05 all cases). Curiously, a significant decrease in C>A 
transversions was also observed for current smokers (Figure 5:3; P<0.05 all cases). 
Conceivably, this suggests either the rate of smoking induced mutations may be 
decreasing, despite continuous exposure to tobacco smoke, or, alternatively, an 
additional mutational process may dominate later in tumour evolution.  
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Figure 5:3 Temporal dissection of multi-region NSCLC 
A) Fraction of early mutations (trunk) and late mutations (branch) accounted for by 
each of the six mutation types in all multi-region NSCLC. B) Tri-nucleotide context 
of three mutation types (C>A; C>G; C>T). For each tumour, early (trunk) mutations 
are depicted on bottom, with late (branch) mutations depicted on top.  
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5.2.4 Temporal heterogeneity of APOBEC mutations in NSCLC 
In every NSCLC tumour, the decreasing proportion of C>A mutations later in 
evolution was accompanied by an increase in C>T and C>G mutations. In order to 
gain further resolution regarding the mutational processes active during the 
evolution of NSCLC tumours, the tri-nucleotide context of each mutation was 
considered. Thus, the nucleotides both 5’ and 3’ to the mutated base were taken 
into account, yielding a total of 96 possible mutation types, and, when focussing on 
substitutions from cytosine to any other base, a total of 48 nucleotide substitutions 
(Figure 5:3 B).  
While no particular tri-nucleotide context preference was observed for C>A 
transversions, C>G and C>T mutations occurring on the branches of NSCLC 
tumours exhibited a clear preference towards occurring at TpCpW sites (where W 
represents A or T) (Figure 5:3 B). This particular mutational motif is similar to that 
of APOBEC3B and APOBEC3A, and may therefore be indicative of APOBEC 
mediated mutagenesis (Roberts et al., 2013, Nik-Zainal et al., 2012a).  
To formally assess the significance of an APOBEC mutagenesis pattern within 
each sample, the frequency of mutations occurring with an APOBEC context 
(TpCpW to TpTpW or TpGpW) was compared to that expected with random 
mutagenesis. Enrichment for APOBEC associated mutations was calculated 
relative to the frequency of the APOBEC mutation motif within the genomic region 
surrounding mutated bases (20 nucleotides on either side). This approach was 
chosen as the APOBEC enzyme is thought to scan a limited area of single 
stranded DNA (Roberts et al., 2013).  
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Figure 5:4 Temporal dissection of APOBEC enrichment 
APOBEC mutation enrichment odds ratio for early (trunk, blue bars) and late 
(branch, red bars) mutations for multi-region NSCLC samples. The APOBEC 
signature encompasses C>T and C>G mutations in a TpC context. . The 95% 
confidence intervals for Fisher’s exact test are indicated. Stars indicate P<0.001 of 
comparison between early and late APOBEC enrichment using Fisher’s exact test.  
APOBEC mutation enrichment was identified in five tumours, L008, L001, L004, 
L011, and L002 R1. In four of these five tumours APOBEC enrichment was found 
to be higher on the branches compared to the trunk (L008, L001, L004, and L002 
R1), and the difference was statistically significant in three cases (L008, L001, and 
L002 R1). On average, in L001, L004, L002 R1 and L008 36% of non-silent branch 
mutations were found to occur in an APOBEC mutation context (range 29-41%), 
significantly more than compared to non-silent trunk mutations (range 7-16%). 
Notably, L011, the only tumour that did not show any evidence for branched 
APOBEC enrichment, was also the least heterogeneous tumour.  
To confirm whether APOBEC3B was responsible for the observed pattern of 
mutagenesis, APOBEC3B mRNA expression was also assessed by qPCR in 5 
tumours (L001; L002; L003; L004 and L011). This experiment was undertaken by 
Elza de Bruin. In every tumour, APOBEC3B expression was enriched compared to 
matched normal, consistent with APOBEC3B being responsible for the observed 
signature.  
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Figure 5:5 APOBEC3B mRNA expression 
Barplot showing APOBEC3B mRNA expression in tumour regions relative to the 
adjacent normal lung for each tumour, using TBP mRNA expression for 
normalization. 
5.2.5 Spatial heterogeneity of APOBEC mediated mutagenesis 
Next, to explore whether APOBEC mediated mutagenesis may not only be 
temporally heterogeneous, but also spatially heterogeneous, tumours with multi-
region WGS data were used.  
Clear differences in mutational spectra and APOBEC enrichment was observed 
between the two tumour regions in L002, derived from a current smoker. While the 
adenocarcinoma region, region R2, showed a highly significant enrichment of 
APOBEC mutagenesis (P<0.001), with over 5378 mutations out of 15285 mutations 
classified as C>T and C>G mutations occurring at TpC sites, no enrichment was 
observed in the squamous cell carcinoma region, region R3. The predominant 
mutation type in region R3 remained C>A transversions, consistent with smoking 
still playing a role in moulding the tumour genome. With regards to mutational load, 
region R1 exhibited 3.6 times more mutations than regions R3, suggesting 
APOBEC mediated mutagenesis results in a highly elevated mutation rate. mRNA 
expression analyses confirmed a higher APOBEC3B expression in L002 region R1 
compared to R3 (Figure 5:5).  
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Spatial heterogeneity in mutational spectra was also observed for L008. While the 
tumour regions from both the middle and upper lobes of the lung exhibited 
mutational signatures consistent with APOBEC mediated mutagenesis, this was 
more pronounced in the tumour from the middle lobe, region R3. In this tumour, no 
significant difference in mutational load was observed between the two tumour 
regions, however, region R3 exhibited a low purity level which may have led to 
many mutations occurring at variant allele frequencies below the level of detection.  
 
Figure 5:6 Spatial heterogeneity of APOBEC mediated mutagenesis 
Three mutation types (C>A; C>G and C>T) at all 16 possible tri-nucleotide contexts 
for L002 (A) and L008 (B). For both samples, trunk mutations as well as branch 
mutations from two regions are depicted. Notably, in both cases one region shows 
a clear preponderance of C>T and C>G mutations at TpC sites, indicative of 
APOBEC mediated mutagenesis.  
5.2.6 Mutational signatures identified in the pan-cancer cohort 
To validate the findings in NSCLC in a larger cohort and further explore the 
dynamics of mutational processes across a range of different cancer types, data 
from the TCGA was used. For this analysis, breast cancer was divided into two 
cohorts, oestrogen receptor positive and oestrogen receptor negative. In total, 10 
cancer types were considered, BLCA, ER-positive BRCA, ER-negative BRCA, 
COAD, GBM, HNSC, KIRC, LUAD, LUSC and SKCM.  
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To explore the mutational signatures present in this large cohort of tumours, 
mathematical tools, principally non-negative matrix factorization (NMF) and model 
selection, were applied separately to each cancer type. In brief, this approach 
considers the tri-nucleotide of the catalogue of mutations contained within each 
tumour genome and attempts to quantify both the underlying signatures 
responsible for the patterns of mutations observed and their abundance within 
individual tumours (Alexandrov et al., 2013b).   
In total, across the 10 cancer types, 10 robust mutational signatures were identified 
(Figure 5:7, Experimental procedures). Each signature was clustered with the set of 
mutational signatures previously identified by Alexandrov et al. (2013a) to assess 
whether the signatures identified in this analysis corresponded to known signatures 
from a larger analysis. Clustering analysis suggested every signature identified 
could be linked to an established mutational signature (Figure 5:7).  
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Figure 5:7 Prevalence and temporal dissection of mutational signatures 
Mutational signatures identified across 9 cancer types and their temporal 
dissection. Signature names correspond to those identified by Alexandrov. For 
each signature present in a cancer type, the proportion of tumours where the 
signature is prominent early (red), compared to more prominent late (blue) is 
shown.   
The two most prominent signatures identified across the pan-cancer cohort were 
Signature 1A and Signature 2. Signature 1A is characterized by C>T mutations at 
CpG sites and has been attributed to spontaneous deamination of methylated 
cytosine.  This signature is thought to reflect cell-turnover, and has been shown to 
correlate with patient age at diagnosis (Alexandrov et al., 2013a).  
Signature 2, on the other hand, is dominated by C>T and C>G mutations at TpC 
sites and is thought to relate to APOBEC3B mediated mutagenesis. To validate the 
similarity between Signature 2 and the APOBEC enrichment signature defined 
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above, the two signatures were compared using all TCGA LUAD samples. 
Reassuringly, Signature 2 was found to significantly correlate with the APOBEC 
signature (P<2.2e-16, R2 = 0.74, Figure 5:8), suggesting the two independent 
methods to define APOBEC mediated mutagenesis are concordant.     
 
Figure 5:8 Comparisons of algorithms to infer mutational processes 
Left panel shows comparison between two independent approaches to identify 
APOBEC mediated mutagenesis patterns. The fold enrichment of APOBEC-
signature mutations was determined for all TCGA LUAD tumours and compared to 
the proportion of mutations identified as Signature 2 using NMF and model 
selection. High correlation, as determined by Pearson correlation, indicates 
concordance between the two approaches. Right panel shows comparison 
between the proportion of C>A transversions within each cancer tumour and the 
proportion of Signature 4 mutations using NMF and model selection. High 
correlation, as determined by Pearson correlation, indicates these independent 
methods are highly concordant.   
In addition, as expected, a signature reflecting exposure to tobacco carcinogens 
was also identified in the cohort. Consistent with multi-region sequencing analysis, 
Signature 4, characterized by a preponderance of C>A transversions was identified 
in both LUAD and LUSC tumours, and this signature was also identified in HNSC 
tumours. Further, the proportion of mutations classified as Signature 4 was found to 
highly correlate with the proportion C>A transversions in LUAD tumours (R2 =0.95, 
P<2.2e-16, Figure 5:8). These data suggest considering the proportion of C>A 
transversion mutations is equivalent to determining the proportion of Signature 4 
mutations.  
Certain signatures were also specific to given cancer types. For example, every 
SKCM tumour was characterized by Signature 7 mutations, which is thought to 
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relate to exposure to UV radiation, and is characterized by a preponderance of C>T 
transition mutations, especially at TpCpC sites (Alexandrov et al., 2013a). 
Signature 6, on the other hand, was specific to COAD tumours and is thought to 
reflect micro-satellite instability (Alexandrov et al., 2013a).  A subset of COAD 
tumours were also characterized by a highly specific mutational profile, involving 
C>A transversion mutations at TpCpT sites and C>T transitions at TpCpG sites. 
The mutational process responsible for this signature is thought to be mutations in 
POLE-E, resulting in a lack of recognition and removal of mis-paired nucleotides by 
the exonucelase activity of DNA polymerase-ɛ (Alexandrov et al., 2013a) 
In both oestrogen positive and oestrogen negative breast cancers, a signature 
(Signature 3) thought to reflect defects in BRCA1 and BRCA2, genes involved in 
DNA double strand break repair by homologous recombination, was identified.  
Mutational signatures where the underlying aetiology remains unclear were also 
identified. In five cancer types, Signature 5 was identified. Given its relatively flat 
profile, with no particular tri-nucleotide context prominent, it is difficult to ascertain 
the mutational process responsible for this signature.  
5.2.7 Temporal dissection of mutations reveals dynamics of mutational 
processes  
Next, temporal dissection of mutations was used to shed light on the dynamics of 
the mutational processes during tumour evolution and to explore whether findings 
using multi-region sequencing in NSCLC could be validated. Mutations were 
classified as ‘early’ or ‘late’ based on both their cancer cell fraction and their 
mutation copy number in given tumours. It was reasoned that clonal mutations 
likely represent relatively early events in tumour evolution, occurring before or at 
the time of the most recent clonal sweep, whereas subclonal mutations represent 
later events. In the case of genome doubling or amplification events, the timing of 
mutations was further refined; a mutation occurring before doubling would be 
expected to be present at multiple copies, whereas a mutation occurring after a 
doubling would only be present at one copy. Thus, mutations were defined as ‘early’ 
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if they were clonal and did not occur after amplification or a genome-doubling event. 
Conversely, ‘late’ mutations were defined as those that were subclonal or occurring 
after genome doubling or amplification events (Figure 5:9).  
 
Figure 5:9 Timing mutations using copy number and clonal status 
Mutations can be timed by using both copy number and clonal status of mutations. 
Clonal mutations occurring prior to genome doubling of amplification events are 
likely ‘early’ mutations, whereas mutations occurring after genome doubling, or only 
in a subset of cancer cells are likely ‘late’ events.  
In four cancer types, Signature 1A was significantly more prevalent in early 
compared to late mutations (BRCA ER-positive, P=0.0359;BRCA ER-negative, P 
=0.000629; COAD, P=7.59e-15; GBM, P=3.55e-10; and HNSC, P=2.26e-09, 
Figure 5:7). These data suggest that a large proportion of early mutations represent 
non-cancer-specific mutational processes, such as aging, and additional cancer-
specific mutational processes may be required for tumour development.  
Consistent with additional cancer-specific mutational processes increasing in 
prevalence later in tumour evolution, and in keeping with temporal dissection of 
multi-region NSCLC, Signature 2, which, as discussed, has been linked with up-
regulation of APOBEC cytosine deaminases, was found to increase over time in 
the majority of tumour types in which it was detected. A highly significant increase 
in Signature 2 was observed for later mutations in LUAD tumours (P=3.33e-06), 
and a similar pattern was observed for HNSC (P=5.57e-07) and BLCA 
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Figure 5:10 Examples of temporal dissection of TCGA LUAD and LUSC tumours 
For three tumours A) LUAD-55-6972; B) LUSC-22-5491; C) LUSC-46-3769 
mutational spectra, showing proportion of mutations at each of the 96 tri-nucleotide 
contexts is shown for all mutations, early mutations and late mutations. In addition, 
mutational signatures for different mutational sets are shown.  
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(P=4.39e-06). LUAD-55-6972 provided a clear example of a TCGA LUAD tumour 
exhibiting an increase APOBEC signature over time (Figure 5:10 A):  while less 
than 25% of early mutations in this tumour were classified as Signature 2, over 
70% of late mutations were found to be potentially APOBEC-related.   
In LUSC tumours, although APOBEC was frequently detected, no clear pattern in 
temporal dissection was observed - with some tumours exhibiting APOBEC as a 
late pattern, and others as early. For example, in LUSC-22-5491, APOBEC 
mediated mutagenesis was a later event, with 69% of late mutations classified as 
belonging to Signature 2, compared to only 21% of early mutations (Figure 5:10 B). 
LUSC-46-3679, by comparison, exhibited strong APOBEC enrichment in its early 
mutations, with less APOBEC enrichment detected in late mutations (Figure 5:10 
C).   
Interestingly, in BRCA a tendency for Signature 2 to increase in frequency in later 
mutations was observed in ER-negative BRCA (P=0.0126), but not in ER-positive 
breast cancers (P=0.597), highlighting the differences between these two subtypes 
of breast cancer.  Signature 13, also linked to APOBEC cytosine deaminases, was 
found to be significantly more prevalent in early compared to late mutations in 
BLCA (P=6.67e-07). Signature 13 has been postulated to be associated with 
APOBEC coupled with excess activity of DNA repair protein REV1. These data 
suggest Signatures 2 and 13 are distinct mutational processes that can be 
separated temporally in BLCA (Figure 5:12).  
In terms of exogenous mutational processes, Signature 4, associated with 
smoking-induced mutations, was significantly more prevalent in early compared to 
late mutations in LUAD (P=4.56e-17) and LUSC (P=8.1e-07), and a similar pattern 
was observed in HNSC (P=0.0338). For example, while over 50% of early 
mutations in LUAD-55-6972 were classified as Signature 4, after the whole 
genome-doubling event, only 10% of late mutations were linked to tobacco 
exposure (Figure 5:10 A). These data act as a validation for the multi-region 
sequencing findings described above and likely reflect the fact that despite the 
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mutagenic effects of tobacco smoke, additional mutational processes occur during 
tumour development.  
Furthermore, in keeping with the small cohort of multi-region NSCLC tumours, the 
temporal decrease in C>A mutations, associated with Signature 4, was observed 
both for smokers and never-smokers, suggesting its proportional decline does not 
simply represent an absence of tobacco induced mutations (Figure 5:11). 
  
 
Figure 5:11 Temporal dissection of LUAD and LUSC TCGA tumours 
Proportion of early and late mutations that correspond to the six different mutation 
types is shown for TCGA LUAD and LUSC tumours, further grouped according to 
smoking status. Significance is shown for a paired t-test for each mutation type.    
To shed further light on the impact of smoking in tumour development, and further 
verify whether tobacco smoke still induces mutations later in tumour evolution, 
mutations occurring in transcribed regions of the genome were considered. Both 
LUAD and LUSC ex-smokers revealed a statistically significant decrease in the 
Chapter 5. Results 
 
 181 
strand bias in late compared to early C>A transversions (LUAD, P=0.00354; LUSC, 
P=0.046), consistent with smoking having left a footprint on these genomes but no 
longer being active. By contrast, no statistically significant difference in strand bias 
was observed between early and late mutations in current-smokers in either cancer 
type (LUAD, P=0.23; LUSC, P=0.220). The data indicate that in current-smokers, 
smoking likely still impacts upon the cancer genome.  
 
Figure 5:12 Mutational signatures in a SKCM and a BLCA tumour 
For two tumours A) SKCM-ER-A2ND; B) BLCA-FJ-A32F mutational spectra, 
showing proportion of mutations at each of the 96 tri-nucleotide contexts is shown 
for all mutations, early mutations and late mutations. In addition, mutational 
signatures for different mutational sets are shown.  
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Similar to Signature 4, Signature 7, related to mutations caused by exposure to UV, 
was elevated in early compared to late mutations in SKCM tumours (P=5.67e-
11;Figure 5:7; Figure 5:12 A). In SKCM, it is also worth noting that most samples 
were derived from metastatic sites, thus many of the later mutations may have 
been acquired when tumour cells were no longer exposed to UV light. 
5.2.8  APOBEC mediated mutagenesis is not merely a transient event 
It is important to note that, when detected in tumours, Signature 2 was most 
frequently identified in both early and late mutations, albeit often to a lesser degree 
in early mutations. This suggest that although APOBEC may dominate later in 
tumour evolution, its activity is not transient and it does not represent an historical 
relic within the tumour genome, active at only one point in time during the disease 
course (Roberts and Gordenin, 2014, Swanton et al., 2015).  
5.2.9 Deciphering dynamics of mutational processes in oesophageal cancer 
using multi-region sequencing 
To further explore the temporal dynamics of mutational processes in cancer 
genome evolution, multi-region sequencing data from oesophageal 
adenocarcinoma was used (Table 3-2). As in multi-region NSCLC, the mutational 
spectra of early (trunk) and late (branch) mutations were compared for each tumour. 
In every case, significant shifts in the mutational spectra over time were observed. 
Notably, in 6 out of 8 cases, a trend for a decrease in the proportion of T>G 
mutations was observed.  
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Figure 5:13 Temporal dissection of mutations in oesophageal adenocarcinoma  
A) Proportions of the six base substitutions is shown for all eight oesophageal 
adenocarcinoma tumours for both early and late base substitutions. B) Proportions 
of base substitutions within each tri-nucleotide context, for early and late mutations, 
are shown. Notably, five of the early oesophageal adenocarcinomas are 
characterized by T>G mutations occurring specifically within a CpTpT context.  
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In the majority of cases, trunk mutations were characterized by a strong enrichment 
for T>G transversion mutations occurring with a CpTpT context (Figure 5:13). 
When focussing on late mutations, however, a relative decrease in the proportion 
of T>G mutations occurring within a CpTpT context was observed, accompanied by 
a relative increase in C>T transition mutations at CpG sites. To formally assess the 
enrichment for T>G transversion mutations and T>C transition mutations occurring 
within a CpTpT context, a test was devised in order to compare the prevalence of 
these mutations compared to random mutagenesis. Significant enrichment for this 
mutational signature was identified in five out of eight tumours, and in general, it 
was found to decrease over time (Figure 5:14).  
 
Figure 5:14 Enrichment of T>G and T>C mutations at CpTpT sites 
Mutation enrichment odds ratio for early (trunk, blue bars) and late (branch, red 
bars) mutations for multi-region NSCLC samples. The 95% confidence intervals for 
Fisher’s exact test are indicated. 
While T>G mutations occurring within a CpTpT context have been linked to acid 
reflux (Dulak et al., 2013, Weaver et al., 2014, Nones et al., 2014), C>T transition 
mutations at CpG sites, as previously discussed, likely correspond to spontaneous 
deamination of methylated cytosines (Yates and Campbell, 2012). Thus, these data 
suggest that founder genomic events occur within an environmental context, 
possibly attributable to exposure to gastric acid, but this is not the major process 
contributing to mutational diversity in the growing neoplasm. 
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5.2.10  Differences between oesophageal adeno and squamous cell 
carcinoma 
To validate the temporal dynamics of observed mutational processes in 
oesophageal adenocarcinoma and compare the differences between oesophageal 
adenocarcinoma and oesophageal squamous cell carcinoma, data from TCGA was 
used. For this analysis, mutations signatures were deciphered using the R package 
deconstructSigs, developed by Rachel Rosenthal.  
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Figure 5:15 Temporal dissection of mutational signatures in oesophageal 
squamous and adenocarcinoma tumours 
Mutational signatures identified across oesophageal adeno and squamous cell 
carcinoma and their temporal dissection. Signature names correspond to those 
identified by Alexandrov (2013a). For each signature present in a cancer type, the 
proportion of tumours where the signature is prominent early (red), compared to 
more prominent late (blue) is shown.   
Signature 17, characterized predominantly by T>G transversion mutations 
occurring with a CpTpT context, was identified in 60 out of 82 patients with 
oesophageal adenocarcinoma. Consistent with multi-region sequencing data, in the 
majority of patients in which this signature was identified, it was found to decrease 
over time. A notable example was ESCA-2H-A9GR, a tumour that exhibited a 
genome-doubling event. A marked decrease in the proportion of mutations 
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corresponding to Signature 17 was observed after the genome doubling, 
accompanied by an increase in the proportion of mutations classified as Signature 
1A. However, a small number of patients were also identified in which the reverse 
was observed. For instance, ESCA-2H-A9GR, exhibited a trend for Signature 17 to 
increase at the expense of Signature 1A (Figure 5:16 B).  
 
Figure 5:16 Example of temporal shift in mutational signature in oesophageal 
adenocarcinoma using TCGA 
A, B) Left panel shows mutational spectra of all, early and late mutations in an 
oesophageal adeno (A) and squamous cell carcinoma (B). Proportion of different 
mutational signatures is shown in right panel.  
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Signature 17 was not detected in oesophageal squamous cell carcinoma tumours, 
highlighting the differences between these two types of tumour. Another notable 
differences between the two cancer types was that a significantly higher proportion 
of oesophageal squamous cell carcinoma tumours were found to exhibit APOBEC 
mediated mutagenesis (P=0.011, Fisher’s Exact test). Similar to LUAD, HNSC, and 
oestrogen negative BRCA, the proportion of APOBEC-related mutations was found 
to be significantly elevated in later compared to early mutations in oesophageal 
squamous cell carcinomas (P=0.004), and a similar trend was observed for 
oesophageal adenocarcinoma (P=0.09).  
5.2.11 A signature of platinum therapy in oesophageal adenocarcinoma 
Therapy may at as an exogenous source of mutations, leaving scars in the cancer 
genome, which are subject to selection and neutral evolution (Ding et al., 2010, 
Johnson et al., 2014). To assess whether platinum therapy directly influenced 
cancer evolution by providing additional mutagenic fuel, the mutational spectra and 
clonal composition of oesophageal adenocarcinoma tumours were investigated 
following treatment with chemotherapy.  
When considered in aggregate, statistically significant shifts in the mutational 
spectra were observed between pre and post-chemotherapy somatic mutations. 
Specifically, a significant decrease in the proportion of C>T transition mutations 
was observed, accompanied by an increase in C>A transversion mutations. 
Furthermore, within post-chemotherapy somatic mutations, C>A transversion 
mutations were found to preferentially occur within a CpC context, more than would 
be expected given random mutagenesis. This mutational signature was also 
identified in C.elegans, following platinum treatment (Meier et al., 2014). 
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Figure 5:17 Mutational spectra pre and post-platinum therapy 
A) Pie-chart showing the fraction of pre-chemotherapy mutations and post-
chemotherapy mutations accounted for by each of the six mutation types in all M-
seq samples. B) Barplot showing platinum signature enrichment odds ratio for pre-
chemotherapy (blue bars) and post-chemotherapy (red bars) mutations. The 
platinum signature encompasses C>A in CpC context (25). 95% confidence 
intervals for Fisher’s exact test are indicated. 
These data are indicative of mutations being directly attributable to exposure to 
platinum therapy. On average, of the mutations identified after treatment with 
platinum therapy, 10% were C>A transversions occurring within a CpC context.  
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Figure 5:18 Clonal architecture of tumour regions following platinum therapy 
For four patients with C>A transversion mutations in post-chemotherapy regions, 
the cancer cell fraction of mutations pre and post chemotherapy are shown. C>A 
mutations occurring at CpC sites are highlighted. Pre-chemotherapy mutations are 
more likely to be clonal compared to post-chemotherapy mutations.   
Almost all of these transversions were found to be present at cancer cell fractions 
below 100%(28/32) in all tumour regions within a given tumour (Figure 5:18). 
Indeed, as a whole, post-chemotherapy mutations were very rarely clonal in any 
tumour region, with less than 3% identified as having a CCF of 100% in any tumour 
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region. By contrast, over 50% of mutations identified prior to adjuvant 
chemotherapy were clonal in at least one tumour region.    
Taken together, these data suggest a lack of a full clonal sweep following adjuvant 
chemotherapy and minimal evolutionary bottlenecking. Moreover, it appears 
chemotherapy may foster subclonal diversity, although further tracking of tumours 
over time will be required to fully elucidate whether the size of clones is driven by 
selection.  
5.2.12 Mutational processes fuel the acquisition of somatic events in cancer 
genes 
Next, the extent to which mutational processes can explain the temporal acquisition 
of non-silent mutations in known cancer genes was explored across cancer types.  
In both LUAD and LUSC TCGA tumours, over 30% of clonal non-silent mutations in 
cancer genes were found to be C>A transversions, consistent with smoking 
providing the mutagenic fuel for tumourigenesis. For example, over 40% of clonal 
mutations in TP53 were C>A transversions. In keeping with these results, in multi-
region NSCLC L011, a clonal C>A TP53 mutation was detected in all tumour 
regions. In BLCA, by contrast, over 40% of clonal mutations in cancer genes were 
found to occur in an APOBEC context, consistent with APOBEC-mediated 
mutagenesis shaping the early evolutionary trajectory of many BLCA tumours. For 
example, BLCA-GU-A42R harboured two clonal APOBEC mutations in ARID1A.  
Focusing on subclonal mutations in known cancer driver genes, APOBEC 
represented a dominant mutational process in at least five cancer types: BLCA, 
BRCA, HNSC, LUAD, and LUSC. In LUAD, LUSC, and HNSC samples showing 
evidence of APOBEC-mediated mutagenesis, on average only 21% (range 19-
24%) of clonal mutations in cancer driver genes occurred in an APOBEC context, 
but over 45% (range 35-59%) of subclonal mutations in cancer genes could be 
explained by APOBEC-mediated mutagenesis. Strikingly, in these cancers, over 
90% of subclonal mutations in PIK3CA occurred in an APOBEC context, subclonal 
APOBEC mutations were identified in multiple other cancer driver genes, including 
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PTEN, EGFR, and TP53. Likewise, in multi-region NSCLC, subclonal mutations in 
driver genes PIK3CA, EP300, TGFBR1 and AKAP9 were identified, and, in 
APOBEC-associated BLCA, over 45% of subclonal mutations in driver genes 
occurred in an APOBEC context. These data suggest that APOBEC cytosine 
deaminases may play a key role in driving subclonal diversification in these cancer 
types.  
 
Figure 5:19 Mutational spectra of mutations in driver genes.  
A) Proportion of 8 distinct mutation types is shown for clonal and subclonal 
mutations within cancer genes in each tumour type. APOBEC refers to C>T or C>G 
mutations at TpCp(CorT) sites. B) Proportion of mutation types for samples 
showing a significant enrichment of APOBEC mediated mutagenesis. Notably, in 
HNSC, LUAD, and LUSC there is a clear enrichment for APOBEC mutations in 
subclonal cancer driver genes compared to clonal mutations. 
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5.2.13 A model of the evolutionary history of NSCLC 
Finally, to gain a deeper understanding of the dynamics of early stage NSCLC 
evolution, two tumours with high coverage whole-genome sequencing were 
considered in detail (Figure 5:20). The mutational processes shaping the cancer 
genome, both before and after the emergence of the most-recent common 
ancestor, were placed on the phylogenetic trees of theses tumours.  
In L002, a current-smoker, tobacco carcinogens clearly played a significant role 
early in tumour development, with over 39% of the truncal mutations being C>A 
transversion mutations. Prior to the emergence of the most recent common 
ancestor, mutations in multiple driver genes were acquired, including mutations in 
TP53 and CHD8. 
After diversification, into a LUAD subclone and a LUSC subclone, APOBEC 
mutational processes were elevated specifically in the LUAD region. Despite 
continual exposure to tobacco carcinogens, on the LUAD branch only 22% of 
mutations were C>A transversions and driver mutations in TGFBR1 and PTPRD 
were found to occur within an APOBEC context.  These data are consistent with 
APOBEC providing the mutagenic fuel for subclonal expansions. Furthermore, the 
LUAD branch of the phylogenetic tree harboured almost 10,000 more mutations 
than the LUSC branch. In the LUSC region 28% of mutations were C>A 
transversions, suggesting smoking remained a key genomic instability process 
shaping the genome on this branch of the phylogenetic tree. Genome doubling 
events were detected in both tumour regions, in both cases occurring towards the 
end of the branches.    
In L008, an ex-smoker who stopped over 20 years ago (Table 1), further temporal 
resolution was gained by exploring the mutations before and after the truncal 
genome-doubling event. Notably, every truncal driver mutation, including mutations 
in TP53 and BRAF, likely occurred before the genome-doubling event. A signature 
of tobacco smoke, characterized by over 30% of mutations being C>A 
transversions, was identified both before and after the genome-doubling event.  
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Figure 5:20 A model of the evolutionary history of NSCLC. 
Evolutionary histories of tumours from patients L002 (A) and L008 (B) are depicted. 
Genomic instability processes defining NSCLC evolution have been placed on their 
phylogenetic trees. In each case, the timing of genome-doubling events is indicated 
with an arrow. CIN, chromosomal instability; muts, mutations. 
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After the emergence of the most recent common ancestor, only 21% and 9% of 
mutations in the upper lobe, region R1 and middle lobe, region R3, were C>A 
transversions. These data imply genome doubling occurred within a smoking 
carcinogenic context, and, by extension therefore, over 20 years ago. In support of 
a prolonged tumour latency period, following genome doubling prior to clinical 
detection in NSCLC, the genome-doubling event in L001 also appeared to occur 
within a smoking context, over 20 years prior to surgery. 
5.3 Conclusions  
Analysis of the catalogues of somatic mutations from both multi-region and single 
samples tumour genomes has yielded several insights into the underlying 
mutational processes that have sculpted the cancer genomes over space and time.  
In most cancers while known mutagenic processes, such spontaneous deamination 
of methylated cytosines and smoking induced C>A transversions, appear to 
dominate the early life history of a tumour, other processes, such as APOBEC 
mediated mutagenesis, frequently dominate later, driving subclonal diversification. 
Indeed, APOBEC mediated mutagenesis could be linked the acquisition of multiple 
subclonal driver events in HNSC, LUAD, LUSC, BLCA, and BRCA. Thus these 
data fit with a model of APOBEC mediated mutagenesis providing a substrate for 
tumour evolution, which may lead to intra-tumour heterogeneity  
Moreover, these findings are indicative of an elevated mutation rate in most 
cancers, characterized by multiple mutational processes that specifically arise after 
or during tumour formation, and support the notion of a mutator phenotype defining 
tumour evolution (Loeb, 2001).  
Analysis of pre- and post-chemotherapy oesophageal adenocarcinoma tumours 
identified a platinum signature following therapy, highlighting how therapy itself can 
directly impact upon the evolutionary trajectory of tumours. Two distinct modes of 
tumour evolution were deciphered following therapy, with both paraphyly and 
monophyly observed (Figure 5:21). Prior to chemotherapy a decrease in mutations 
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potentially attributable to gastric acid exposure was observed, at the expense of an 
increase in C>T mutations at CpG sites, potentially indicating increased cell-
turnover and proliferation after tumour formation (Figure 5:21), consistent with 
previous findings in KIRC (Gerlinger et al., 2014a).  
 
Figure 5:21 A model of tumour progression in oesophageal adenocarcinoma 
Following treatment, two distinct modes of tumour evolution were observed, 
paraphyly and monophyly.  
While extremely useful in deconstructing the mutational processes present in large 
catalogues of mutation from hundreds of cancers, it is also worth considering some 
of the limitations of NMF and model selection to identify the mutational signatures. 
Most notably, the process makes the assumption that every mutational signature is 
present to some degree in all samples, which can mean signatures with little effect 
may be missed, or dominant signatures within specific samples may be over 
estimated across the cohort. In the future it will be worth exploring novel 
computational tools that reduce parameter space, and moreover tools that search 
for signatures that allow SNVs, copy number and epigenetic space to be evaluated.  
Understanding how the mutations derived from the vast array of mutational 
processes can be exploited in the clinical setting and the clinical significance of 
intra-tumour heterogeneity revealed in this thesis will be explored further in the next 
chapter. 
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Chapter 6. Neo-antigens and intra-tumour 
heterogeneity  
6.1 Introduction 
In the previous chapters of this thesis I have investigated the extent of diversity 
within tumours and explored the processes driving cancer genome evolution and 
intra-tumour heterogeneity and also considered their timing. In this chapter, I 
explore how cancer genome sequencing data can be used to inform 
immunotherapy approaches and the clinical relevance of intra-tumour 
heterogeneity.  
Given the dynamic and heterogeneous nature of tumour evolution, an optimal 
therapy may need to be highly personal, customized based on the specific 
mutational processes and somatic events present in a patient’s tumour, ideally 
targeting multiple clonal events in each tumour. As demonstrated in Chapter 3, 
targeted therapy approaches may be hampered by the fact that many actionable 
mutations are frequently only present in a subset of cancer cells within a tumour.  
Recent studies have shed light on the immunotherapeutic potential of immune-
blockade and tumour neo-antigens. Studies in both mice and humans have 
demonstrated T-cell responses elicited towards neo-antigens (Castle et al., 2012, 
Rizvi et al., 2015, Linnemann et al., 2015), and a recent study suggested the 
presence of tumour neo-antigens might lead to improved overall survival (Brown et 
al., 2014). Relatedly, modulation of the immune system through blockade of the 
immune inhibitory receptors PD-1, PD-L1 or CTLA-4 has been shown to produce 
significant clinical benefits against a variety of cancers, including NSCLC (Jamal-
Hanjani et al., 2013, Sharma and Allison, 2015, Soria et al., 2015). However, 
further work is needed to fully understand the repertoire of tumour neo-antigens in 
tumours, and an understanding of neo-antigens in the context of intra-tumour 
heterogeneity is lacking.  
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In this chapter, I develop a pipeline to decipher the neo-antigen repertoire in 
tumours. The extent to which neo-antigens may be heterogeneous, and the clinical 
relevance of this to checkpoint inhibitor response, is explored in NSCLC.  
The work presented in this chapter of the thesis is currently in preparation for 
submission. Some of the bioinformatics work presented here was conducted in 
collaboration with Rachel Rosenthal, while the experimental work was performed 
by Andrew Furness and collaborators at the Danish Technical University.  
6.2 Results 
6.2.1 A pipeline to identify putative neo-antigens 
Each mutation that results in an altered protein product has the potential to give 
rise to a tumour neo-antigen, thereby eliciting an immune response. In order to 
identify putative neo-antigens in NSCLC a pipeline was devised. In brief, the 
pipeline incorporates the following steps: 
1. Determine patient’s HLA class I alleles using Optitype (this part of the pipeline 
was developed by Rachel Rosenthal)  
2. Identify amino acid substitutions associated with each coding non-synonymous 
mutation 
3. Create mutant peptide sequencing of 9-11 amino acids in length, including 
every possible position for altered amino acid to sit. Also create equivalent wild-
type peptides.  
4. Determine binding of each peptide to patient’s HLA-class I alleles using 
netMHCpan (Hoof et al., 2009). netMHCpan relies on a neural network-based 
learning approach to predict binding affinity of peptides to class I MHC 
molecules 
5. Evaluate binding scores of mutant and wild-type peptides to obtain a filtered list 
of putative neo-antigens 
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6.2.2 Considerable variation in number of putative neo-antigens across 
LUAD tumours 
To explore the presence of putative neo-antigens across a large cohort of tumours, 
data from the TCGA was used. Application of the pipeline to 124 LUAD and 124 
LUSC TCGA tumours revealed the presence of putative neo-antigens in the 
majority of tumours (Figure 6:1). Consistent with previous reports, each LUAD 
tumour harboured on average 122 putative neo-antigens, while each LUSC tumour 
an average of 142 (Rajasagi et al., 2014). Notably, a considerable range in neo-
antigens per tumour was observed, especially in LUAD tumours (Figure 6:1A), with 
a median absolute deviation of 82 and interquartile range of 112.  
As might be expected, the number of predicted neo-antigens was significantly 
correlated with the mutational burden of the tumour (P< 2.2e-16, r= 0.95). 
 
 
Figure 6:1 Putative neo-antigens in TCGA LUAD and LUSC tumours 
Number of putative neo-antigens identified in (A) TCGA LUAD and (B) TCGA 
LUSC tumours is depicted. Each bar represents one tumour, and neo-antigens are 
labelled as deriving from clonal, subclonal or mutations of unknown clonal status.    
6.2.3 Relationship between survival and number of putative neo-antigens in 
LUAD tumours 
Conceivably, the presence of a large number of tumour neo-antigens may impede 
the ability of a tumour to successfully evade the immune system through immune 
escape (Schumacher and Schreiber, 2015). Accordingly, one would predict a high 
number of tumour neo-antigens might be associated with improved patient 
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prognosis. To assess this hypothesis, matched clinical data for TCGA samples was 
obtained.  
In support of the clinical importance of neo-antigens (Brown et al., 2014), in the 
LUAD cohort, a high neo-antigen load (defined as the upper quartile of the number 
of putative neo-antigens in the cohort) was associated with significantly longer 
overall survival times compared to tumours in the remaining three quartiles (Figure 
6:2, P=0.011, log-rank test). For tumours in the LUSC cohort, which exhibited a 
narrower range of putative neo-antigens (with a median absolute deviation of 50 
and interquartile range of 71), a statistically significant association between overall 
survival and neo-antigen load was not observed (Figure 6:2, P=0.81, log-rank test). 
 
Figure 6:2 Relationship between survival and neo-antigenic load  
Overall survival for (A) TCGA LUAD tumours and (B) TCGA LUSC tumours 
comparing tumours with a high neo-antigenic load (upper quartile) versus all other 
quartiles. For TCGA LUAD, tumours with a high neo-antigens load have 
significantly improved survival (P=0.011, log-rank test). For TCGA LUSC, no 
relationship between neo-antigenic load and survival was observed (P=0.81, log-
rank test).  
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6.2.4 Relationship between survival and number of clonal putative neo-
antigens in LUAD tumours 
Next, for TCGA LUAD tumours, the clonal status of each putative neo-antigen was 
determined and the relationship between the number of clonal neo-antigens and 
overall survival was considered (Figure 6:3).  
 
Figure 6:3 Clonality and number of epitopes in relation to overall survival in 
NSCLC 
A) Overall survival for TCGA LUAD tumours with a high clonal neo-antigenic load 
(upper quartile) versus lower clonal neo-antigenic load (all other tumours). B) 
Overall survival for tumours with a high subclonal neo-antigenic load (upper 
quartile) versus lower subclonal neo-antigenic load (all other tumours).  
LUAD tumours harbouring a high number of predicted clonal neo-antigens (defined 
as the upper quartile of the cohort) were associated with significantly longer overall 
survival compared to all other tumours in the cohort (Figure 6:3, P=0.0077, log-rank 
test). Conversely, the number of predicted subclonal neo-antigens was not 
significantly associated with overall survival (Figure 6:3, P=0.12, log-rank test). The 
relationship between clonal neo-antigens and overall-survival also remained 
significant in a multivariate analysis, including stage and age in the model 
(P=0.00389, Table 6-1) 
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Table 6-1 Clonal neo-antigen survival analysis 
Variable Univariate Multivariate 
HR (95%) p-val  
(log-rank) 
HR (95%) p-val  
(Wald) 
Clonal neo-antigens  
(other vs. upper quartile) 
3.08 
(1.29-7.36) 
0.0077 3.96 
(1.55-10.08) 
0.0039 
Age (continuous) 1.01  
(0.98-1.04) 
0.67 1.01  
(0.98-1.04) 
0.51 
Stage II (vs. I) 1.77  
(0.78-4.01) 
0.17 1.74  
(0.75-4.04) 
0.20 
Stage III (vs. I) 4.03 
(2.04-7.99) 
6.38e-05 5.141  
(2.50-10.59) 
8.97e-06 
Stage IV (vs. I) 2.64  
(0.60-11.60) 
0.20 2.49  
(0.54 - 11.30) 
0.24 
  
While a significant association was also observed between high clonal SNV load 
and poor prognosis (P=0.018, log-rank-test, HR=2.0 [1.1 − 3.7]), this association 
was less evident compared to clonal neo-antigenic burden, suggesting the 
estimated neo-antigenic burden is not simply a proxy for SNV load. 
Finally, tumours with a high burden of clonal neo-antigens were found to be 
significantly more homogenous compared to other tumours in the cohort (Figure 
6:4, P=0.005, Student’s t-test).  
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Figure 6:4 Relationship between number of clonal neo-antigens and neo-antigen 
subclonal fraction in TCGA LUAD tumours 
Boxplot showing difference in neo-antigen subclonal fraction between tumours 
harbouring a high number of clonal neo-antigens (upper quartile) and those 
harbouring intermediate to intermediate to low numbers of clonal neo-antigens 
(remaining quartiles). A significant difference is observed between the two groups, 
P=0.005, Student’s T-test.   
Taken together, these data suggest the number and clonal status of neo-antigens 
may impact upon the likelihood of immune escape, and thereby patient prognosis. 
However, additional samples are needed to reliably assess the importance of 
clonal neo-antigens in relation to survival. Moreover, given the myriad of potential 
mechanisms leading to immune escape, and the many checkpoints of the immune 
system, it is likely that many tumours with clonal neo-antigens still eventually evade 
the immune system.  
6.2.5 Identification of putative neo-antigens in multi-region tumours  
Next, to address whether CD8+ T cells reactive to clonal neo-antigens could be 
identified in primary NSCLC tumours, the neo-antigen pipeline was implemented on 
two multi-region sequenced tumours, L011 and L012 (Figure 6:5). 
While both tumours were derived from female heavy smokers (>40 pack-years), 
their mutation burden and the extent of their intra-tumour heterogeneity was 
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considerably different (Figure 6:5 A). L011, an adenocarcinoma, exhibited a 
relatively homogenous primary tumour and metastatic dissemination to the brain 
(M1-M4), likely originating from tumour region R3 (Figure 6:5 A). A total of 313 neo-
antigens were predicted from the mutations contained within the primary tumour of 
L011, 88% of which were clonal, identified in every region of the primary tumour 
(Figure 6:5 B). Conversely, L012, a squamous cell carcinoma, exhibited a relatively 
low mutation burden and extensive heterogeneity, with 75% of the predicted neo-
antigens deriving from subclonal mutations, only present in a subset of cancer cells 
(Figure 6:5 A,C).  
6.2.5.1  Confirmation of predicted neo-antigens  
To assess whether predicted neo-antigens resulted in a T-cell response, MHC-
multimers were loaded with predicted neo-antigens and screened for CD8+ T cells 
expanded from different tumour regions and adjacent normal lung tissue. In total, 
290 and 355 putative neo-antigens (with predicted HLA binding affinity <500nM, 
including multiple potential peptide variations from the same missense mutation) 
were synthesized and used to screen expanded L011 and L012 tumour infiltrating 
lymphocytes (TILs) respectively. This experimental work was performed by Andrew 
Furness.  
In L011, CD8+ T cells reactive to an HLA-B3501-multimer derived from mutant 
MTFR2D326Y (FAFQEYDSF), a clonal mutation with high predicted HLA binding to 
HLA-B3501 in wild type (10nM) and mutant (22nM) forms (Figure 6:5 B), were 
identified in all tumour regions (2.8-4.4%) and at lower frequency in normal regions 
(0.1%) (Figure 6:5 D). No CD8+ T cells reactive to the wild type multimer with 
sequence FAFQEDDSF were identified. Likewise, no responses were found 
against multimers with overlapping mutant peptides AFQEYDSFEK and 
KFAFQEYDSF, suggesting CD8+ T cells were highly specific.  
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Figure 6:5 Phylogenetic trees and neo-antigens in L011 and L012 
A) Phylogenetic trees for L011 and L012, with branch lengths proportional to 
number of non-silent mutations. B) Putative neo-antigens predicted for all missense 
mutations in L011. The MTFR2D326Y neo-antigen (FAFQEYDSF) is highlighted. C) 
Putative neo-antigens predicted for all missense mutations in L012. The CHTF18 
L769V neo-antigen (LLLDIVAPK) and MYADMR30W neo-antigen (SPMIVGSPW) are 
indicated. D, E) MHC-multimer analysis of in-vitro expanded CD8+ T lymphocytes 
deriving from three tumour regions and normal tissues for L011 (D) and L012 (E). 
In both cases, frequency of CD3+CD8+ T lymphocytes reactive to mutant peptides 
is indicated.  
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In L012, CD8+ T cells reactive to an HLA-A1101-multimer derived from mutant 
CHTF18L769V (LLDIVAPK) and an HLA-B0702-multimer derived from MYADMR30W 
(SPMIVGSPW) were identified in all tumour regions and at lower frequencies in 
normal tissue (Figure 6:5 E). Both were clonal mutations, CHTF18 with high-
predicted binding to HLA-A1101 (<50nM) in mutant and wild type forms, and 
MYADM with lower predicted binding in wild type to HLA-B0702 (>1000nM) 
compared to mutant form (<50nM) (Figure 6:5 C). An HLA-A1101-multimer derived 
from the wild type sequence LLLDILAPK (41 nM), for CHTF18 was not found to 
illicit a T-cell response. However, an HLA-B0702-multimer derived from the wild 
type sequence SPMIVGSPR (1329 nM) for MYADM was found to provoke a T-cell 
response. Notably, as the wild type peptide had a very weak predicting peptide to 
HLA binding score (>1000 nM), it is predicted that the actual tetramer may be very 
unstable, and therefore rarely, if ever, seen by the immune system. Thus the 
perceived T cell response may reflect T-cells primed towards the mutant peptide.  
6.2.6 Clonal dissection of tumour exomes from patients treated with 
pembrolizumab 
Blockade of immune inhibitory receptors, such as PD-1, PD-L1 and CTLA-4, has 
been shown to be associated with significantly improved response rates in NSCLC 
(Topalian et al., 2012, Garon et al., 2015, Soria et al., 2015). Relatedly, a higher 
neo-antigen burden – predicted by a pipeline similar to that described above – has 
been shown to be associated with improved objective response, durable clinical 
benefit, and progression free survival in NSCLC patients treated with pemrolizumab, 
an antibody targeting PD-1 (Rizvi et al., 2015).  
To explore whether the clonal status of putative neo-antigens impacts upon 
sensitivity to PD-1 blockade, exome sequencing data from a recent study in which 
two independent NSCLC cohorts were treated with pembrolizumab was obtained 
(Rizvi et al., 2015). In total, sequencing data from 32 NSCLC tumours was acquired, 
16 of which were originally designated as a discovery cohort, and 18 of which were 
considered a validation cohort. The clinical characteristics of all patients can be 
found in Table 8-11, in Appendix 3.  
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The clonal architecture of each tumour was dissected by estimating the cancer cell 
fraction of each mutation and clustering these using a Dirichlet clustering process 
(see Experimental procedures). (For two tumours, ZA6965 and GR0134, reliable 
copy number, mutation and purity estimations could not be extracted, rendering 
clonal architecture analysis intractable.) Both the mutational burden and the degree 
of intra-tumour heterogeneity, as measured by the proportion of subclonal 
mutations, varied considerably for tumours across the two tumour cohorts (Figure 
6:6). 
 
Figure 6:6 Mutation burden and subclonal fraction in discovery and validation 
cohort.  
Total number of SNVs identified for each sequenced tumour, with number of clonal 
(red) and subclonal (blue) displayed in the barplot.  
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6.2.7  Relationship between number of clonal neo-antigens and sensitivity 
to PD-1 blockade in NSCLC 
To determine the number of neo-antigens within the discovery and validation cohort, 
the neo-antigen prediction pipeline described above was applied to all sequenced 
tumours.  
As previously reported (Rizvi et al., 2015), neo-antigen burden was related to the 
clinical efficacy of pembrolizumab in the discovery and validation cohort, with a 
high neo-antigen repertoire associated with improved outcome (Figure 6:7). This 
relationship was also contingent upon the clonal architecture of each tumour 
(Figure 6:7 A-H). In the discovery cohort, every tumour exhibiting durable clinical 
benefit  (DCB, defined as in (Rizvi et al., 2015) as partial response or stable 
disease lasting > 6 months) harboured a high clonal neo-antigen burden (defined 
as above or equal to the median number of clonal neo-antigens in the discovery 
cohort, 91) coupled with a neo-antigen subclonal fraction lower than 5% (Figure 
6:7). Conversely, every tumour exhibiting a non-durable benefit (NDB) exhibited 
either a low clonal neo-antigen repertoire (<91) or a high neo-antigen subclonal 
fraction (>5%). Indeed, the only tumour with a high neo-antigenic load and a non-
durable response, TU0428, was an extremely heterogeneous tumour, with 301 out 
of 902 somatic mutations classified as subclonal. Thus, in the discovery cohort, 
combining both neo-antigen repertoire and neo-antigen heterogeneity was able to 
predict sensitivity to pembrolizumab, better than either measure alone (Figure 6:7 
A-C).  
Similarly, in the validation cohort, five of six tumours with a high clonal neo-antigen 
burden (defined as greater than or equal to the median of the validation cohort, 69) 
and low subclonal neo-antigen fraction (<5%) were associated with DCB (Figure 
6:7). Conversely, eight out of ten tumours with low clonal neo-antigen burdens or 
high neo-antigen heterogeneity were associated with NDB. For example, SA9755, 
a homogenous tumour with a high clonal neo-antigenic burden, responded well to 
treatment, exhibiting an on-going durable clinical response at the time of data lock 
(Figure 6:8 A). By contrast, despite a large neo-antigen burden, ZA6505 exhibited a 
Chapter 6. Results 
 
 209 
non-durable clinical response, relapsing after 2 months (Figure 6:8 A). ZA6505 was 
the one of most heterogeneous tumour within the cohort, with over 80% of 
mutations classified as present in only a subset of tumour cells within this 
metastatic liver sample. Moreover, consistent with many of the mutations occurring 
after the emergence of the founding cancer clone and metastatic dissemination to 
the liver, two mutational signatures that have been identified in liver tumours, 
Signature 16 and Signature 12, were identified within ZA6505 (Figure 6:8 B). 
In summary, when the extent of neo-antigen heterogeneity and the clonal neo-
antigen burden were considered together, clinical benefit could be predicted in 
almost all cases (Figure 6:7). Notably, two of the three outliers were LUSC tumours 
(CU9061 and SB010944) and consistent with survival analysis from TCGA data, 
when the four LUSC tumours in both cohorts were removed, an even clearer 
relationship was observed. Moreover, a greater PD-L1 expression was observed in 
tumours harbouring a large clonal neo-antigen burden and low neo-antigen 
heterogeneity compared to those with a low neo-antigen load or high neo-antigen 
heterogeneity (P=0.0017, chi-square test; Figure 6:9).  
These results also remained consistent when considering all mutations rather than 
class-I restricted putative neo-antigens, supporting the notion that unidentified MHC 
class II-restricted neo-antigens may also play a significant role in immune reactivity 
(Linnemann et al., 2015) and the need for refinement of neo-antigen prediction 
algorithms (Schumacher and Schreiber, 2015).  
 
Chapter 6. Results 
 
 210 
 
Figure 6:7 Relationships of clonal neo-antigens and intra-tumour heterogeneity 
with clinical benefit of anti-PD-1 therapy  
For discovery (A-C) and validation cohort (D-F), number of clonal neo-antigens and 
fraction of subclonal neo-antigens is shown for patients with a durable clinical 
benefit (DCB), or non-durable benefit (NDB). Progression free survival in tumours 
with a higher number of neo-antigens and low subclonal fraction compared to those 
with a lower number of neo-antigens or high subclonal fraction is shown for 
discovery (C) and validation (F) cohorts. G) Clonal architecture for each sequenced 
tumour. PFS are reported under bar-plot and those with on-going progression-free 
survival are labelled with +. PD-L1 is indicated below bar-plot: Strong (+) 50% 
membranous staining; Weak (+/-), 1-49% membranous staining; Negative (-),<1% 
membranous staining; Unknown (?). (H) Progression free survival in combined 
tumour cohort comparing tumours with a higher number of neo-antigens and low 
subclonal fraction with those with a lower number of neo-antigens or high subclonal 
fraction. 
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Figure 6:8 Clonal architecture and mutational signatures in two tumours 
For two tumours the clonal architecture and mutational signatures identified using 
the deconstructSigs mutational signatures package are depicted. Notably, ZA6505 
harbours mutational signatures that are generally found in liver tumours, 
suggesting a large proportion of mutations occurred after metastatic dissemination 
to the liver. Names of mutational signatures correspond to those used by 
Alexandrov et al. (2013a).  
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Figure 6:9 PD-L1 expression for two groups of tumours 
PD-L1 exhibits significantly stronger expression in tumours harbouring a high clonal 
neo-antigen burden and a low subclonal neo-antigen fraction compared to tumours 
harbouring a low clonal neo-antigen burden or high subclonal neo-antigen fraction.   
6.2.8 A clonal neo-antigen specific CD8+ T cell response reflects tumour 
regression 
Finally, given that candidate neo-antigens had previously been examined in a 
tumour (CA9903) with exceptional response to pembrolizumab within this cohort 
(Rizvi et al., 2015), the clonal status of mutations and candidate neo-antigens were 
further considered, specifically for this tumour.  
Previous analysis demonstrated a CD8+ T cell response against a neo-antigen 
resulting from a HERC1 P3278S mutation (ASNASSAAK). Subclonal architecture 
analysis revealed that this mutation was likely present in all tumour cells within the 
sequenced tumour and exhibited mutation copy number of 1.73, suggesting it was 
likely clonal within the tumour population and present at multiple copies (Figure 
6:10)  
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Figure 6:10 Clonal status of neo-antigen in CA9903 
A) Putative neo-antigens predicted for all non-synonymous mutations in CA9903. 
The HERC1 P3278S neo-antigen (ASNASSAAK) is highlighted. Each dot 
represents one peptide. Binding scores IC50 (nM) is indicated, a lower binding 
score indicates stronger binding affinity. B) Clonal architecture of CA9903 tumour 
sample with HERC1 mutation highlighted. A small subclonal population, 
representing 3% of the mutational burden, is detected.  
6.3 Conclusions  
Exploration of neo-antigens in LUAD and LUSC tumours revealed that the majority 
of these tumours harbour putative neo-antigens, however there was considerable 
range across cancers. Consistent with the clinical importance of neo-antigens 
(Schumacher and Schreiber, 2015, Brown et al., 2014, Rooney et al., 2015), LUAD 
tumours with a high neo-antigen burden were associated with significantly longer 
overall survival times. Clonal neo-antigens eliciting a T-cell response could be 
identified in multi-region sequenced NSCLC tumours. 
Importantly, the relationship between neo-antigens and survival was also found to 
be more pronounced when considering clonal neo-antigens. Likewise, the 
established clinical benefit associated with immune modulation through anti-PD-1 
(Rizvi et al., 2015) was found to be related to both the number of clonal neo-
antigens and the neo-antigen subclonal fraction  
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These data suggest that clonal and subclonal neo-antigens might not drive equally 
effective anti-tumour immunity. Low intra-tumour heterogeneity and high clonal 
neo-antigen burden might result in higher antigen dosage compared to tumours 
with low clonal neo-antigen burden and high heterogeneity.  Moreover, extensive 
heterogeneity might foster generation of T cells favouring the recognition of 
mutations not expressed by all tumour cells, limiting tumour control.  
Targeting clonal mutations, shared by all tumour cells might hold promise to 
address the challenges of intra-tumour heterogeneity outlined in the preceding 
chapters.  
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Chapter 7. Discussion  
7.1 Introduction 
Precision medicine will ultimately require not only a catalogue of driver mutations 
and mutational processes, but also an understanding of their spatial and temporal 
dynamics during a tumour’s evolution. More specifically, the drivers of intra-tumour 
heterogeneity, which provides a substrate for tumour evolution, will need to be 
understood in order to identify the key causes of tumour adaptation and resistance 
to cancer therapies (Greaves, 2015).  
In the course of this thesis, detailed genomic analysis of tumours from ten cancer 
types has yielded insights into the clonal status of somatic events in cancer, as well 
as the temporal dynamics of mutational processes. Analysis of allele specific 
tumour copy number data and a colorectal cancer cell-line system has shed light 
on the importance of genome doubling in cancer genome evolution. Finally, the 
clinical relevance of tumour heterogeneity in NSCLC has been explored in the 
context of cancer neo-antigens and immune modulation.  
In this chapter, the biological insights engendered by this analysis are explored and 
considered within the context of the current literature. Potential future directions 
and the clinical implications of these findings are also discussed. 
7.2 Heterogeneity is widespread across human cancers  
Consistent with emerging data from multiple studies undertaken since the start of 
this PhD (Gerlinger et al., 2012, Gerlinger et al., 2014a, Shah et al., 2012, Yates et 
al., 2015, Greaves, 2015, Landau et al., 2013, Lohr et al., 2014, Alexandrov et al., 
2013a, Suzuki et al., 2015), the results of this thesis highlight that intra-tumour 
heterogeneity is widespread across cancers.  
For the first time, multi-region whole-exome and/or whole genome sequencing was 
applied to both NSCLC and oesophageal adenocarcinoma primary tumours 
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(Chapter 3). In every tumour sequenced, branched evolution was observed, with 
distinct subclonal populations spatially separated within the primary tumour.  
The heterogeneity observed in LUAD, with a median of 30% of non-silent mutations 
classified as heterogeneous (Figure 3:3), is consistent with a recent study, which 
also performed multi-region sequencing in this cancer type, and identified, on 
average, 24% of mutations as heterogeneous (Zhang et al., 2014). Zhang and 
colleagues (2014) also found that the number of trunk mutations increased upon 
deep sequencing of mutations. Arguably, however, this superficially intriguing 
finding is the result of their definition of a trunk mutation, which is both confusing 
and flawed. From a phylogenetic perspective, placing a mutation on the trunk of a 
phylogenetic tree implies it occurred prior to the emergence of the most recent 
common ancestor. Thus, a trunk mutation should be clonal, or at least exhibit 
evidence for having been clonal at one point in time. According to Zhang and 
colleagues (2014) a mutation identified as subclonal in all tumour regions can be 
truncal, which is counterintuitive and does not fit within a logical evolutionary 
framework. As such, the results of their deep sequencing analysis does not 
suggest there is an illusion of heterogeneity that is resolved upon deeper 
sequencing; rather, deep sequencing can further elucidate the subclonal structure 
of a tumour, identifying branched mutations present in only a small subset of 
tumour cells that may be missed at lower sequencing depths.  
Moreover, it is worth considering that although multi-region sampling permits 
spatial heterogeneity to be evaluated, it still does not equate to comprehensive 
sampling of the tumour. Indeed, in the analysis of multi-region NSCLC tumours, on 
average <5% of the tumour was sequenced, thus it is likely that the extent of 
heterogeneity in these tumours exceeds that estimated here.  Further research will 
be required to explore the optimum number of biopsies and optimum depth 
required to adequately capture the extent of heterogeneity in NSCLC tumours. In 
the future, it will also be important to explore the extent and importance of 
heterogeneity at the transcriptomics and epi-genomics levels. 
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The extent of heterogeneity observed can also be put into context by a comparison 
with tumours from other cancer types where multi-region sequencing has been 
performed. While the proportion of heterogeneous mutation was greater in stage IV 
KIRC compared to the early stage NSCLC tumours explored here  (76% vs. 30%) 
(Gerlinger et al., 2012, Gerlinger et al., 2014a), the actual number of subclonal 
mutations was, on average, slightly greater in NSCLC with 98 (range, 19-300) non-
silent mutations identified as subclonal per tumour in NSCLC, compared to 57 
(range, 21-122) in KIRC. These data likely reflect differences in mutational 
processes operating in these tumour types over time (see below). In oesophageal 
adenocarcinoma, a median of 56% of non-silent mutations were classified as 
heterogeneous (range 12.6% to 69.4%), and the average non-silent mutation 
burden was 206.75 (range 127-320), greater than KIRC (85.6, range 54-140) yet 
smaller than NSCLC (280.5, range 58-476). Unfortunately, it is difficult to compare 
to ovarian cancer given the considerable inconsistencies in supplementary tables 
associated with this study (Bashashati et al., 2013).  
7.2.1 Illusion of clonality and clonal architecture of tumours 
The results presented here also highlight the potential limitations of using a single 
sample to identify the driver events of a tumour and to characterize its subclonal 
architecture.  
In both lung cancer and oesophageal adenocarcinoma a large proportion of 
mutations analysed in a single tumour region context were found to exhibit an 
illusion of clonality (Chapter 3). That is, mutations appeared fully clonal in one 
tumour region while they were entirely absent or subclonal in other tumour regions. 
For instance, in L002, over 10,000 mutations from region R1 were identified as 
clonal, but not identified as present in region R3. Similarly, in oesophageal 
adenocarcinoma, driver mutations exhibiting an illusion of clonality were identified 
in all but one of eight tumours. These findings extend the observations of Gerlinger 
(Gerlinger et al., 2014a), highlighting that multi-region sequencing may be required 
to gain a more complete picture of the genomic landscape of tumours. More 
recently, similar findings have also been documented in breast cancer (Yates et al., 
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2015), where seven of twelve tumours subject to multi-region sequencing were 
found to harbour driver mutations that could erroneously be classified as clonal, 
based on a single sample.  
From a clinical perspective, these results emphasize how intra-tumour 
heterogeneity can compromise the utility of a single biopsy to inform treatment 
strategies, and suggest targeting truncal drivers may be necessary (Yap et al., 
2012b).  For instance, L008 presented with an activating BRAF (G469A) mutation 
(Davies et al., 2002) in all tumour regions and an activating PIK3CA (E542K) 
mutation (Kang et al., 2005) only in region R3 (Figure 3:3). Thus, a biopsy taken 
from region R3 might suggest treatment with an inhibitor of the PI3K/mTOR 
signalling axis and combination therapy. Conversely, a single biopsy from any other 
region would suggest treatment with a BRAF inhibitor, for which the tumour cells 
from region R3 might be resistant as a result of the activating PIK3CA mutation 
(Shi et al., 2014). 
The clinical implications of heterogeneity are also underlined by the analysis of 
oesophageal adenocarcinoma, where a strong correlation between the 
heterogeneity index and response to neo-adjuvant platinum chemotherapy was 
observed (Figure 3:19), suggesting a simple heterogeneity score may predict 
response to chemotherapy. However, given the limited number of cases in the 
cohort (n=8), there is a need to confirm these results in an appropriately powered 
prospective cohort study. Prospective studies such as TRACERX (Jamal-Hanjani 
et al., 2014) will shed light on the clinical relevance of intra-tumour heterogeneity in 
NSCLC.  
7.2.2 Parallel evolution 
In keeping with accumulating evidence across cancers (Johnson et al., 2014, 
Gerlinger et al., 2012, Gerlinger et al., 2014a, Yates et al., 2015, Suzuki et al., 
2015), in oesophageal adenocarcinoma and using single samples across the pan-
cancer cohort it was also possible to identify evidence for parallel evolution of 
subclones, with distinct somatic events affecting the same gene or pathway 
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appearing to occur in distinct branches of the tumour phylogenetic tree. These data 
likely reflect constraints to tumours’ evolution that conceivably might be 
therapeutically exploitable in the future.  As additional data accumulates it will be 
interesting to explore whether further patterns across cancer types can be 
deciphered.  
7.2.3 Driver genes can be subclonal  
Most drug development programs employing next-generation sequencing as a 
stratification tool do not consider the clonal or subclonal frequencies of a driver 
alteration, simply their presence or absence (Swanton, 2012). Using both multi-
region sequencing and single sample sequencing data, it was possible to assess 
the extent to which driver mutations are subclonal, present in only a subset of 
cancer cells, or clonal, present in all tumour cells (Chapter 3).  
Across the pan-cancer cohort, and multi-region sequencing data, the presence of 
considerable intra-tumour heterogeneity in driver events, including known canonical 
hotspot mutations such as IDH1 (R132H) and PIK3CA (E545K), was identified. 
Indeed, almost every gene linked with a target therapy was found to harbour a 
subclonal mutation in at least one tumour. Intriguingly, in the pan-cancer analysis, 
genes involved in the PI3K-AKT-mTOR pathway were found to harbour a higher 
proportion of subclonal mutations compared to genes associated with cyclins or 
cyclin-dependent kinases or the RAS-MEK pathway (Figure 3:15). Conceivably, 
this may shed light on the limited success of drugs targeting the PI3K signalling 
axis (Khan et al., 2013).  
Importantly, targeted therapy applied to cancer cells lacking the targeted mutation 
could also have a paradoxical stimulatory effect, resulting in increased growth of 
wild-type subclones (Lohr et al., 2014). The results therefore suggest the need to 
stratify targeted therapy response according to the proportion of tumour cells in 
which the driver is identified and, moreover, indicate that certain pathways may be 
more actionable than others. Clinical trials such as the DARWIN program 
(Deciphering Anti-tumour Response With INtra-tumour heterogeneity) may shed 
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light on whether targeting a clonally dominant driver event results in improved 
progression free survival outcomes relative to targeting the same driver event when 
it is present subclonally.  
7.2.4 Mutations in known cancer genes tend to occur early 
Nevertheless, despite evidence for subclonal mutations in cancer genes, it is 
important to emphasize that the majority of known driver mutations were found to 
be clonal, present in all tumour cells, using both multi-region and single sample 
analysis. In oesophageal adenocarcinoma, when focussing on mutations in known 
cancer genes there was a trend for mutations to be clonal, and, likewise, in NSCLC, 
there was a significant enrichment for mutations in cancer genes to be clonal. In 
the pan-cancer cohort, non-silent mutations in known cancer across every cancer 
type harboured a significantly higher proportion of clonal mutations compared to 
non-silent mutations in other genes, with the exception of KIRC (Figure 3:12), 
where VHL was the only cancer gene with a clear enrichment of clonal mutations.    
These observations extend previous findings across cancer types (Shah et al., 
2012, Weaver et al., 2014, Yachida et al., 2010). For instance, Shah (Shah et al., 
2012) and Nik-Zainal (Nik-Zainal et al., 2012b) found that non-silent mutations in 
TP53 in breast cancer exhibited a tendency to be clonal, while evidence from 
Zhang and colleagues (Zhang et al., 2014) suggests known driver mutations are 
predominantly clonal in NSCLC.  In KIRC, the only cancer driver found to harbour a 
significant enrichment of clonal mutations was VHL, consistent with previous 
findings (Gerlinger et al., 2012, Gerlinger et al., 2014a).  
7.2.5 New cancer genes can be identified based on subclonal analysis 
The tendency for known canonical driver mutations to occur early in tumour 
evolution may also reflect the fact that current methods of defining driver mutations 
are biased to detect clonal drivers, present in all cancer cells. Consistent with this, 
for the first time, by focusing on later mutations, it was possible to detect novel 
putative cancer genes (Table 8-3). These genes may play roles in tumour 
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maintenance and progression. Indeed, some of the cancer genes that were 
identified, such as ATXN1 and CTNNA2, have been linked to tumour metastasis 
and cell migration (Lee et al., 2011b). Although follow-up studies will be required to 
validate the functional impact of these genes, these results suggest that the 
catalogue of cancer genes is far from complete, consistent with saturation studies 
carried out by Lawrence and colleagues (2014). Future studies, involving multi-
region sequencing in hundreds of tumours, may reveal the extent to which 
selection or neutral evolution is the dominant process driving tumour evolution after 
subclonal diversification.  
7.3 Mutational processes vary over time 
Temporal dissection of mutations also permitted insights into the dynamics of 
mutational processes during the disease course (Chapter 5). 
7.3.1 An aging signature dominates early tumour evolution in most cancer 
types 
A mutational signature dominated by C>T transitions at CpG sites was found to 
dominate early mutations in four cancer types, COAD, GBM, HNSC and BRCA 
(Figure 5:7). This signature has been linked to aging and likely reflects 
spontaneous deamination of methylated cytosines (Yates and Campbell, 2012). 
The results therefore suggest a large proportion of mutations in cancer genomes 
precede tumour formation, consistent with mutational signature analysis of 20 
breast cancers (Nik-Zainal et al., 2012a) and mathematical modelling studies 
(Tomasetti et al., 2013).  
In oesophageal primary tumours, however, a similar ‘aging’ signature was found to 
increase in prevalence on the branches of phylogenetic trees (Figure 5:13). In this 
case, this likely reflects the fact that founder genomic events are caused by a 
distinct, oesophageal adenocarcinoma signature (T>G at CpTpT sites), potentially 
attributable to gastric acid exposure (Dulak et al., 2013, Weaver et al., 2014, Nones 
et al., 2014), which reduces in prevalence after tumour formation. The increase in 
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C>T mutations at CpG sites could also reflect more rapid cell turnover induced by 
the onset of chromosomal instability.  
7.3.2 Exogenous mutational processes decrease over time 
Concordant with previous studies (Govindan et al., 2012, Imielinski et al., 2012, 
Lee et al., 2010, Pleasance et al., 2010b) a smoking signature, characterized by 
C>A transversion mutations, was identified in LUAD and LUSC tumours, both from 
single sample and multi-region data (Figure 5:1,Figure 5:7). Temporal dissection of 
mutations revealed that the smoking induced mutations are likely the principal 
cause of many early clonal mutations, yet their relative contribution to the 
mutational load decreases during the evolution of tumours, both in current smokers 
and ex-smokers. These data suggest that even in the face of the continued 
mutagenic insults of tobacco carcinogens, an additional mutational process may 
often be required for tumour progression and maintenance, supporting the notion of 
a mutator phenotype in cancer (Loeb, 2001).  
7.3.3 APOBEC mediated mutagenesis occurs later in tumour evolution 
In multi-region NSCLC tumours, the subclonal mutational spectrum was 
characterized by C>T and C>G mutations, particularly at TpC sites (Figure 5:3).  
This mutational signature has been linked to cytosine deamination by APOBEC 
enzymes (Nik-Zainal et al., 2012a, Roberts et al., 2013), and suggests APOBEC 
mediated mutagenesis may become a pervasive mutational force later in tumour 
evolution. In keeping with these results, in the pan-cancer analysis, mutations 
within an APOBEC motif were found to increase in prevalence during the disease 
course (Figure 5:7), in LUAD as well as HNSC and ER-negative BRCA. APOBEC-
mediated mutagenesis could also be linked to the acquisition of subclonal driver 
events (Figure 5:19), highlighting how mutational processes can alter the 
evolutionary trajectory of tumours consistent with findings in HNSC (Henderson et 
al., 2014).  
Chapter 7. Discussion 
 
 223 
Clearly an understanding of the underlying mechanisms that trigger APOBEC 
mediated mutagenesis is of paramount importance and an important avenue for 
future work. A recent paper highlighted the need to consider both APOBEC3A and 
APOBEC3B as potential culprits (Chan et al., 2015).  
7.3.4 A platinum signature may contribute to intra-tumour heterogeneity   
Multi-region sequencing of oesophageal adenocarcinoma tumour samples obtained 
before and after adjuvant platinum chemotherapy provided insights into how 
therapy can shape the genomic landscape of tumours (Chapter 5).  
Combined analysis of post-chemotherapy mutations from five tumours revealed an 
enrichment of C>A mutations at CpC sites (Figure 5:17), a signature that has been 
linked to exposure to platinum chemotherapy in model organisms (Meier et al., 
2014). In two tumours that exhibited a poor response to chemotherapy, tumour 
regions collected after therapy clustered together on the phylogenetic tree as a 
monophyletic group, potentially indicating a common somatic event conferring 
resistance. Conversely, the three other tumours, associated with good or 
intermediate response, exhibited paraphyly, whereby post-chemotherapy regions 
did not form a distinct branch on the evolutionary tree. In all tumours, mutations 
identified after treatment were often subclonal (Figure 5:18). While it is difficult to 
discern how many of these mutations can be directly linked to chemotherapy, these 
data highlight that a greater understanding of the impact of chemotherapy on the 
evolutionary trajectory of tumours is required and emphasize the need to identify 
patients that are unlikely to benefit from chemotherapy (Devarakonda and 
Govindan, 2015).  
7.3.5 Genome doubling may represent an evolutionary leap 
In four of six multi-region NSCLC tumours, genome-doubling events were observed 
(Chapter 4).  In one tumour there was evidence that the doubling event occurred 
after a TP53 mutation, but within a smoking signature context, 20 years prior to 
clinical detection (de Bruin et al., 2014). This indicates a prolonged tumour latency 
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period after genome doubling and before clinical detection in NSCLC and supports 
recent approaches for screening in this cancer type (Peled and Ilouze, 2015).  
In oesophageal adenocarcinoma tumours, clonal disruption to TP53 and early 
genome-doubling events were identified in every tumour, suggesting mutations to 
this gene and tetraploidisation events may serve as useful clinical biomarkers. 
These findings corroborate observations that mutations to TP53 occur early in 
oesophageal adenocarcinomas (Weaver et al., 2014), and support the results from 
a previous longitudinal case-control study that found chromosomal instability, 
genome doubling and genome diversity in samples obtained from patients with 
Barrett’s oesophagus could predict progression to oesophageal adenocarcinoma 
(Li et al., 2014).   
Conceivably, large-scale genomic changes such as genome doubling may often be 
required for cells to make the leap from a benign to a malignant phase and 
therefore may serve as useful markers for clinical risk prediction in other cancer 
types. Indeed, in support of the notion that genome doubling may facilitate 
accelerated cancer genome evolution, using a colorectal cancer cell-line system it 
was demonstrated that rare cells that survive genome-doubling display an 
increased tolerance to chromosome aberrations compared to their diploid 
counterparts (Figure 4:10). Moreover, genome doubling was found to be 
associated elevated genomic complexity and with reduced relapse-free survival 
times in two independent cohorts in this cancer type (Figure 4:14). In keeping with 
these results, a recent study found multi-drug resistance is promoted upon 
tetraploidisation in human cells (Kuznetsova et al., 2015), and modelling of the 
dynamics of tumour heterogeneity suggested a genome-doubling event provides 
the most parsimonious explanation for the frequency of triploid tumours across 
cancer types (Laughney et al., 2015). Moreover, a recent pan-cancer study also 
found a relationship between genome doubling an elevated genomic complexity 
(Zack et al., 2013). 
Taken together, these results suggest a genome-doubling event could represent a 
macro-evolutionary leap in tumours, which can precipitate and sustain extensive 
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chromosomal rearrangements. Indeed, a recent study in yeast found that 
compared with haploids and diploids, tetraploids undergo significantly faster 
adaptation (Selmecki et al., 2015). In the future, it will be important to investigate 
mechanisms leading to the emergence of genome doubled cells in tumours, such 
as, for example, cellular stress, cytokinesis failure or telomere shortening (Davoli 
and de Lange, 2011), and, moreover, the reason why its timing appears to vary 
across tumours.  
7.4 Clonal cancer neo-antigens elicit T cell immunoreactivity 
and anti-PD-1 response 
As illustrated in this thesis, NSCLCs often harbour a considerable mutation burden, 
a large proportion of which can be attributed to smoking related carcinogens. This 
mutational burden may be associated with a substantial neo-antigen repertoire, 
which may be clinically relevant. Indeed, a link between high tumour burden and 
efficacy of immune checkpoint blockade has been demonstrated in NSCLC (Rizvi 
et al., 2015), and the presence of neo-antigens has been associated with improved 
prognosis in a meta-analysis of cancer types (Brown et al., 2014). 
In support of the importance of neo-antigens, patients with LUAD tumours 
harbouring a high burden of predicted neo-antigens were found to have 
significantly improved overall survival compared to patients carrying tumours with 
intermediate or low numbers of predicted neo-antigens (Figure 6:2). This 
relationship was more pronounced when considering specifically clonal neo-
antigens, present in all tumour cells (Figure 6:3). These observations therefore 
extend previous observations (Brown et al., 2014, Rooney et al., 2015), suggesting 
not only the presence of neo-antigens but also that their number and clonal status 
may impact upon the likelihood of effective immune surveillance. Moreover, T cells 
reactive to clonal neo-antigens were identified from two multi-region sequenced 
NSCLC tumours, validating the ability of the neo-antigen pipeline to predict bona-
fide neo-antigens (Figure 6:5).  
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Analysis of the clonal architecture of NSCLC tumours treated with pembrolizumab 
revealed that progression free survival benefit was dependent on both the number 
of neo-antigens and their clonal status, with tumours harbouring a high clonal neo-
antigen burden coupled with low neo-antigen intra-tumour heterogeneity exhibiting 
durable complete responses (Figure 6:7). This relationship may reflect the fact that 
high intra-tumour heterogeneity results in a lower antigen dosage and higher T-cell 
clonal competition compared to tumours harbouring a high clonal neo-antigen 
burden (Kedl et al., 2000).  
Larger perspective studies using multi-region sequencing to evaluate intra-tumour 
heterogeneity may be required to further validate these observations, and, in the 
future, it will be important to explore the impact of intra-tumour heterogeneity and 
immune modulation in early-stage primary tumours (Soria et al., 2015). Data from 
DARWIN II will shed further light on the relationship between intra-tumour neo-
antigen heterogeneity and neo-antigen burden and progression free survival in 
patients treated with a monoclonal antibody targeting anti-PD-L1. It also remains to 
be elucidated why this relationship is observed particularly in LUAD tumours and 
not LUSC tumours and whether the same relationship holds for tumour types such 
as melanoma.  Finally, it will also be important to consider whether filtering neo-
antigens based on those that can also be identified through mass-spectrometry 
data can refine and improve the analysis considerably.   
Nevertheless, taken together, these results suggest the extensive clonal mutational 
repertoire present in smoking-associated LUAD might render this disease 
vulnerable to vaccination or T cell therapies, targeting multiple clonal neo-epitopes, 
in combination with checkpoint blockade.  
7.5 Conclusions 
The data presented in this thesis suggest diversity within tumours is widespread 
across tumour types and represents a significant clinical challenge. While temporal 
and clonal dissection of mutations revealed subclonal mutations in established 
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cancer genes, in general these genes show a significant enrichment of clonal 
mutations, present in all tumour cells.  
Dissection of mutational signatures suggests exogenous processes, including 
tobacco carcinogens, dominate the early life history of tumours, while endogenous 
processes gone awry, such as APOBEC mediated mutagenesis, become pervasive 
mutational forces later in tumour evolution, contributing to the acquisition of 
subclonal driver events. Platinum chemotherapy can also leave scars in the tumour 
genome, potentially leading to elevated tumour diversity. Analyses of tumour copy 
number data shed light on the importance of genome doubling in cancer genome 
evolution, conceivably acting as an evolutionary leap, facilitating propagation of 
chromosomal instability.  
Finally, the clinical relevance of intra-tumour heterogeneity was demonstrated in 
the context of immune modulation and neo-antigens. The number of clonal neo-
antigens was found to correlate with lung adenocarcinoma survival outcome and T 
cells reactive to clonal neo-antigens were identified. Sensitivity to anti-PD-1 therapy 
was found to be dependent on neo-antigen clonal burden and the extent of intra-
tumour heterogeneity. Thus, immunotherapeutic strategies targeting clonal neo-
antigens, present in all tumour cells, in combination with checkpoint-blockade, may 
provide a tractable approach to tackling lung adenocarcinomas.  
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